JAK1 selective inhibitors

By developing compounds with chemical formula (I), the problem of insufficient selectivity of existing JAK1 selective inhibitors was solved, and the high selective inhibition of JAK1 was achieved, which reduced the inhibition of other JAK kinases, reduced side effects, and effectively treated JAK1-related inflammatory and autoimmune diseases.

CN115925693BActive Publication Date: 2024-11-12ASTRAZENECA AB
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202211243959.9
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2017-01-17
Filing Date
2018-01-16
Publication Date
2024-11-12
Estimated Expiration
2038-01-16

AI Technical Summary

Technical Problem

Existing JAK1-selective inhibitors show marginal JAK1 selectivity in clinical development, resulting in target activity and side effects on other JAK kinases, making it difficult to effectively treat inflammatory and autoimmune diseases associated with JAK1.

Method used

A novel compound with the chemical formula (I) was developed which exhibits a highly selective JAK1 inhibitor through specific structural compositions (R1, R2, R3, R4, R5, R6, R7, R8) for use in Treat JAK1-related disorders, such as type 1 diabetes, lupus, multiple sclerosis and other diseases.

Benefits of technology

Compound (I) showed a low IC50 value inhibitory activity on JAK1, while a low inhibitory activity on JAK2 and JAK3, reducing side effects and effectively treating JAK1-related inflammatory and autoimmune diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN115925693B_ABST
    Figure CN115925693B_ABST
Patent Text Reader

Abstract

The present application relates to a JAK1 selective inhibitor. Disclosed herein are compounds of formula (I), #imgabs0# and pharmaceutically acceptable salts thereof, wherein R1-R8 has any of the meanings defined herein. Also disclosed are pharmaceutical compositions comprising compounds of formula (I) and methods of use thereof.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application is a divisional application of the invention patent application with application date of January 16, 2018, application number 201880018044.3, and invention name “JAK1 selective inhibitor”. Background Art

[0002] The JAK (Janus-associated kinase) family includes four non-receptor tyrosine kinases, JAK1, JAK2, JAK3 and Tyk2, which play a key role in cytokine and growth factor-mediated signal transduction (Schindler C and Darnell JE Jr., Annu. Rev. Biochem 1995; 64: 621-651). The kinase JAK1 interacts in particular with type I interferons (e.g., IFNα), type II interferons (e.g., IFNγ), common γc chains (e.g., IL-2, IL-4, IL-7, IL-9, IL-15 and IL-21) and the interleukin-6 family (IL-10, IL-13 and IL-22) (NEngl J Med 2013, 368, 161-170). After these cytokines bind to their receptors, receptor oligomerization occurs, causing the cytoplasmic tail of the associated JAK kinase to move into proximity and promote transphosphorylation and activation of tyrosine residues on the JAK kinase. Phosphorylated JAK kinases bind and activate various signal transducers and activators of transcription (STAT) proteins. These STAT proteins then dimerize and translocate to the nucleus, where they act as both signaling molecules and transcription factors, and ultimately bind to specific DNA sequences present in the promoters of cytokine-responsive genes (Leonard et al., (2000), J. Allergy Clin. Immunol. 105: 877-888). Signaling disruptions in the JAK / STAT pathway lead to various immune deficiencies and autoimmune diseases, such as allergies, asthma, alopecia areata, transplant (allogeneic) rejection, rheumatoid arthritis, amyotrophic lateral sclerosis and multiple sclerosis, as well as solid and hematological cancers.See, for example, Frank, (1999), Mol. Med. 5: 432-456, Vijayakriishnan et al., Trends Pharmacol. Sci 2011, 32, 25-34, and Flanagan et al.; Open Rheumatol J. 2012, 6, 232-244; N Engl J Med 2013, 368, 161-170; Exp. Dermatol. 2014, 23, 7-11; J. Med. Chem. 2014, 57, 5023-5038, J Allergy Clin Immunol 2014; 133: 1162-74, and Expert Opin Orp. Drug (Expert Opinion on Over-the-Counter Drugs) (2015) 3(4), 419-431.

[0003] An important principle of JAK1 is that it can be paired with other JAK kinases at the intracellular domain of different subunits of the receptor. For example, JAK3 is associated with the common γ chain (γc) of various cytokine receptors and paired with JAK1 (Immunol.Rev. (Immunology Review) 2008, 223, 132-142). It has been shown that JAK1 is more significant than JAK3, and although JAK3 is active (Chem.Biol. (Chemical Biology) 2011, 18 (3), 314-323), the inhibition of JAK1 is sufficient to inactivate the signal transduction through the common γ chain. Therefore, the selective inhibition of JAK1 is sufficient to treat many inflammatory and autoimmune diseases related to cytokine signal transduction via the JAK1 / JAK3-STAT pathway. However, it has been challenging to develop selective JAK1 inhibitors that have little or no off-target activity for other JAK kinases. Specifically, compounds currently identified as JAK1 selective inhibitors in clinical development only show marginal JAK1 selectivity. (Future Med. Chem. (2015) 7 (2), 203-235). For example, the JAK1 / JAK2 selectivity ratio reported in biochemical assays for JAK1 inhibitors in active development for the treatment of autoimmune diseases (e.g., Filgotinib (J. Med. Chem. (Journal of Medicinal Chemistry) 2014, 57, 9323-9342) and ABT-494 (WO 2015061665- Figure 1 ) is 2.8, based on the IC measured at approximately the Km of ATP 50. Therefore, it is expected that these compounds will have some on-target activity against other JAK kinases, as well as additional side effects that are therefore limited by the use of more selective JAK1 inhibitors. Therefore, there is a need to develop highly potent and selective JAK1 inhibitors to treat JAK1-related disorders such as leukemias, lymphomas, transplant rejection (e.g., islet transplant rejection, bone marrow transplant applications (e.g., graft-versus-host disease)), autoimmune diseases (e.g., type 1 diabetes), and inflammatory diseases (e.g., asthma, allergic reactions), while being free of actual or perceived side effects associated with off-target activity, such as anemia.

[0004] Overview

[0005] The present disclosure relates to novel compounds with selective JAK1 inhibition. Accordingly, provided herein are compounds of formula (I):

[0006]

[0007] in:

[0008] R1, R3, and R4 are each independently selected from hydrogen and methyl;

[0009] R2 is selected from hydrogen, methyl, and -CH2CH2OH;

[0010] n is 1 or 2;

[0011] R5 is selected from methyl, ethyl, and -CH2OR8;

[0012] R6 is selected from methyl, chloro, and fluoro;

[0013] R7 is selected from methyl, ethyl, and cyclopropyl; and

[0014] R8 is selected from methyl, ethyl and benzyl;

[0015] or a pharmaceutically acceptable salt thereof.

[0016] The present disclosure also provides a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable diluent, excipient or carrier.

[0017] Also disclosed are methods for treating JAK1-related disorders (e.g., type 1 diabetes, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis, asthma, atopic dermatitis, autoimmune thyroid disease, ulcerative colitis, Crohn's disease, COPD, vitiligo, and alopecia areata), comprising administering to a subject an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof. In another embodiment, disclosed are uses of a compound of formula (I) for treating JAK1-related disorders, comprising administering to a subject an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof. In another embodiment, disclosed are uses of a compound of formula (I) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament or formulation for treating JAK1-related disorders. In another embodiment, disclosed are pharmaceutical compositions comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, for treating JAK1-related disorders.

[0018] Also disclosed are methods for inhibiting JAK1 in a subject, comprising administering to the subject an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof. In another embodiment, disclosed are uses of a compound of formula (I) or a pharmaceutically acceptable salt thereof for inhibiting JAK1 in a subject, comprising administering to the subject an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof. In another embodiment, disclosed are uses of a compound of formula (I) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament or formulation for inhibiting JAK1 in a subject. In another embodiment, disclosed are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof for inhibiting JAK1 in a subject.

[0019] The disclosure also provides methods and intermediates that can be used to prepare compounds of formula (I). BRIEF DESCRIPTION OF THE DRAWINGS

[0020] Figure 1 The powder X-ray diffraction pattern of the crystalline form of the title compound listed for Example 35 is shown.

[0021] Figure 2 Shown are the Hair Index Scores (HIS) of C3H / HeJ mice with established alopecia areata treated with 0.5 mg / kg of the compound of Example 35 compared to untreated mice.

[0022] Figure 3 Shown is the percent reduction in eosinophils in bronchoalveolar lavage in OVA-challenged Brown Norway rats following treatment with the compound of Example 35 compared to challenged but untreated rats. DETAILED DESCRIPTION OF THE INVENTION

[0023] Compound

[0024] In one embodiment, a compound having the chemical formula (I) is disclosed:

[0025]

[0026] in:

[0027] R1, R3, and R4 are each independently selected from hydrogen and methyl;

[0028] R2 is selected from hydrogen, methyl, and -CH2CH2OH;

[0029] n is 1 or 2;

[0030] R5 is selected from methyl, ethyl, and -CH2OR8;

[0031] R6 is selected from methyl, chloro, and fluoro;

[0032] R7 is selected from methyl, ethyl, and cyclopropyl; and

[0033] R8 is selected from methyl, ethyl and benzyl;

[0034] or a pharmaceutically acceptable salt thereof.

[0035] In some embodiments, each of R1-R4 is independently selected from hydrogen and methyl.

[0036] In some embodiments, R1, R3, and R4 are all hydrogen.

[0037] In some embodiments, n is 1.

[0038] In some embodiments, R5 is methyl or -CH2OR8.

[0039] In some embodiments, R6 is methyl or fluoro.

[0040] In some embodiments, R7 is methyl.

[0041] In some embodiments, R8 is methyl.

[0042] In at least one embodiment, R1, R3 and R4 are H; R2 is methyl; R6 is fluoro; R7 is methyl; R5 is -CH2OR8; and R8 is methyl.

[0043] In one embodiment, the compound of formula (I) is a compound of formula (la):

[0044]

[0045] in:

[0046] R 1a , R 3a , and R 4a are each independently selected from hydrogen and methyl;

[0047] R 2a is selected from hydrogen, methyl, and -CH2CH2OH;

[0048] n is 1 or 2:

[0049] R 5a Selected from methyl, ethyl, and -CH2OR 8a ;

[0050] R 6a is selected from methyl, chlorine, and fluorine;

[0051] R 7a is selected from methyl, ethyl, and cyclopropyl; and

[0052] R 8a is selected from methyl, ethyl and benzyl;

[0053] or a pharmaceutically acceptable salt thereof.

[0054] In some embodiments, R 1a -R 4a Each of is independently selected from hydrogen and methyl.

[0055] In some embodiments, R 1a , R 3a , and R 4a It's all hydrogen.

[0056] In some embodiments, n is 1.

[0057] In some embodiments, R 5a is methyl or -CH2OR 8a .

[0058] In some embodiments, R 6a It is methyl or fluorine.

[0059] In some embodiments, R 7a It's methyl.

[0060] In some embodiments, R 8a It's methyl.

[0061] In at least one embodiment, R 1a , R 3a and R 4a It is H; R 2a is methyl; R6a is fluorine; R 7a is methyl; R 5a Yes-CH2OR 8a ; and R 8a It's methyl.

[0062] In one embodiment, the compound of formula (I) is a compound of formula (Ib):

[0063]

[0064] in:

[0065] R 5b Selected from methyl, ethyl, and -CH2OR 8b ;

[0066] R 6b is selected from methyl, chlorine, and fluorine;

[0067] R 7b is selected from methyl, ethyl, and cyclopropyl; and

[0068] R 8b is selected from methyl, ethyl and benzyl;

[0069] or a pharmaceutically acceptable salt thereof.

[0070] In some embodiments, R 5b is methyl or -CH2OR 8b .

[0071] In some embodiments, R 6b It is methyl or fluorine.

[0072] In some embodiments, R 7b It's methyl.

[0073] In some embodiments, R 8b It's methyl.

[0074] In at least one embodiment, R 6b is fluorine; R 7b is methyl; R 5b Yes-CH2OR 8b ; and R 8b It's methyl.

[0075] In some embodiments, a compound of Table 1 or a pharmaceutical salt thereof is disclosed:

[0076] Table 1

[0077]

[0078]

[0079]

[0080]

[0081]

[0082]

[0083]

[0084]

[0085]

[0086]

[0087] The disclosed compounds of formula (I), (Ia), (Ib) or compounds of Table 1 can be prepared using the methods and processes described herein. In one aspect, the disclosed compounds of formula (I), (Ia), (Ib) or compounds of Table 1 are prepared according to the methods described in the Examples.

[0088] Compounds of formula (I), (Ia), (Ib) or compounds of Table 1 can exist in various stereoisomeric forms, and the present disclosure relates to each stereoisomeric form in which each compound may exist and mixtures thereof (including racemates). It should be understood that substituents may be attached at chiral centers of carbon atoms, and therefore, the disclosed compounds include enantiomers, diastereomers and racemates. The term "enantiomer" includes pairs of stereoisomers that are non-superimposable mirror images of each other. A 1:1 mixture of a pair of enantiomers is a racemic mixture. Where appropriate, the term is used to designate a racemic mixture. The term "diastereomer" or "enantiomer" includes stereoisomers that have at least two asymmetric atoms but are not mirror images of each other. Absolute stereochemistry is specified according to the Cahn-Ingold-Prelog RS system. When a compound is a pure enantiomer, the stereochemistry at each chiral center can be specified by R or S. For resolved compounds whose absolute configuration is unknown, they may be assigned (+) or (-) depending on the direction (right-handed or left-handed) in which they rotate plane polarized light at the wavelength of the sodium D line. To the extent that a structure or chemical name does not indicate chirality, the structure or name is intended to encompass any single stereoisomer corresponding to the structure or name, as well as any mixture of stereoisomers, including racemates.

[0089] The language "pharmaceutically acceptable salts" includes acid addition salts that retain the biological effectiveness and properties of the compounds of Formula (I), (Ia), (Ib) or Table 1. Pharmaceutically acceptable salts can be formed using inorganic or organic acids, for example, acetate, aspartate, benzoate, benzenesulfonate, bromide / hydrobromide, bicarbonate / carbonate, bisulfate / sulfate, camphorsulfonate, chloride / hydrochloride, chlortheophyllonate, citrate, ethandisulfonate, fumarate, glucoheptonate, gluconate, glucuronate, hippurate, hydroiodide / iodide, isethionate, lactate, lactobionate, lauryl salt, malate, maleate, malonate, mandelate, methanesulfonate, methylsulfate, naphthoate, naphthylate, nicotinate, nitrate, octadecanoate, oleate, oxalate, palmitate, palmoate, phosphate / hydrogenphosphate / dihydrogenphosphate, polygalacturonate, propionate, stearate, succinate, subsalicylate, tartrate, toluenesulfonate, and trifluoroacetate. Inorganic acids from which salts can be derived include, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like. Organic acids from which salts can be derived include, for example, acetic acid, propionic acid, glycolic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, toluenesulfonic acid, trifluoroacetic acid, sulfosalicylic acid, and the like.

[0090] Pharmaceutically acceptable salts of compounds of formula (I), (Ia), (Ib) or Table 1 can be synthesized from basic or acidic moieties by conventional chemical methods. Generally, such salts can be prepared by reacting the free acid form of these compounds with an appropriate base (e.g., Na + , Ca 2+ Mg 2+ , or K +The present invention relates to a method for preparing a salt of a pharmaceutical composition comprising reacting a stoichiometric amount of a compound of formula (I) or a stoichiometric amount of a free base form of a compound of formula (II) with an appropriate acid (hydroxyl, carbonate, bicarbonate, etc.) or with a stoichiometric amount of a free base form of the compound with an appropriate acid. Typically, such reactions are carried out in water or in an organic solvent or in a mixture of the two. Generally, where feasible, it is desirable to use a non-aqueous medium such as ether, ethyl acetate, ethanol, isopropanol, or acetonitrile. Additional lists of suitable salts can be found, for example, in "Remington's Pharmaceutical Sciences", 20th edition, Mack Publishing Company, Easton, Pennsylvania, (1985); Stahl and Wermuth, "Handbook of Pharmaceutical Salts: Properties, Selection, and Use" (Wiley-VCH, Weinheim, Germany, 2002).

[0091] Any formula given herein is also intended to represent unlabeled forms as well as isotopically labeled forms for compounds of formula (I), (Ia), (Ib) or Table 1. Isotopically labeled compounds have structures depicted by the formulas given herein except that one or more atoms are replaced by atoms having a selected atomic mass or mass number. Examples of isotopes that can be incorporated into compounds of formula (I), (Ia), (Ib) or Table 1 include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, fluorine and chlorine, such as 2 H. 3 H. 11 C. 13 C. 14 C. 15 N. 16 F. 31 P. 32 P. 35 S. 36 Cl and 125 I. Compounds of formula (I), (Ia), (Ib) or Table 1 may include various isotopically labeled compounds, wherein radioactive isotopes are present, such as 2 H. 3 H. 13 C and 14 C. Isotopically labeled compounds of Formula (I), (Ia), (Ib) or Table 1 can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described in the accompanying Examples using an appropriate isotopically labeled reagent in place of the non-labeled reagent previously employed.

[0092] Pharmaceutical composition

[0093] In at least one embodiment, the present disclosure includes pharmaceutical compositions comprising a compound of Formula (I), (Ia), (Ib) or Table 1, and a pharmaceutically acceptable excipient, carrier or diluent.

[0094] The language "pharmaceutically acceptable excipients, carriers or diluents" includes those compounds, materials, compositions, and / or dosage forms that are suitable for use in contact with human and animal tissues without excessive toxicity, irritation, allergic response, or other problems or complications, and with a commensurate reasonable benefit / risk ratio, within the scope of sound medical judgment. Pharmaceutically acceptable excipients, carriers and diluents are well known in the art, and any actual choice of pharmaceutically acceptable excipients, carriers and diluents depends on the intended use and method of administration of the pharmaceutical composition.

[0095] The disclosed compositions can be in a form suitable for oral use (e.g., as tablets, lozenges, hard or soft capsules, aqueous or oily suspensions, emulsions, dispersible powders or granules, syrups or elixirs), in a form suitable for topical use (e.g., as creams, ointments, gels, or aqueous or oily solutions or suspensions), in a form suitable for administration by inhalation (e.g., as finely divided powders or liquid aerosols), in a form suitable for administration by insufflation (e.g., as finely divided powders) or in a form suitable for parenteral administration (e.g., as sterile aqueous or oily solutions for intravenous, subcutaneous, intramuscular or intramuscular administration or as suppositories for rectal administration).

[0096] The disclosed compositions can be obtained by conventional procedures using conventional pharmaceutical excipients well known in the art. Thus, compositions intended for oral use may contain, for example, one or more coloring agents, sweetening agents, flavoring agents and / or preservatives.

[0097] Suitable pharmaceutically acceptable excipients for tablet formulations include, for example, inert diluents such as lactose, sodium carbonate, calcium phosphate or calcium carbonate; granulating and disintegrating agents such as corn starch or alginic acid; binders such as starch; lubricants such as magnesium stearate, stearic acid or talc; preservatives such as ethyl or propyl parabens; and antioxidants such as ascorbic acid. Tablet formulations may be uncoated or coated to modify their decomposition in the gastrointestinal tract and subsequent absorption of the active ingredient, or use conventional coating agents and procedures well known in the art to improve their stability and / or appearance.

[0098] Compositions for oral use may be in the form of hard capsules in which the active ingredient is mixed with an inert solid diluent (e.g., calcium carbonate, calcium phosphate or kaolin), or soft capsules in which the active ingredient is mixed with water or oil (e.g., peanut oil, liquid paraffin, or olive oil).

[0099] Aqueous suspensions generally contain the active ingredient in fine powder form or in the form of nano- or micronized particles, together with one or more suspending agents, for example sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose, sodium alginate, polyvinyl-pyrrolidone, gum tragacanth and gum arabic; a dispersant or wetting agent such as lecithin or a condensation product of an alkylene oxide with a fatty acid (for example polyoxyethylene stearate), or a condensation product of ethylene oxide with a long-chain fatty alcohol (for example heptadecaethyleneoxycetanol), or a condensation product of ethylene oxide with a partial ester derived from a fatty acid and a hexitol (for example polyoxyethylene sorbitan monooleate), or a condensation product of ethylene oxide with a long-chain fatty alcohol (for example heptadecaethyleneoxycetanol), or a condensation product of ethylene oxide with a partial ester derived from a fatty acid and a hexitol (for example polyoxyethylene sorbitan monooleate), or a condensation product of ethylene oxide with a partial ester derived from a fatty acid and a hexitol anhydride (for example polyethylene sorbitan monooleate). The aqueous suspensions may also contain one or more preservatives such as ethyl or propyl p-hydroxybenzoate; an antioxidant, such as ascorbic acid; a coloring agent; a flavoring agent; and / or a sweetening agent, such as sucrose, saccharin or aspartame.

[0100] Oily suspensions can be prepared by suspending the active ingredient in vegetable oils such as groundnut oil, olive oil, sesame oil or coconut oil or in mineral oils such as liquid paraffin. The oily suspension can also include thickeners, such as beeswax, hard paraffin or cetyl alcohol. Sweeteners (such as those listed above) and flavorings can be added to provide a palatable oral formulation. These compositions can be preserved by adding antioxidants (such as ascorbic acid).

[0101] Dispersible powders and granules suitable for preparing aqueous suspensions by adding water generally comprise the active ingredient together with a dispersant or wetting agent, a suspending agent and one or more preservatives. Suitable dispersants or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients (such as sweeteners, flavorings and coloring agents) may also be present.

[0102] These pharmaceutical compositions can also be in the form of oil-in-water emulsions. The oily phase can be a vegetable oil (such as olive oil or groundnut oil) or a mineral oil (such as liquid paraffin) or a mixture of any of these. Suitable emulsifiers can be, for example, naturally occurring gums (such as gum arabic or tragacanth), naturally occurring phosphatides (such as soybeans, lecithin), esters derived from fatty acids and hexitol anhydrides or partial esters (such as sorbitan monooleate) and condensation products of the partial esters and ethylene oxide such as polyoxyethylene sorbitan monooleate. These emulsions can also include sweeteners, flavorings and preservatives.

[0103] The pharmaceutical composition can also be in the form of a sterile injectable aqueous or oily suspension, which can be prepared according to known procedures using one or more of the above-mentioned appropriate dispersants or wetting agents and suspending agents. The sterile injectable preparation can also be a sterile injectable solution or suspension in a non-toxic, parenterally acceptable diluent or solvent (e.g., 1,3-butanediol solution).

[0104] Compositions for administration by inhalation and / or insufflation may be in the form of conventional pressurized aerosols, arranged to dispense the active ingredient as either an aerosol or liquid droplets containing finely dispersed solids. Conventional aerosol propellants such as volatile fluorinated hydrocarbons may be used and the aerosol device conveniently arranged to dispense a metered amount of the active ingredient. For further information on formulations, the reader is referred to the Comprehensive Medicinal Chemistry database (Corwin Hansch, ed.), Vol. 5, Chapter 25.2, Pergamon Press, 1990.

[0105] The amount of active ingredient combined with one or more excipients to produce a single dosage form will necessarily vary, depending on the subject being treated and the particular route of administration. For further information on routes of administration and dosing regimens, the reader is referred to Comprehensive Medicinal Chemistry (Corwin Hansch; ed.), Volume 5, Chapter 25.3, Pergamon Press, 1990. Depending on the potency and physical characteristics of, for example, the compound of formula (I), (Ia), (Ib) or Table 1, or a pharmaceutically acceptable salt thereof (i.e., the active ingredient), pharmaceutical compositions that may be mentioned include those in which the active ingredient is present in at least 1% (or at least 10%, at least 30%, or at least 50% by weight). That is, the ratio of the active ingredient to the other components (i.e., additions of excipients, carriers, and diluents) of the pharmaceutical composition is at least 1:99 (or at least 10:90, at least 30:70, or at least 50:50 by weight).

[0106] The compounds of formula (I), (Ia), (Ib) or Table 1 and pharmaceutically acceptable salts thereof can be administered once, twice, three times a day or as often as medically necessary over a 24 hour period. One skilled in the art will readily be able to determine the amount of each individual dose based on the subject. In some embodiments, the compounds of formula (I), (Ia), (Ib) or Table 1 and pharmaceutically acceptable salts thereof are administered in one dosage form, or in some embodiments in multiple dosage forms.

[0107] method

[0108] Compounds of formula (I), (Ia), (Ib) or Table 1 and pharmaceutically acceptable salts thereof can inhibit JAK1 kinase and related protein activities associated with JAK1 kinase, such as can be shown in the following illustrative tests, and are therefore useful for treating those disorders where such inhibition is desired and / or required. Thus, compounds of formula (I), (Ia), (Ib) or Table 1 and pharmaceutically acceptable salts thereof can be used to treat those disorders where inhibition or reduction of JAK1 kinase is desired and / or required, or in some embodiments, where inhibition or reduction of protein activities associated with JAK1 kinase is desired and / or required. It is therefore contemplated that compounds of formula (I), (Ia), (Ib) or Table 1 and pharmaceutically acceptable salts thereof can be used to treat disorders that can benefit from inhibition of JAK1 kinase, such as respiratory diseases / disorders and / or inflammation and / or diseases with an inflammatory component.

[0109] Therefore, in at least one embodiment, methods of inhibiting JAK1 kinase in a subject are also disclosed, comprising administering to the subject an effective amount of a compound of Formula (I), (Ia), (Ib) or Table 1 or a pharmaceutically acceptable salt thereof.

[0110] In another embodiment, disclosed is a use of a compound of Formula (I), (Ia), (Ib) or Table 1 or a pharmaceutically acceptable salt thereof for inhibiting JAK1 kinase.

[0111] In another embodiment, disclosed is the use of a compound of Formula (I), (Ia), (Ib) or Table 1, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for inhibiting JAK1 kinase.

[0112] In yet another embodiment, pharmaceutical compositions are disclosed, comprising a compound of Formula (I), (Ia), (Ib) or Table 1, or a pharmaceutically acceptable salt thereof, for inhibiting JAK1 kinase.

[0113] In at least one embodiment of the present disclosure, the compound of Formula (I), (Ia), (Ib) or Table 1, or a pharmaceutically acceptable salt thereof, exhibits a JAK1 enzyme inhibitory activity (IC) of less than or equal to about 0.010 micromolar at a physiological ATP concentration of 5 mM. 50 In at least one other embodiment, the compound of Formula (I), (Ia), (Ib) or Table 1, or a pharmaceutically acceptable salt thereof, exhibits an inhibitory activity (IC) of less than or equal to about 0.050 micromolar in a cellular IL-13-induced JAK-STAT6-luciferase assay. 50 ).

[0114] In one embodiment of the present disclosure, the compound of Formula (I), (Ia), (Ib) or Table 1, or a pharmaceutically acceptable salt thereof, exhibits a JAK1 enzyme inhibitory activity (IC) of less than or equal to about 0.010 micromolar at a physiological ATP concentration of 5 mM. 50 ), and exhibited JAK2 and JAK3 enzyme inhibitory activity (IC) greater than or equal to about 0.5 micromolar at a physiological ATP concentration of 5 mM. 50 In at least one other embodiment, the compound of Formula (I), (Ia), (Ib) or Table 1, or a pharmaceutically acceptable salt thereof, exhibits a JAK1 enzyme inhibitory activity (IC) of less than or equal to about 0.010 micromolar at a physiological ATP concentration of 5 mM. 50 ), and exhibited JAK2 and JAK3 enzyme inhibitory activity (IC) greater than or equal to about 0.5 micromolar at a physiological ATP concentration of 5 mM. 50 ), and exhibited an inhibitory activity (IC 50 ).

[0115] In another embodiment, methods of treating JAK1-related disorders are disclosed, comprising administering to a subject an effective amount of a compound of Formula (I), (Ia), (Ib) or Table 1 or a pharmaceutically acceptable salt thereof.

[0116] In another embodiment, disclosed is a use of a compound of Formula (I), (Ia), (Ib) or Table 1 for treating a JAK1-related disorder, comprising administering to a subject an effective amount of a compound of Formula (I), (Ia), (Ib) or Table 1 or a pharmaceutically acceptable salt thereof.

[0117] In another embodiment, disclosed is a use of a compound of Formula (I), (Ia), (Ib) or Table 1, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament or formulation for treating a JAK1-related disorder.

[0118] In another embodiment, disclosed is a use of a compound of Formula (I), (Ia), (Ib) or Table 1, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating a JAK-related disorder.

[0119] In another embodiment, pharmaceutical compositions are disclosed, comprising a compound of Formula (I), (Ia), (Ib) or Table 1, or a pharmaceutically acceptable salt thereof, for use in treating a JAK1-related disorder.

[0120] According to the present disclosure, the term "JAK1-associated disorder" includes, for example, type 1 diabetes, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis, asthma, atopic dermatitis, autoimmune thyroid disease, ulcerative colitis, Crohn's disease, COPD, vitiligo, and alopecia areata.

[0121] Compounds with chemical formula (I), (Ia), (Ib) or Table 1 and pharmaceutically acceptable salts thereof can be administered in different dosages, depending on the route of administration. For example, oral doses can be between about 0.01 mg / kg body weight / day (mg / kg / day) to about 100 mg / kg / day, for example, between about 0.01 to about 20 mg / kg / day, for example, about 1.0 to about 15 mg / kg / day, for example, about 12.5 mg / kg / day. During constant rate infusion, intravenous dose ranges can be from about 0.5 mg / kg / day to about 50 mg / kg / day. Inhaled doses can be from about 0.0001 mg / kg / day to about 0.10000 mg / kg / day, for example, from about 0.0001 mg / kg / day to about 0.001 mg / kg / day, for example, in the range of about 0.0006 mg / kg / day. Inhaled doses can also vary according to the delivery device used. For example, the inhaled dosage range via a dry powder inhaler device may be between about 0.010 mg / kg / day to about 0.020 mg / kg / day.

[0122] In any case, the physician or technician will be able to determine the most appropriate actual dosage for an individual patient, which may vary with the route of administration, the type and severity of the condition to be treated, as well as the species, age, weight, sex, renal function, liver function and the response of the patient to be specifically treated. The above dosages are examples of average situations; there may of course be individual situations where higher or lower dosage ranges are advantageous, and these are within the scope of the present invention.

[0123] As used herein, the term "effective amount" includes an amount of a compound of Formula (I), (Ia), (Ib) or Table 1, or a pharmaceutically acceptable salt thereof, that will cause a biological or medical response in a subject, such as reducing or inhibiting the activity of an enzyme or protein associated with JAK1 and / or improving the symptoms of a JAK1-related disorder and / or slowing or delaying the progression of a JAK1-related disorder. This effect can be objective (i.e., measurable by some test or marker) or subjective (i.e., the subject gives or feels an indication of the effect).

[0124] The term "subject" includes warm-blooded mammals, e.g., primates, cattle, pigs, sheep, dogs, cats, rabbits, rats, and mice. In some embodiments, the subject is a primate, e.g., a human. In some embodiments, the subject suffers from a JAK1-related disorder. In some embodiments, the subject is in need of treatment (e.g., the subject will benefit from a biological or medical treatment).

[0125] The language "inhibit," "inhibition," or "inhibiting" includes a decrease in the baseline activity of a biological activity or process. In some embodiments, a compound of Formula (I), (Ia), (Ib), or Table 1, or a pharmaceutically acceptable salt thereof, inhibits JAK1 kinase. In some embodiments, a compound of Formula (I), (Ia), (Ib), or Table 1, or a pharmaceutically acceptable salt thereof, is a selective JAK1 inhibitor. The language "selective JAK1 inhibitor" includes a compound of Formula (I), (Ia), (Ib), or Table 1, or a pharmaceutically acceptable salt thereof, that inhibits JAK1 but is inactive or less active against JAK2 or JAK3 or against both JAK2 and JAK3. Thus, in some embodiments, a compound of Formula (I), (Ia), (Ib), or Table 1, or a pharmaceutically acceptable salt thereof, inhibits JAK1 kinase but is inactive or less active against JAK2 or JAK3 or against both JAK2 and JAK3. For example, the compound of Formula (I), (Ia), (Ib) or Table 1, or a pharmaceutically acceptable salt thereof, exhibits a JAK1 enzyme inhibitory activity (IC) of less than or equal to about 0.010 micromolar at a physiological ATP concentration of 5 mM. 50 ), and exhibited JAK2 and JAK3 enzyme inhibitory activity (IC) greater than or equal to about 0.5 micromolar at a physiological ATP concentration of 5 mM. 50 In at least one other embodiment, the compound of Formula (I), (Ia), (Ib) or Table 1, or a pharmaceutically acceptable salt thereof, exhibits a JAK1 enzyme inhibitory activity (IC) of less than or equal to about 0.010 micromolar at a physiological ATP concentration of 5 mM. 50), and exhibited JAK2 and JAK3 enzyme inhibitory activity (IC) greater than or equal to about 0.5 micromolar at a physiological ATP concentration of 5 mM. 50 ), and exhibited an inhibitory activity (IC50) of less than or equal to about 0.050 micromolar in a cellular IL-13-induced JAK-STAT6-luciferase assay.

[0126] The language "treat", "treating" and "treatment" includes reducing or inhibiting the activity of an enzyme or protein associated with JAK1 kinase in a subject, improving one or more symptoms of a JAK1-related disorder in a subject, or slowing or delaying the progression of a JAK1-related disorder in a subject. Therefore, the compounds of Formula (I), (Ia), (Ib) or Table 1, or pharmaceutically acceptable salts thereof, are indicated for therapeutic and / or prophylactic treatment of the above-mentioned conditions.

[0127] Examples

[0128] Compounds of Formula (I), (Ia), (Ib) or Table 1, and pharmaceutically acceptable salts thereof, can be prepared using the methods and procedures described herein or using similar methods and procedures. It should be understood that where typical or exemplary process conditions (i.e., reaction temperature, time, molar ratio of reactants, solvent, pressure, etc.) are given, other process conditions may also be used unless otherwise stated. Optimal reaction conditions may vary with the specific reactants or solvents used, but such conditions can be determined by those skilled in the art.

[0129] In addition, it will be apparent to those skilled in the art that conventional protecting groups may be necessary to prevent certain functional groups from undesirable reactions. The selection of suitable protecting groups for specific functional groups and suitable protection and deprotection conditions are well known in the art. For example, TW Greene and GM Wuts, Protecting Groups in Organic Synthesis, 3rd edition, Wiley, New York, 1999 and references cited therein describe many protecting groups and their introduction and removal. A method for preparing the compounds of the invention is provided as a further embodiment of the invention and is illustrated by the following procedure. The stereochemical assignment of the separated enantiomers is based on the biological activity of JAK1 in enzyme inhibition studies, as shown in Table 17.

[0130] Intermediate 1: 7-nitro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-toluenesulfonyl-1H-indole

[0131] Step 1

[0132] At 25 ℃, under air, a solution of NaOH (599g, 14986.55mmol) in water (1500mL) was added dropwise to a mixture of 7-nitro-1H-indole (243g, 1498.65mmol) and tetrabutylammonium hydrogen sulfate (50.9g, 149.87mmol) in DCM (3000mL) over a period of 5 minutes. The resulting mixture was stirred for 20 minutes at 25 ℃. 4-methylphenylsulfonyl chloride (371g, 1948.25mmol) was added under air, and the resulting mixture was stirred for 16 hours at 25 ℃. The reaction mixture was diluted with DCM (2000mL), and washed with water (2x500mL), 10% aqueous KCO (2x500mL) and 1M HCl (2x500mL) and saturated NaCl (2x500mL) in sequence. The organic layer was dried over Na2SO4, filtered and evaporated. When about 200 mL of DCM was left, EtOAc (500 mL) was added. The solvent was removed under reduced pressure. When about 200 mL of EtOAc was left, MTBE (1000 mL) was added. The precipitate was collected by filtration, washed with MTBE (1000 mL) and dried under vacuum to give 7-nitro-1-tosyl-1H-indole (402 g, 85%) as a white solid.

[0133] 1 H NMR (300MHz, DMSO-d6) δ2.39 (s, 3H), 7.09 (d, 1H), 7.40-7.55 (m, 3H), 7.75-7.85 (m, 3H), 7.95-8.00 (m, 1H), 8.06 (d, 1H).

[0134] m / z(ES+), [M+H] + =317.

[0135] Step 2

[0136] Bromine (81 mL, 1580 mmol) was added dropwise to 7-nitro-1-tosyl-1H-indole (50 g, 158 mmol) in CCl4 (1000 mL) at 80° C. The resulting solution was stirred at 80° C. for 6 hours. The mixture was cooled to room temperature, concentrated in vacuo, and the residue was washed with EtOAc to give 3-bromo-7-nitro-1-tosyl-1H-indole (53 g, 85%) as a brown solid.

[0137] 1H NMR (300MHz, DMSO-d6) δ2.41 (s, 3H), 7.55-7.62 (m, 2H), 7.57 (t, 1H), 7.85-7.92 (m, 3H), 7.96 (d, 1H), 8.49 (s, 1H).

[0138] m / z(ES-), [MH] + =393.

[0139] Step 3

[0140] A solution of 3-bromo-7-nitro-1-tosyl-1H-indole (200 g, 506 mmol), 4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-di(1,3,2-dioxaborolane) (193 g, 759 mmol), potassium acetate (99 g, 1012 mmol) and PdCl2(dppf) (18.5 g, 25.3 mmol) in 1,4-dioxane (1500 mL) was degassed 3 times with nitrogen and the reaction mixture was stirred at 90° C. for 8 hours. The mixture was cooled to room temperature and concentrated in vacuo. The solid was treated with water, filtered, washed with methanol and dried in vacuo to give 7-nitro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-tosyl-1H-indole (150 g, 67%) as a grey solid.

[0141] 1 H NMR (400MHz, CDCl3) δ1.41 (s, 12H), 2.47 (s, 3H), 7.38-7.43 (m, 3H), 7.66 (d, 1H), 7.87 (d, 2H), 8.24 (s, 1H), 8.29-8.32 (d, 1H).m / z (ES+), [M+H] + =443.

[0142] Intermediate 2: 3-(2-chloro-5-methylpyrimidin-4-yl)-7-nitro-1-toluenesulfonyl-1H-indole

[0143] 7-Nitro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-tosyl-1H-indole, Intermediate 1 (50 g, 113 mmol) was charged into a 1 L reactor equipped with a condenser and a nitrogen inlet. 2,4-Dichloro-5-methylpyrimidine (24 g, 147 mmol) and 2-methyltetrahydrofuran (200 mL, 4 volumes) were added to the reactor. A solution of potassium carbonate (46.9 g, 339 mmol) in water (10 mL, 2 volumes) was degassed and backfilled with N2 and added to the reaction mixture. The reactor is degassed and backfilled (3xN2), dichloro [1,1 '-bis (diphenylphosphino) ferrocene] palladium dichloromethane adduct (4.62g, 5.65mmol) is added to the reaction mixture, degassed and backfilled (3x) with N2 again and then the reaction is slowly heated to 60 ℃. A precipitate is formed after 30 minutes. The reaction is stirred for 1 hour, and the reactor temperature is set to 25 ℃. After cooling for 30 minutes, the internal temperature is 42 ℃ and heptane (1 volume) is added. The reactor temperature is then set to +5 ℃. At 20 ℃, water (4 volumes) is added and continued to cool to +5 ℃ in 1 hour, and then stirred for 2 hours. The reaction mixture is filtered with a Buchner funnel, and the solid is washed with water (4 volumes) and EtOAc (2 volumes) to obtain a light yellow solid, which is dried under a stream of nitrogen. The solid is stirred, filtered and the resulting solid is vacuum dried in EtOAc (1 volume) to obtain (42.8g). The mother liquors were combined and evaporated in vacuo to give (20 g). 700 g of silica slurried in heptane was filled on a column (10 × 300 mm). The solid was dissolved in DCM, combined and loaded onto the column. After DCM was completely eluted, the column was eluted with 20% EtOAc in heptane, followed by a 20%-50% EtOAc gradient elution in heptane. The desired compound was combined and evaporated in vacuo. The residue was slurried in 50% EtOAc in heptane (0.5 volume), filtered and dried under a stream of nitrogen to give 3-(2-chloro-5-methylpyrimidin-4-yl)-7-nitro-1-tosyl-1H-indole (35.6 g, 71%) as a solid.

[0144] 1 H NMR (400MHz, DMSO-d6) δ2.40 (s, 3H), 2.44 (s, 3H), 7.54 (d, 2H), 7.61 (t, 1H ), 7.91(d, 2H), 7.95-8.04(m, 1H), 8.40(dd, 1H), 8.62(s, 1H), 8.79(s, 1H).

[0145] m / z(ES+), [M+H] + =442.9.

[0146] Intermediate 3: 3-(2-chloro-5-methylpyrimidin-4-yl)-7-nitro-1H-indole

[0147] 3-(2-Chloro-5-methylpyrimidin-4-yl)-7-nitro-1-tosyl-1H-indole, intermediate 2 (2.477 g, 5.59 mmol) was dissolved in 1,4-dioxane / water 2:1 (75 mL) and 3.8 M sodium hydroxide (22 mL, 83.9 mmol) was added. The resulting reaction mixture was heated to 50° C. for 2 h. The reaction mixture was cooled to room temperature and neutralized by the addition of 2 M HCl. The solid formed was filtered off, washed with EtOAc, Et2O and dried in vacuo to give 3-(2-chloro-5-methylpyrimidin-4-yl)-7-nitro-1H-indole (1.894 g, 117% (wet)) as a solid.

[0148] 1 H NMR (500MHz, DMSO-d6) δ2.52 (s, 3H), 7.47 (t, 1H), 8.20 (d, 1H), 8.25 (d, 1H), 8.63 (s, 1H), 8.90 (d, 1H), 12.66 (s, 1H).m / z (ES+), [M+H] + =289.2.

[0149] Intermediate 4: 3-(2,5-dichloropyrimidin-4-yl)-7-nitro-1H-indole

[0150] Step 1

[0151] PdCl2(dppf)*CH2Cl2 (0.554 g, 0.68 mmol) was added to 7-nitro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-tosyl-1H-indole, intermediate 1 (3.00 g, 6.78 mmol), 2,4,5-trichloropyrimidine (1.617 g, 8.82 mmol) and K2CO3 (2.81 g, 20.35 mmol) in THF / water 4:1 (75 mL) at 25°C under nitrogen. The resulting mixture was stirred at 80°C for 4 hours. The reaction mixture was cooled to room temperature, diluted with EtOAc (150 mL) and washed with brine (150 mL). The organic layer was dried over Na2SO4, filtered and evaporated in vacuo. The residue was purified by flash silica chromatography using a gradient of 8% to 30% EtOAc in petroleum ether as mobile phase. Pure fractions were evaporated in vacuo and the residue was crystallized from acetonitrile to give 1-((4-chlorophenyl)sulfonyl)-3-(2,5-dichloropyrimidin-4-yl)-7-nitro-1H-indole (1.43 g, 43.4%) as a white solid.

[0152] 1 H NMR (300MHz, DMSO-d6) δ2.42 (s, 3H), 7.52 (d, 2H), 7.66 (t, 1H), 7.91-8.14 (m, 3H), 8.52 (dd, 1H), 8.90 (s, 1H), 9.08 (s, 1H).

[0153] m / z(ES+), [M+H] + =463.

[0154] Step 2

[0155] A solution of NaOH (2.202 g, 55.05 mmol) in water (30 mL) was added to a stirred suspension of 3-(2,5-dichloropyrimidin-4-yl)-7-nitro-1-tosyl-1H-indole (1.7 g, 3.67 mmol) in 1,4-dioxane (30 mL) at 25°C. The resulting mixture was stirred at 50°C for 1 hour and then cooled to room temperature. The reaction mixture was diluted with EtOAc (200 mL), washed with water (50 mL), saturated NaHCO (50 mL), brine (50 mL). The organic layer was dried over NaSO, filtered and evaporated in vacuo to give 3-(2,5-dichloropyrimidin-4-yl)-7-nitro-1H-indole, (0.500 g, 44.1%) as a yellow solid.

[0156] 1 H NMR (300MHz, DMSO-d6) δ7.34 (t, 1H), 8.06 (dd, 1H), 8.67 (s, 1H), 8.78 (s, 1H), 8.87 (dd, 1H).

[0157] m / z(ES+), [M+H] + =309.

[0158] Intermediate 5: 2-Fluoro-3-(methylsulfonyl)aniline

[0159] Step 1

[0160] At 25 ℃ under nitrogen in the time of 1 minute, cuprous iodide (I) (1.002g, 5.26mmol) is added to 3-bromo-2-fluoroaniline (5g, 26.31mmol), N1, N2-dimethylethane-1,2-diamine (0.464g, 5.26mmol) and sodium iodide (7.89g, 52.63mmol) in 1,4-dioxane (10mL) at one time. The resulting suspension is stirred at 110 ℃ for 1 day. The reaction mixture is filtered through diatomite and concentrated in vacuo. The crude product is purified by rapid silica chromatography, using the 5%-30%EtOAc gradient in petroleum ether as mobile phase. Pure fractions are evaporated in a vacuum, and 2-fluoro-3-iodoaniline (5.00g, 80%) is obtained, which is a brown oil.

[0161] 1 H NMR (400MHz, DMSO-d6) δ5.32 (bs, 2H), 6.59-6.83 (m, 2H), 6.83-6.93 (m, 1H).

[0162] m / z(ES+), [M+H] + =238.

[0163] Step 2

[0164] Copper (I) iodide (0.402 g, 2.11 mmol) was added to 2-fluoro-3-iodoaniline (5.00 g, 21.10 mmol), sodium methanesulfinate (3.23 g, 31.64 mmol), N1, N2-dimethylethane-1,2-diamine (0.558 g, 6.33 mmol) in DMSO (20 mL) under nitrogen. The resulting suspension was stirred at 95 ° C for 18 hours. The reaction mixture was diluted with EtOAc (50 mL), washed with water (50 mL) and brine (50 mL). The organic layer was dried over Na2SO4, filtered and evaporated in vacuo. The residue was purified by preparative TLC using EtOAc / petroleum ether 1: 1 to give 2-fluoro-3-(methylsulfonyl)aniline (3.20 g, 80%) as a colorless oil, which solidified upon standing.

[0165] 1 H NMR (400MHz, CDCl3) δ3.20 (s, 3H), 3.96 (bs, 2H), 6.97-7.13 (m, 2H), 7.20-7.31 (m, 1H).m / z (ES+), [M+H] + =190.

[0166] Repeating the above process with the indicated sulfinates gave intermediates 6 described in Table 2:

[0167] Table 2

[0168]

[0169] Intermediate 7: (3-bromo-2-fluorophenyl)(ethyl)sulfane

[0170] At -78 ℃ under nitrogen for 10 minutes, lithium diisopropylamide (17.14mL, 34.29mmol) was added dropwise to 1-bromo-2-fluorobenzene (5.00g, 28.57mmol) in THF (250mL). The resulting mixture was stirred at -78 ℃ for 60 minutes. It took 20 minutes to drop 1,2-diethyl disulfane (5.20g, 42.54mmol). The resulting mixture was stirred at -78 ℃ for 60 minutes, then at room temperature overnight. The reaction mixture was quenched with water (50mL), and extracted with EtOAc (2x250mL). The organic extracts merged were dried with Na2SO4, filtered and evaporated in vacuo. By rapid silica chromatography, 0-10% EtOAc gradient in pentane was used as eluent to purify the residue. Pure fractions were evaporated in vacuo to afford (3-bromo-2-fluorophenyl)(ethyl)sulfane (5.27 g, 78%) as a colorless oil.

[0171] 1 H NMR (300MHz, CDCl3) 1.32 (t, 3H), 2.95 (q, 2H), 6.90-7.04 (m, 1H), 7.22-7.34 (m, 1H), 7.35-7.47 (m, 1H).

[0172] Intermediate 8: tert-Butyl (3-(ethylthio)-2-fluorophenyl)carbamate

[0173] At 25 ℃ under nitrogen by (3-bromo-2-fluorophenyl) (ethyl) sulfane, intermediate 7 (4.14g, 17.61mmol) was added to cyclohexane-1,2-diamine (6.03g, 52.82mmol), potassium phosphate (3.74g, 17.61mmol), cuprous (I) iodide (8.38g, 44.02mmol) and tert-butyl carbamate (10.31g, 88.04mmol) in 1,4-dioxane (80mL) at one time. The resulting mixture was stirred at 100 ℃ for 6 hours and then cooled to room temperature. The reaction mixture was filtered and evaporated in vacuo. The residue was purified by flash silica chromatography using a gradient of 0-10% EtOAc in pentane. The pure fraction was evaporated in vacuo to give tert-butyl (3-(ethylthio)-2-fluorophenyl) carbamate (1.412g, 29.6%) as a yellow oil.

[0174] 1 H NMR (400MHz, CDCl3) δ1.31 (t, 3H), 1.55 (s, 9H), 2.94 (q, 2H), 6.73 (bs, 1H), 6.91-7.19 (m, 2H), 7.92-8.05 (m, 1H).

[0175] Intermediate 9: tert-Butyl (3-(ethylsulfonyl)-2-fluorophenyl)carbamate

[0176] Tert-butyl (3- (ethylthio) -2-fluorophenyl) carbamate, intermediate 8 (1.4 g, 5.16 mmol) was added to 3-chlorobenzene-1-carboperoxy acid (2.67 g, 15.48 mmol) in DCM (15 mL) at 0 ° C and nitrogen. The resulting mixture was stirred at room temperature for 16 hours. The reaction mixture was diluted with DCM (50 mL), filtered, and washed with saturated NaHCO (2×50 mL) and brine (50 mL). The organic layer was dried over Na SO, filtered and evaporated in vacuo. The residue was purified by preparative TLC developed with petroleum ether / EtOAc 3: 1 to provide tert-butyl (3- (ethylsulfonyl) -2-fluorophenyl) carbamate, (1.650 g, 105%) as a yellow oil. m / z (ES-), [MH] + =302.

[0177] Intermediate 10: 3-(Ethylsulfonyl)-2-fluoroaniline

[0178] 2,2,2-Trifluoroacetic acid (10.0 g, 87.70 mmol) was added to tert-butyl (3-(ethylsulfonyl)-2-fluorophenyl) carbamate, intermediate 9 (1.65 g, 5.44 mmol) in DCM (20 mL) at 20°C. The resulting mixture was stirred at 25°C for 1 hour. The reaction mixture was evaporated in vacuo, redissolved in DCM (50 mL), washed with saturated NaHCO (2 x 100 mL) and brine (100 mL). The organic layer was dried over NaSO, filtered and evaporated in vacuo to provide 3-(ethylsulfonyl)-2-fluoroaniline (0.786 g, 71.1%) as a yellow oil.

[0179] 1 H NMR δ (CDCl3, 400MHz) δ1.32 (t, 3H), 3.32 (q, 2H), 3.60-4.10 (bs, 2H), 7.00-7.17 (m, 2H), 7.17-7.34 (m, 1H).m / z (ES+), [M+H] + =204.

[0180] Intermediate 11: 3-(2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)-5-methylpyrimidin-4-yl)-1H-indol-7-amine

[0181] Step 1

[0182] 3-(2-Chloro-5-methylpyrimidin-4-yl)-7-nitro-1-toluenesulfonyl-1H-indole, intermediate 2 (20.0 g, 45.16 mmol), 2-fluoro-3-(methylsulfonyl)aniline hydrochloride, intermediate 5 (11.2 g, 49.68 mmol), cesium carbonate (30.9 g, 94.8 mmol), Pd2(dba)3 (4.14 g, 4.52 mmol) and 2'-(dicyclohexylphosphino)-N, N-dimethyl-[1,1'-biphenyl]2-amine (3.55 g, 9.03 mmol) were charged to a 1 L reactor under nitrogen. 2-Methyltetrahydrofuran (200 mL) and water (100 mL) were added at room temperature. The reaction was evacuated and backfilled with N2 (3x), and then heated to 72.5°C (T r =80°C) and stirred for 4 hours (a brown precipitate formed after 3 hours). Heptane (400 mL, 20 vol) was added, heating was stopped and the reaction was cooled to 17°C over 30 minutes. The precipitate was stirred for 10 minutes and then filtered on a Buchner funnel. The filter cake was washed with water (2 vol x 3), EtOAc / heptane 1:2 (3 vol x 3), and then dried under vacuum / nitrogen to provide N-(2-fluoro-3-(methylsulfonyl)phenyl)-5-methyl-4-(7-nitro-1-tosyl-1H-indol-3-yl)pyrimidin-2-amine (25.93 g, 96%) as a brown solid. Proceed without further purification. m / z (ES+), [M+H] + =596.2.

[0183] Step 2

[0184] In a 1 L reactor, 3-(2-chloro-5-methylpyrimidin-4-yl)-7-nitro-1-tosyl-1H-indole (27.0 g, 45.3 mmol) was charged at room temperature, 2-methyltetrahydrofuran (250 mL) and 3.8 M NaOH (aqueous) (250 mL) were added to give a brown insoluble mixture. The mixture was heated to 85 ° C and stirred overnight. Heptane (10 vol) was charged into the reaction mixture, cooled to 17 ° C in 40 min and stirred for 30 min. The solid was filtered with a Buchner funnel, and the filter cake was washed with water (3x40 mL), and the water wash pH was determined to be 10-11 with pH paper. 40 mL of water was added to the filter cake and slurried while adjusting the pH to 7 with 0.5 N HCl. The solid was filtered again with a Buchner funnel, washed with water (50 mL), dried under nitrogen / vacuum for 20 min, and then washed with heptane / EtOAc (4×40 mL). (45% unreacted starting material was found by LCMS, and the compound was reacted again under the same conditions). The solid was charged into a 1L reactor, and 2-methyltetrahydrofuran (250 mL) and 3.8M NaOH (aqueous) (250 mL) were added to give a brown insoluble mixture. The mixture was heated to 85°C and stirred overnight. Heptane (10 vol) was charged into the reaction mixture, cooled to 17°C in 40 min and stirred for 30 min. The solid was filtered with a Buchner funnel, and the filter cake was washed with water (3×40 mL), and the water wash pH value: pH paper was 10-11. 40 mL of water was added to the filter cake and slurried, while adjusting the pH to 7 with 0.5N HCl. The solid was filtered again with a Buchner funnel, washed with water (50 mL), dried under nitrogen / vacuum for 20 min, and then washed with heptane / EtOAc (4×40 mL) and dried to provide N-(2-fluoro-3-(methylsulfonyl)phenyl)-5-methyl-4-(7-nitro-1H-indol-3-yl)pyrimidin-2-amine (20.0 g, 100%).

[0185] m / z(ES+), [M+H] + =442.1.

[0186] Step 3

[0187] N-(2-Fluoro-3-(methylsulfonyl)phenyl)-5-methyl-4-(7-nitro-1H-indol-3-yl)pyrimidin-2-amine (11.0 g, 24.9 mmol) was charged into a 1 L reactor and 2-methyltetrahydrofuran / EtOH 2:1 (330 mL) was added. The reactor was heated to 80° C., stirred for 10 min to obtain dissolution, and then slowly cooled to 30° C. 10% Pd—C (2.00 g, 24.9 mmol, 50% humidity) and ammonium formate (9.43 g, 149.5 mmol) solution in water (10 mL) (absorbent) were added at room temperature and nitrogen. The reaction mixture was slowly heated to 80° C. and stirred for 15 min. It was then cooled to 40-50°C, filtered on a Buchner funnel under nitrogen (caution), the filter cake was washed with hot THF / EtOH 1:1 (50 mL), the filtrate was concentrated and evaporated under vacuum with DCM (50 mL) to afford 3-(2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)-5-methylpyrimidin-4-yl)-1H-indol-7-amine 10.0 g, 98%) as a brown solid.

[0188] m / z(ES+), [M+H] + =412.4.

[0189] Intermediate 12: N-(3-(ethylsulfonyl)-2-fluorophenyl)-5-methyl-4-(7-nitro-1H-indol-3-yl)pyrimidin-2-amine

[0190] Pd2(dba)3 (159 mg, 0.17 mmol) and 2'-(dicyclohexylphosphino)-N,N-dimethyl-[1,1'-biphenyl]-2-amine (136 mg, 0.35 mmol) were added to 3-(2-chloro-5-methylpyrimidin-4-yl)-7-nitro-1H-indole, intermediate 3 (500 mg, 1.73 mmol), 3-(ethylsulfonyl)-2-fluoroaniline, intermediate 10 (352 mg, 1.73 mmol) and cesium carbonate (1693 mg, 5.20 mmol) in DMF (15 mL) at 23° C. under nitrogen. The resulting solution was stirred at 80° C. for 3 hours. The reaction mixture was filtered through celite and the solvent was evaporated under vacuum to provide N-(3-(ethylsulfonyl)-2-fluorophenyl)-5-methyl-4-(7-nitro-1H-indol-3-yl)pyrimidin-2-amine (1.22 g, 155%) as a black solid. Used without further purification. m / z (ES+), [M+H] + =456.

[0191] The above process was repeated using the indicated starting intermediates to give intermediates 13-14 as described in Table 3:

[0192] Table 3

[0193]

[0194] a The reaction mixture was concentrated in vacuo.

[0195] b The reaction mixture was diluted with EtOAc (200 mL), washed with water (50 mL) and brine (200 mL). The organic layer was dried over Na2SO4, filtered and evaporated in vacuo. The residue was purified by preparative TLC using DCM / MeOH 5:1 as eluent.

[0196] Intermediate 15: 3-(2-((3-(ethylsulfonyl)-2-fluorophenyl)amino)-5-methylpyrimidin-4-yl)-1H-indol-7-amine

[0197] N-(3-(ethylsulfonyl)-2-fluorophenyl)-5-methyl-4-(7-nitro-1H-indol-3-yl)pyrimidin-2-amine, intermediate 12 (1.406 g, 3.09 mmol), ammonium chloride (0.991 g, 18.52 mmol) and iron (1.034 g, 18.52 mmol) in MeOH / THF / water 1:1:1 (75 mL) were stirred at 60 °C for 3 hours. The reaction mixture was filtered through celite and the solvent was removed under reduced pressure. The residue was purified by preparative TLC using DCM / MeOH 10:1 as eluent to provide 3-(2-((3-(ethylsulfonyl)-2-fluorophenyl)amino)-5-methylpyrimidin-4-yl)-1H-indol-7-amine (0.600 g, 46%) as a brown solid.

[0198] 1 H NMR (300MHz, DMSO-d6) δ1.11(t, 3H), 2.37(s, 3H), 3.33(q, 2H), 5.12(bs, 2H), 6.39(d, 1H), 6.74(t, 1H), 7.38(t, 1 H), 7.44-7.66 (m, 2H), 7.94 (d, 1H), 8.25 (s, 1H), 8.34 (t, 1H), 9.03 (s, 1H), 11.34 (s, 1H). m / z (ES+), [M+H]+=426.

[0199] The above steps were repeated with the indicated starting intermediates to give intermediates 16-17 as described in Table 4:

[0200] Table 4

[0201]

[0202] a The reaction mixture was filtered through celite, evaporated in vacuo and redissolved in DCM (50 mL).The organic phase was washed with water (2 x 50 mL), dried over Na2SO4, filtered and evaporated in vacuo.

[0203] b The reaction was stirred for 2 h. The reaction mixture was filtered through celite and diluted with EtOAc (100 mL). The organic layer was dried over Na2SO4, filtered and evaporated in vacuo.

[0204] Intermediate 18: 3-(5-fluoro-2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)pyrimidin-4-yl)-1H-indol-7-amine Step 1

[0205] A solution of potassium carbonate (40.9 mL, 678.28 mmol) was charged into a 1 L reactor equipped with a thermometer and a nitrogen inlet. The mixture was degassed three times with N2 at room temperature (23 ° C). 7-nitro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolane-2-yl)-1-tosyl-1H-indole, intermediate 1 (100 g, 226.09 mmol), 2,4-dichloro-5-fluoropyrimidine (49.1 g, 293.92 mmol) and methyl THF (1000 mL) were added and stirred at room temperature for 10 min. The resulting mixture was degassed 3 times with nitrogen. Dichloro[1,1′-bis(diphenylphosphino)ferrocene]palladium dichloromethane adduct (9.23 g, 11.30 mmol) was added to the reaction mixture, the resulting mixture was degassed and backfilled (3xN2) again, and stirred overnight at 23°C to give a yellow precipitate. Heptane (500 mL) was charged to the reaction mixture at room temperature and stirred for 10 min. Stirring was then stopped and the precipitate was allowed to settle. The reaction mixture was cooled to 5°C and stirred for 1 h. The precipitate was filtered through a glass funnel and washed with water until the water reached a neutral pH (13 vol, displacement wash, 1.3 L). The filter cake was then washed with EtOAc / heptane mixture 1:1 (5x2 vol, 1 L), heptane (2x200 mL, 2x2 vol) at room temperature, and the solid was dried under vacuum at 35 °C overnight to afford 3-(2-chloro-5-fluoropyrimidin-4-yl)-7-nitro-1-tosyl-1H-indole (97 g, effective yield 89%).

[0206] 1H NMR (400MHz, DMSO-d6) δ2.41 (s, 3H), 7.51 (d, 2H), 7.69 (t, 1H), 7.95 (d, 2H), 8.01 (dd, 1H), 8.75 (d, 1H), 8.81 (dd, 1H), 9.01 (d, 1H).m / z (ES+), [M+H] + =447.2.

[0207] Step 2

[0208] 3-(2-chloro-5-fluoropyrimidin-4-yl)-7-nitro-1-tosyl-1H-indole (89.5g, 200.30mmol), 2-fluoro-3-(methylsulfonyl)aniline hydrochloride, intermediate 5 (54.2g, 240.36mmol), Pd2(dba)3(9.17g, 10.01mmol) and 2'-(dicyclohexyl)-N, N-dimethyl-[1,1'-biphenyl]-2-amine (7.88g, 20.03mmol) are added to a 2L reactor under nitrogen. Degassed 2-2-methyltetrahydrofuran (1000mL) and cesium carbonate (137g, 420.62mmol) solution in water (450mL) are added at room temperature, and the reaction mixture is degassed (x7). The reaction is then heated to 72.6°C, and then stirred overnight. The reaction was cooled to 4-5°C and stirred for at least 30 min. The solid was filtered with a Buchner funnel, washed with cold 2-2-methyltetrahydrofuran (300 mL, 3 vol), water (3x300 mL, 3 vol) and EtOAc / heptane mixture 1:2 (3x300 mL, 3 vol), and dried under vacuum at 40°C to provide 5-fluoro-N-(2-fluoro-3-(methylsulfonyl)phenyl)-4-(7-nitro-1-tosyl-1H-indol-3-yl)pyrimidin-2-amine (77.89 g, 65% effective yield) as a brown solid.

[0209] 1 H NMR (400MHz, DMSO-d6) δ2.56-2.64(m, 3H), 3.42(d, 3H), 7.52-7.64(m, 4H), 7.73(t, 1H ), 7.98-8.09(m, 3H), 8.22(t, 1H), 8.71(s, 1H), 8.79(d, 1H), 8.94(d, 1H), 9.89(s, 1H).

[0210] m / z(ES+), [M+H] + =600.2.

[0211] Step 3

[0212] At room temperature, 5-fluoro-N-(2-fluoro-3-(methylsulfonyl)phenyl)-4-(7-nitro-1-tosyl-1H-indol-3-yl)pyrimidin-2-amine (97.7 g, 129.87 mmol) was loaded into a 5L reactor. A mixture of THF (100 mL) and 3.8 M NaOH (aqueous) (1000 mL) was added to give a brown insoluble mixture. The mixture was heated to 75 ° C at reflux and stirred over the weekend. THF (10 vol) and heptane (10 vol) were loaded into the reaction mixture. It was then cooled to 17 ° C in 40 min, stirred for 60 min, and the solid was filtered on a Buchner funnel. The filter cake was washed with 1 M citric acid (500 mL, until pH neutral), water (5x300 mL, until pH neutral), and then with heptane / EtOAc (4x400 mL). The solid was dried under vacuum to afford 5-fluoro-N-(2-fluoro-3-(methylsulfonyl)phenyl)-4-(7-nitro-1H-indol-3-yl)pyrimidin-2-amine (55.0 g, 95%).

[0213] 1 H NMR (400MHz, DMSO-d6) δ3.27-3.38(m, 3H), 7.30(t, 1H), 7.47(t, 1H), 7.64(t, 1H), 8.11-8.29(m, 3H), 8.52(d, 1H), 8.98(d, 1H), 9.60(s, 1H), 12.57(s, 1H).

[0214] m / z(ES+), [M+H] + =446.2.

[0215] Step 4

[0216] To a stirred suspension of 5-fluoro-N-(2-fluoro-3-(methylsulfonyl)phenyl)-4-(7-nitro-1H-indol-3-yl)pyrimidin-2-amine (59.5 g, 123.5 mmol, 92.5% wt) in THF / EtOH 2:1 (600 mL) was added 10% Pd / C (12.0 g, 123.5 mmol, 50% humidity) and ammonium formate (46.8 g, 741.4 mmol) solution in water (50 mL) at room temperature under nitrogen. The reaction mixture was slowly heated to 70°C and stirred for 30 min. 12 g of activated carbon was charged and the mixture was stirred for 15 min. The reaction mixture was cooled to 40°C and filtered with a Buchner funnel (paper) under nitrogen. The filter cake was washed with THF / EtOH (160 mL). The filtrate was concentrated to 4 vol, and the resulting slurry was cooled to room temperature and filtered under nitrogen. The solid was washed with water (2 vol), ethanol (2 vol) and dried at 40 °C under nitrogen / vacuum to afford 3-(5-fluoro-2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)pyrimidin-4-yl)-1H-indol-7-amine (44.3 g, 86%) as a light brown solid.

[0217] 1 H NMR (400MHz, DMSO-d6) δ3.28 (s, 3H), 5.20 (bs, 2H), 6.43 (dd, 1H), 6.78 (t, 1H), 7.44 (t, 1H), 7.57-7. 63(m,1H),7.66(d,1H),8.09-8.25(m,2H),8.38(d,1H),9.34(s,1H),11.57(s,1H).m / z(ES+),[M+H] + =416.3.

[0218] Intermediate 19: 3-(2-chloro-5-methylpyrimidin-4-yl)-7-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indole

[0219] Sodium hydride (60% dispersion in mineral oil) (1.32 g, 33.10 mmol) was added portionwise to a yellow stirred suspension of 3-(2-chloro-5-methylpyrimidin-4-yl)-7-nitro-1H-indole, intermediate 3 (6.37 g, 22.07 mmol) in anhydrous THF (150 mL) at 0°C. After stirring for 25 min (gas evolution ceased), (2-(chloromethoxy)ethyl)trimethylsilane (4.10 mL, 23.17 mmol) was added dropwise rapidly. After 5 minutes, the cooling bath was removed and the reaction was stirred at ambient temperature for 1.5 hours. Additional sodium hydride (60% dispersion in mineral oil) (130 mg, 3.3 mmol) and (2-(chloromethoxy)ethyl)trimethylsilane (0.4 mL, 2.3 mmol) were added. The reaction is stirred for another 40min, then saturated NaHCO (aqueous) is quenched, and the light yellow mixture is diluted with Et o. The layer is separated, and Et o (x2) aqueous layer is extracted. The organic layer washed with salt water combined, through MgSO dried, filtered and evaporated in a vacuum. Residue is dissolved in chloroform and 120g column purification is used by automatic silica gel flash chromatography. Use 5%EtOAc gradient in hexane to continue 3min, then use 5%-45%EtOAc in hexane through 25 minutes gradient as mobile phase. Use wavelength 254nm to collect product, to provide 3-(2-chloro-5-methylpyrimidine-4-yl)-7-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indole (9.21g, 100%), in yellow solid.

[0220] 1 H NMR (400MHz, DMSO-d6) δ-0.16 (s, 9H) 0.60-0.73 (m, 2H) 2.51-2.52 (m, 3H) 3.11-3. 22(m,2H)5.72(s,2H)7.48(t,1H)7.94(d,1H)8.57(s,1H)8.64(s,1H)8.84(d,1H).

[0221] m / z(ES+), [M+H] + =419.2.

[0222] Intermediate 20: 3-(2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)-5-methylpyrimidin-4-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indol-7-amine

[0223] Step 1

[0224] Cesium carbonate (2.333 g, 7.16 mmol) was added to 3-(2-chloro-5-methylpyrimidin-4-yl)-7-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indole, Intermediate 19 (1.0 g, 2.39 mmol), 2-fluoro-3-(methylsulfonyl)aniline, Intermediate 5 (0.542 g, 2.86 mmol), Pd2(dba)3 (0.219 g, 0.24 mmol) and 2-dicyclohexyl-2′-(N,N-dimethylamino)-biphenyl (Davephos) (0.188 g, 0.48 mmol) in DMF (20 mL) under nitrogen at 25° C. The resulting mixture was stirred at 80° C. for 3 hours and then allowed to cool to room temperature. The reaction mixture is diluted with EtOAc (200mL), washed with water (50mL), saturated NaHCO (50mL) and salt solution (100mL). The organic layer is dried, filtered and evaporated in a vacuum. Residue is purified by flash silica gel chromatography, using the 5%-60% EtOAc gradient in petroleum ether as mobile phase. Pure fraction is evaporated in a vacuum, to provide N-(2-fluoro-3-(methylsulfonyl)phenyl)-5-methyl-4-(7-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indol-3-yl)pyrimidine-2-amine (0.940g, 69%), as a yellow solid.

[0225] 1 H NMR (300MHz, CDCl3) δ-0.08 (s, 9H), 0.74-0.87 (m, 2H), 2.44 (s, 3H), 3.22-3.38 (m, 5H), 5.67 (s, 2H), 7.21-7. 33(m, 2H), 7.42(s, 1H), 7.48-7.60(m, 1H), 7.72(s, 1H), 7.89(d, 1H), 8.39(s, 1H), 8.62(d, 1H), 8.89(t, 1H).

[0226] m / z(ES+), [M+H] + =572.2.

[0227] Step 2

[0228] N-(2-fluoro-3-(methylsulfonyl)phenyl)-5-methyl-4-(7-nitro-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indol-3-yl)pyrimidin-2-amine (2.76 g, 4.83 mmol), iron (11.59 g, 207.59 mmol) and ammonium hydrochloride (11.10 g, 207.59 mmol) were dissolved in MeOH / THF / water 1:1:1 (120 mL) and stirred at 70°C for 4 h. The reaction mixture was allowed to cool to room temperature. The solid was filtered off and the filtrate was poured into water (200 mL) and extracted with DCM (8x40 mL). The combined organic extracts were filtered through a phase separator and evaporated in vacuo to afford 3-(2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)-5-methylpyrimidin-4-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indol-7-amine (2.52 g, 96%) as an orange gum.

[0229] 1 H NMR (500MHz, DMSO-d6) δ-0.05 (s, 9H), 0.87-0.93 (m, 2H), 2.37 (s, 3H), 3.22 (s, 3H), 3.56-3.65 (m, 2H), 5.05 (s, 2H), 5.73 (s, 2 H), 6.53(d, 1H), 6.78(t, 1H), 7.38(t, 1H), 7.53(d, 1H), 7.58(d, 1H), 8.03(s, 1H), 8.28(d, 2H), 9.13(s, 1H).m / z(ES+), [M+H] + =542.3.

[0230] Intermediate 21: (S)-2-Bromo-N-(3-(2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)-5-methylpyrimidin-4-yl)-1H-indol-7-yl)propanamide

[0231] At 25°C, DIPEA (0.679 mL, 3.89 mmol) was added once to 3-(2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)-5-methylpyrimidin-4-yl)-1H-indole-7-amine, intermediate 11 (200 mg, 0.49 mmol) and (S)-2-bromopropionic acid (149 mg, 0.97 mmol) in DMF (3 mL). The resulting solution was cooled to -40°C, 1-propanephosphonic acid cyclic anhydride (619 mg, 0.97 mmol) was added dropwise at -40°C, and stirring was continued for 30 min. The reaction mixture was diluted with DCM (25 mL) and washed with brine (2x50 mL). The organic layer was dried over Na2SO4, filtered and evaporated in vacuo. The residue was purified by preparative TLC using MeOH / DCM 1:20 as eluent to afford (S)-2-bromo-N-(3-(2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)-5-methylpyrimidin-4-yl)-1H-indol-7-yl)propanamide, (224 mg, 84%) as a brown solid.

[0232] 1 H NMR (300MHz, DMSO-d6) δ1.86 (d, 3H), 2.42 (s, 3H), 3.26 (s, 3H), 4.78-4.90 (m, 1H), 7.01 (t, 1H), 7.38-7.52 (m, 2H), 7 .57(t,1H),8.09(d,1H),8.18(d,1H),8.25-8.34(m,2H),9.21(s,1H),10.20(s,1H),11.37(s,1H).m / z(ES+),[M+H] + =546.

[0233] Intermediate 22: (R)-2-(4-methylpiperazin-1-yl)propionic acid dihydrochloride

[0234] Step 1

[0235] (S)-methyl 2-hydroxypropanoate (250g, 2.40mol), DCM (1500mL) and 2,6-lutidine (656.7g, 6.13mol) are placed in a 3000mL four-necked round-bottom flask, and the mixture is cooled to-78°C. Trifluoromethanesulfonic anhydride (630g, 2.23mol) is added dropwise at-78°C stirring, and then the resulting solution is stirred at room temperature for 3h. The reaction mixture is diluted with water (1000mL), washed with 1M HCl (3x500mL) and salt solution (1x500mL). By anhydrous Na for organic phase SO Dry, filter and concentrate in a vacuum. Then at 0 ℃, the residue was added dropwise to a 3000mL four-necked round-bottom flask containing 1-methylpiperazine (213.3g, 2.13mol), DCM (800mL), water (400mL,) and potassium carbonate (491.3g, 3.53mol) stirred. The resulting solution was stirred at room temperature overnight and then diluted with DCM (500mL). The resulting mixture was washed with water (1x500mL) and brine (500mL). The organic phase was dried over Na2SO4, filtered and concentrated in vacuo. By preparative silica gel chromatography, 17%-50% ethyl acetate gradient in petroleum ether was used as a mobile phase to purify the residue, to provide (R)-methyl 2-(4-methylpiperazine-1-yl) propanoate (226g, 68%) as a light yellow oil. m / z (ES+), [M+H] + =187.

[0236] Step 2

[0237] In 3000mL four-necked round-bottom flask, add hydrogen chloride (2000mL, 60.34mol, 6M / L) then add (R)-methyl 2-(4-methylpiperazine-1-yl) propionate (226g, 1.21mol). The resulting solution is stirred overnight at 100 ℃, and then concentrated in a vacuum. The resulting mixture is diluted with acetonitrile (1000mL), and the collected solid is filtered. The product is recrystallized (x5) with ethanol (1g / 20mL) at room temperature, to provide (R)-2-(4-methylpiperazine-1-yl) propionic acid dihydrochloride (124g, 42%), as a white solid. 1 H NMR (300MHZ, CD3OD) δ1.69-1.71 (d, 3H), 3.04 (s, 3H), 3.83 (m, 8H), 4.35-4.42 (m, 1H).m / z (ES+), [M+H] + =173.

[0238] Intermediate 23: (R)-methyl 2-((S)-3,4-dimethylpiperazin-1-yl)propionate

[0239] 2,6-lutidine (0.672mL, 5.77mmol) is added to a solution of (S)-methyl 2-hydroxypropionate (500mg, 4.81mmol) in DCM (5mL) cooled to -78°C. The mixture is stirred for 5min, and then trifluoromethanesulfonic anhydride (0.974mL, 5.77mmol) is added dropwise. The reactant is stirred for 30min, the cooling is removed and the reaction mixture is allowed to reach room temperature over 30min. The solution is washed with 1M HCl (aqueous) (20mL), dried with a phase separator, and then slowly added to a mixture of (S)-1,2-dimethylpiperazine dihydrochloride (0.944g, 5.05mmol) and potassium carbonate (1.993g, 14.42mmol) solution suspended in DCM (10mL). The reaction is stirred at room temperature for 18h. Each phase is separated. The organic phase was washed with brine (25 mL), dried using a phase separator and evaporated in vacuo to afford (R)-methyl 2-((S)-3,4-dimethylpiperazin-1-yl)propanoate (0.726 g, 75%) as a light orange oil.

[0240] 1 H NMR (500MHz, CDCl3) δ1.05 (d, 3H), 1.29 (d, 3H), 2.1-2.25 (m, 2H), 2.25-2.37 (m, 4H), 2.46 (t, 1H), 2.69-2.83 (m, 3H), 3.28 (q, 1H), 3.70 (s, 3H).

[0241] The above procedure was repeated using the indicated amines to give intermediates 24 as described in Table 5:

[0242] Table 5

[0243]

[0244] Intermediate 25: (R)-2-((S)-3,4-dimethylpiperazin-1-yl)propanoic acid dihydrochloride

[0245] (R)-methyl 2-((S)-3,4-dimethylpiperazin-1-yl)propanoate, intermediate 23 (726 mg, 3.62 mmol) was stirred at reflux for 16 h in 6M HCl (6 mL, 36.00 mmol). (The reaction was dried). Water (6 mL) was added and stirred for 2 h. The reaction was cooled to room temperature and the solvent was concentrated in vacuo. The residue was suspended in acetonitrile and stirred at room temperature for 1 h. The solid was filtered off, washed with acetonitrile and dried in vacuo to obtain (R)-2-((S)-3,4-dimethylpiperazin-1-yl)propanoic acid dihydrochloride (626 mg, 66.6%) as a solid. 1H NMR (500MHz, D2O) δ1.33 (d, 3H), 1.37-1.48 (m, 3H), 2.88 (s, 3H), 3.07-3.23 (m, 1H), 3.28-3.85 (m, 7H).

[0246] The above procedure was repeated using the indicated starting intermediates to give intermediates 26 as described in Table 6:

[0247] Table 6

[0248]

[0249] a The residue was dissolved in water / acetonitrile and freeze dried. The remaining semi-solid was suspended in acetonitrile and stirred at room temperature for 1 h. The solid was filtered, washed with acetonitrile and dried in vacuo.

[0250] Intermediate 27: (R)-2-((R)-2,4-dimethylpiperazin-1-yl)propanoic acid dihydrochloride

[0251] Step 1

[0252] 2,6-lutidine (0.868mL, 7.45mmol) is added to a cooled -78°C solution of (S)-methyl 2-hydroxypropionate (0.646g, 6.21mmol) in DCM (10mL). The mixture is stirred for 5min, and then trifluoromethanesulfonic anhydride (1.259mL, 7.45mmol) is added dropwise. The reactant is stirred for 45min, cooling is removed, and the reaction mixture is brought to room temperature and stirred for 1h. The solution is washed with 1M HCl (aqueous) (20mL), dried with a phase separator and concentrated in vacuo. The residue is dissolved in acetonitrile (5mL) and added to a suspension of (R)-1,3-dimethylpiperazine dihydrochloride (1.22g, 6.52mmol) and potassium carbonate (2.57g, 18.63mmol) in acetonitrile (10mL). The reactant is heated to 60°C for 20h under N2 atmosphere. The reaction is cooled to room temperature, solid is filtered out, washed with acetonitrile, and the filtrate is evaporated in a vacuum. Residue is dissolved in DCM (10mL) and 8% NaHCO (aqueous) (10mL), shake and separate each phase. The aqueous phase is extracted with DCM (10mL). The combined extracts are dried with a phase separator and evaporated in a vacuum to obtain (R)-methyl 2-((R)-2,4-dimethylpiperazine-1-yl) propanoate (0.589g, 47.4%, 80%de), which is a light oil.

[0253] 1H NMR (500 MHz, DMSO-d6) δ 0.94 (d, 3H), 1.06 (d, 3H), 1.82 (t, 1H), 2.03 (t, 1H), 2.10 (s, 3H), 2.37-2.55 (m, 3H), 2.55-2.67 (m, 2H), 3.61 (s, 3H), 3.66-3.74 (m, 1H). (The most abundant diastereomer described)

[0254] Step 2

[0255] (R)-methyl 2-((R)-2,4-dimethylpiperazine-1-yl)propanoate (589 mg, 2.94 mmol) was dissolved in 6M HCl (aqueous) (5 mL, 30.00 mmol) and refluxed for 18 h. The reactant was cooled to room temperature and the solvent was evaporated in vacuo to a semisolid residue. Diethyl ether was added to the residue, stirred for 30 min, the solid was filtered off and dried in vacuo to obtain (R)-2-((R)-2,4-dimethylpiperazine-1-yl)propanoic acid dihydrochloride (623 mg, 82%) as a light solid.

[0256] 1 H NMR (500 MHz, D2O) δ 1.32 (d, 3H), 1.41 (d, 3H), 2.89 (s, 3H), 3.08-3.91 (m, 7H), 4.25-4.51 (m, 1H). (The most abundant diastereomer described)

[0257] Intermediate 28: Methyl 3-methoxy-2-(4-methylpiperazin-1-yl) propionate

[0258] Under nitrogen, 1-methylpiperazine (100g, 988.4mmol) and potassium carbonate (164g, 1186mmol) are slurried in anhydrous acetonitrile (800mL).Methyl 2-bromo-3-methoxy propionate (201g, 988.4mmol) is added to the slurry at 50 ℃-60 ℃ over a period of 40 minutes.The resulting mixture is heated at 61 ℃ for 23 hours under nitrogen, and then cooled to 20 ℃.The solid is filtered out.The filtrate is evaporated into an oily residue, which is dissolved in 1M HCl (1000mL).Then pH is adjusted to 1 with 4M HCl (~300mL).The resulting solution is extracted with DCM (200mL).The aqueous solution is alkalized to pH 9 with saturated NaCO (1000mL), and extracted with DCM (2x500mL). The pH of the aqueous phase was then raised to 10-11 with sodium hydroxide and extracted with DCM (2 x 500 mL).The four organic phases were combined and evaporated in vacuo to afford methyl 3-methoxy-2-(4-methylpiperazin-1-yl)propanoate (181 g, 85%).

[0259] 1 H NMR (400MHz, CDCl3) δ2.07 (s, 3H), 2.14-2.34 (m, 4H), 2.39-2.52 (m, 4H), 3.14 (s, 3H), 3.22 (dd, 1H), 3.42 (dd, 1H), 3.48-3.56 (m, 4H).

[0260] Intermediate 29: Methyl 2-(4-methylpiperazin-1-yl)propionate

[0261] At 20 ℃, under nitrogen, potassium carbonate (1.987g, 14.38mmol) is added to methyl 2-bromopropionate (2.041g, 12.22mmol) and 1-methylpiperazine (1.20g, 11.98mmol) in acetonitrile (20mL). The resulting mixture is stirred at 60 ℃ for 18 hours. The vibrating orange mixture is cooled to room temperature, diluted with ethyl acetate and filtered. The orange solution is concentrated in vacuo. The residue is dissolved in ether and filtered. The filtrate is evaporated in vacuo to provide methyl 2-(4-methylpiperazine-1-yl) propionate, (2.2g, 99%), in an oily state.

[0262] 1 H NMR (400MHz, CDCl3) δ1.23 (dd, 3H), 2.21 (d, 3H), 2.28-2.65 (m, 8H), 3.16-3.27 (m, 1H), 3.63 (s, 3H).m / z (ES+), [M+H] + =187.

[0263] The above procedure was repeated using the indicated reactants to give intermediates 30-44 as described in Table 7:

[0264] Table 7

[0265]

[0266]

[0267]

[0268]

[0269]

[0270] aThe reaction mixture was diluted with ethyl acetate (50 mL). The reaction mixture was filtered through diatomaceous earth. The solvent was distilled off under vacuum. The reaction mixture was diluted with Et2O (50 mL). The reaction mixture was filtered through diatomaceous earth. The solvent was removed by vacuum distillation.

[0271] b 3 equivalents of potassium carbonate were used.

[0272] C The reaction mixture was filtered. The solvent was removed under reduced pressure. The mixture was redissolved in EA and washed with HCl. The aqueous layers were combined and the pH was adjusted to 8 with Na2CO3. The aqueous layer was washed with EtOAc. The organic layers were combined and evaporated in vacuo.

[0273] D The reaction mixture was filtered and the solvent was evaporated in vacuo.The residue was diluted with EtOAc (50 mL), filtered through celite and the filtrate was evaporated in vacuo.

[0274] e 2 equivalents of potassium carbonate were used.

[0275] f The product of 4-nitropropene was added in 4-nitropropene (2-nitropropene) (4-nitropropene) (5-nitropropene) (6-nitropropene) (7-nitropropene) (8-nitropropene) (9-nitropropene) (10-nitropropene) (20-nitropropene) (15-nitropropene).After concentrated filtrate.Resistate is dissolved in DCM (150mL), back-extracted in 0.1M HCl (aqueous) (200mL) and separated each phase.Water is washed with DCM (150mL), and then by adding K CO (s) alkalize to pH 10.Then compound is extracted with DCM (3x125mL) and evaporated in vacuum.

[0276] Intermediate 45: 2-(4-methylpiperazin-1-yl)propionic acid dihydrochloride

[0277] At 0 ° C, methyl 2- (4-methylpiperazine -1- base) propanoate, intermediate 29 (6.00g, 32.21mmol) was added dropwise to 6M HCl (70mL, 420.00mmol). The resulting mixture was stirred at 100 ° C for 12 hours. The mixture was cooled to room temperature and washed with DCM (2x2000mL). The aqueous phase was removed under reduced pressure to provide 2- (4-methylpiperazine -1- base) propionic acid dihydrochloride (6.00g, 76%) as a white solid.

[0278] 1 H NMR (400MHz, DMSO-d6) δ1.54 (d, 3H), 2.83 (s, 3H), 3.47-3.90 (m, 8H), 4.25-4.45 (m, 1H), 12.21 (bs, 1H).m / z (ES+), [M+H] + =173.

[0279] The above process was repeated using the indicated starting intermediates to give intermediates 46-47 as described in Table 8:

[0280] Table 8

[0281]

[0282] a The reaction mixture was cooled to room temperature and then concentrated in vacuo. The residue was suspended in acetonitrile or ether and stirred at room temperature. The solid was filtered off and dried in vacuo.

[0283] Intermediate 48: Lithium 3-methoxy-2-(4-methylpiperazin-1-yl)propionate

[0284] A solution of lithium hydroxide (0.321 g, 13.39 mmol) in water (5 mL) was added to a solution of methyl 3-methoxy-2-(4-methylpiperazine-1-yl) propionate, intermediate 28 (1.93 g, 8.92 mmol) in THF (5 mL). A few drops of MeOH were added until the reaction mixture became clear. The reaction was heated at 40 ° C for 24 h. The organic matter was evaporated in vacuo. The residue was diluted with water and freeze-dried (x3) to obtain 3-methoxy-2-(4-methylpiperazine-1-yl) lithium propionate, (1.92 g, 103%) as a solid.

[0285] 1 H NMR (500MHz, D2O) δ2.06 (s, 3H), 2.48 (bs, 8H), 2.99 (t, 1H), 3.20 (s, 3H), 3.46-3.57 (m, 2H).

[0286] The above procedure was repeated using the indicated starting intermediates to give intermediates 49-59 as described in Table 9:

[0287] Table 9

[0288]

[0289]

[0290]

[0291] a THF / MeOH 1:1 was used as solvent.

[0292] b 3 equivalents of LiOH were used.

[0293] CThe reaction mixture was diluted with water (30 mL).The aqueous layer was washed with EtOAc or ether and lyophilized.

[0294] d MeOH was used as solvent.

[0295] e Reaction temperature: 50℃

[0296] f Reaction temperature: 60℃.

[0297] g 1 M HCl (10 mL) was added to the reaction mixture, which was then lyophilized.

[0298] h 2 eq. LiOH was used.

[0299] Intermediate 60: (S)-Methyl 3-ethoxy-2-hydroxypropionate

[0300] At 25 ℃, under nitrogen, magnesium trifluoromethanesulfonate (1.577g, 4.90mmol) is added to (S)-methyl oxirane-2-formate (2.00g, 19.59mmol) dissolved in ethanol (10mL). The resulting mixture is stirred at 50 ℃ for 30 hours. The solvent is removed under reduced pressure. The reaction mixture is diluted with EtOAc (50mL) and washed with brine (25mL). The organic layer is dried over Na2SO4, filtered and evaporated in vacuo. The residue is purified by preparative TLC (using EtOAc / petroleum ether 1: 1) to provide (S)-methyl 3-ethoxy-2-hydroxypropanoate, (1.788g, 61.6%), which is colorless oil.

[0301] 1 H NMR (300MHz, CDCl3) δ1.20 (t, 3H), 2.46 (bs, 1H), 3.45-3.67 (m, 2H), 3.74 (d, 2H), 3.83 (s, 3H), 4.19-4.41 (m, 1H).m / z (ES+), [M+H] + =203.

[0302] Intermediate 61: (S)-Methyl 3-ethoxy-2-(((trifluoromethyl)sulfonyl)oxy)propionate

[0303] At -78 ° C, under nitrogen, 2,6-lutidine (1.643 mL, 14.11 mmol) was added to (S)-methyl 3-ethoxy-2-hydroxypropionate, intermediate 60 (1.9 g, 12.82 mmol) in DCM (30 mL). After maintaining complete cooling again, trifluoromethanesulfonic anhydride (2.341 mL, 14.11 mmol) was added dropwise over 1 hour with a syringe pump. The resulting solution was stirred at -78 ° C for 30 minutes, then warmed to room temperature and stirred for another 1 hour. The reaction mixture was diluted with DCM (100 mL), washed with 1M HCL (75 mL), and the organic phase was dried under vacuum to provide (S)-methyl 3-ethoxy-2-(((trifluoromethyl)sulfonyl)oxy)propionate (3.30 g, 92%) as a light brown oil.

[0304] 1 H NMR (300MHz, CDCl3) δ1.23 (t, 3H), 3.48-3.75 (m, 2H), 3.82-4.01 (m, 3H), 4.23-4.46 (m, 2H), 5.22-5.36 (m, 1H).

[0305] Intermediate 62: (R)-methyl 3-ethoxy-2-(4-methylpiperazin-1-yl) propionate

[0306] Potassium carbonate (3.26 g, 23.55 mmol) was dissolved in water (420 mL) and added dropwise to a solution of (S)-methyl 3-ethoxy-2-(((trifluoromethyl)sulfonyl)oxy)propanoate, intermediate 61 (3.3 g, 11.78 mmol) and 1-methylpiperazine (1.769 g, 17.66 mmol) in DCM (15 mL) at 0°C for 5 minutes. The resulting mixture was stirred at room temperature for 15 hours. The reaction mixture was diluted with DCM (500 mL) and washed with water (100 mL) and brine (100 mL). The organic layer was dried over Na2SO4, filtered and evaporated in vacuo. The residue was purified by preparative TLC (using petroleum ether / EtOAc 1:1) to provide (R)-methyl 3-ethoxy-2-(4-methylpiperazin-1-yl)propanoate (2.40 g, 88%) as a yellow oil.

[0307] 1 H NMR (300MHz, CDCl3) δ1.18 (t, 3H), 2.30 (s, 3H), 2.36-2.60 (m, 4H), 2.60-2.79 (m, 4H), 3.35-3.60 (m, 3H), 3.61-3.84 (m, 4H), 4.21 (q, 1H).

[0308] m / z(ES+), [M+H] + =231.

[0309] Intermediate 63: (R)-3-ethoxy-2-(4-methylpiperazin-1-yl) lithium propionate

[0310] At 25 ° C, lithium hydroxide (204 mg, 8.51 mmol) in water (6 mL) was added to (R)-methyl 3-ethoxy-2-(4-methylpiperazine-1-yl) propanoate, intermediate 62 (980 mg, 4.26 mmol) in THF / MeOH 1: 1 (12 mL). The resulting solution was stirred at room temperature for 15 hours. The solvent was removed under reduced pressure. The residue was diluted with MeOH (50 mL), washed with petroleum ether (2x50 mL) and evaporated in vacuo to provide (R)-3-ethoxy-2-(4-methylpiperazine-1-yl) propionic acid (421 mg, 45.7%).

[0311] 1 H NMR (300MHz, CDCl3) δ1.19 (t, 3H), 2.27 (s, 3H), 2.34-2.78 (m, 8H), 2.97-3.08 (m, 1H), 3.42-3.59 (m, 2H), 3.70 (dd, 1H), 3.76-3.87 (m, 1H).m / z (ES+), [M+H] + =217.

[0312] Intermediate 64: Sodium 3-(benzyloxy)-2-(4-methylpiperazin-1-yl)propionate

[0313] Step 1

[0314] In a round-bottom flask equipped with a thermometer, (S)-2-amino-3-(benzyloxy)propionic acid (3.00g, 15.37mmol) was dissolved in sulfuric acid (18.44mL, 36.88mmol) and cooled to 0°C with an ice bath. In 60min, a solution of sodium nitrite (1.696g, 24.59mmol) in water (10mL) was added in small portions, keeping the internal temperature below 3°C. The reaction mixture was stirred at 0°C, and allowed to slowly warm to room temperature overnight. NaOH (50%, aqueous, w / w, 2.8mL) was added until pH 4. Ethyl acetate (25mL) was then added, the reaction mixture was stirred vigorously, and 2M H was added simultaneously SO (aqueous) pH was reduced to pH 3. Each phase was separated, and aqueous phase was extracted with EtOAc (3x25mL). The combined organic phases were dried over MgSO 4 , filtered through a phase separator and concentrated in vacuo to provide (S)-3-(benzyloxy)-2-hydroxypropanoic acid (2.55 g, 85%, 98.0% ee).

[0315] 1 H NMR (500 MHz, CDCl3) 63.78 (dd, 1H), 3.83 (dd, 1H), 4.37 (t, 1H), 4.61 (d, 2H), 7.28-7.4 (m, 5H). No exchangeable protons were observed.

[0316] Step 2

[0317] Acetyl chloride (4.28mL, 60.14mmol) was added dropwise to cold methanol (14mL) in an ice bath at 0°C. The mixture was stirred at 0°C for 5 minutes and transferred to a solution of (S)-3-(benzyloxy)-2-hydroxypropionic acid (2.36g, 12.03mmol) in methanol (14.00mL) at 0°C. The resulting mixture was stirred at room temperature for 40 minutes. Trimethyl orthoformate (2.66mL, 24.06mmol) was added and the reaction mixture was stirred at room temperature overnight. The reaction mixture was concentrated in vacuo. The residue was purified by automatic flash chromatography at KP-SIL 50g column purification, using 50% EtOAc in heptane for 12CV as mobile phase. Compounds were detected using a wavelength of 257nm. The product was collected and evaporated in vacuo to provide (S)-methyl 3-(benzyloxy)-2-hydroxypropanoate (1.94g, 77%).

[0318] 1 H NMR (500MHz, CDCl3) δ3.04 (d, 1H), 3.76 (d, 2H), 3.79 (s, 3H), 4.31-4.36 (m, 1H), 4.54 (d, 1H), 4.61 (d, 1H), 7.27-7.37 (m, 5H).

[0319] Step 3

[0320] Trifluoromethanesulfonic anhydride (1.543mL, 9.13mmol) was added dropwise to an ice bath 0°C cold solution of (S)-methyl 3-(benzyloxy)-2-hydroxypropanoate (1.92g, 9.13mmol) and DIPEA (1.595mL, 9.13mmol) in toluene (20mL). The reaction was stirred at 25°C for 30 minutes and then cooled to -78°C. A mixture of 1-methylpiperazine (1.013mL, 9.13mmol) and DIPEA (1.595mL, 9.13mmol) in toluene (20mL) was added (keeping the temperature below -70°C). The reaction mixture was stirred overnight with cooling, during which the cooling bath reached -40°C. The reaction mixture was allowed to warm to room temperature, filtered and concentrated in vacuo. The residue was purified by automated flash chromatography at 40°C. KP-SIL 50g column purification, using 66% EtOAc in heptane for 12CV as mobile phase, followed by 0.2M NH3 in MeOH for 10CV as mobile phase. The product was detected using a wavelength of 250nm. The product fractions were collected and evaporated in vacuo to provide (R)-methyl 3-(benzyloxy)-2-(4-methylpiperazin-1-yl)propanoate (1.32g, 66%, 96.0%ee).

[0321] 1 H NMR (500MHz, CDCl3) δ2.42 (s, 3H), 2.5-2.71 (m, 4H), 2.71-2.83 (m, 4H), 3.49 (t, 1H) , 3.66-3.74(m, 4H), 3.78(dd, 1H), 4.53(dd, 2H), 7.24-7.39(m, 5H).m / z(ES+), [M+H] + =293.6.

[0322] Step 4

[0323] (R)-Methyl 3-(benzyloxy)-2-(4-methylpiperazin-1-yl)propanoate (308 mg, 1.05 mmol) was dissolved in methanol (1.5 mL) and aqueous 1 M sodium hydroxide (1.05 mL) and stirred at room temperature for 16 h. Additional aqueous 1 M sodium hydroxide (0.2 mL) was added and the reaction mixture was stirred for another 2 h at room temperature and at 45° C. for 3 h. The reaction was then allowed to reach room temperature and diluted with water (5 mL) and lyophilized to give crude sodium-3-(benzyloxy)-2-(4-methylpiperazin-1-yl)propanoate (356 mg) as a solid.

[0324] 1 H NMR (500MHz, DMSO-d6) δ2.10 (s, 3H), 2.16-2.34 (m, 4H), 2.52-2.63 (m, 4H), 2.91 (dd, 1H), 3.58 ( dd, 1H), 3.65 (dd, 1H), 4.39-4.48 (m, 2H), 7.23-7.28 (m, 1H), 7.28-7.36 (m, 4H).m / z (ES+), [M+H] + =279.2.

[0325] Intermediate 65: Lithium 2-(4-methylpiperazin-1-yl)butyrate

[0326] Under nitrogen, lithium hydroxide (0.335g, 14.00mmol) is added to ethyl 2-(4-methylpiperazine-1-yl) butyrate in THF (6mL), water (6mL) and MeOH (1mL), intermediate 30 (2.00g, 9.33mmol). The resulting suspension is stirred at 40°C for 24 hours. The reaction mixture is concentrated in vacuo. The residue is diluted with water (10mL), extracted with ether (2x10mL), and the water layer is freeze-dried to provide 2-(4-methylpiperazine-1-yl) butyrate lithium (1.680g, 97%) as a light yellow solid.

[0327] 1 H NMR (400MHz, DMSO-d6) δ0.82 (t, 3H), 1.38-1.68 (m, 2H), 2.11 (s, 3H), 2.16-2.48 (m, 4H), 2.49-2.67 (m, 5H).

[0328] Intermediate 66: Lithium 2-(4-(tert-butoxycarbonyl)piperazin-1-yl)propionate

[0329] Step 1

[0330] At 20 ° C, under nitrogen, potassium carbonate (0.890g, 6.44mmol) is added to methyl 2-bromopropionate (0.897g, 5.37mmol) and tert-butyl piperazine-1-carboxylate (1.00g, 5.37mmol) in acetonitrile (10mL). The resulting mixture is stirred at 60 ° C for 18 hours. The reaction mixture is diluted with ethyl acetate (50mL), filtered through diatomaceous earth and the filtrate is evaporated in a vacuum. The reaction mixture is diluted with ether (50mL). The reaction mixture is filtered through diatomaceous earth, and the filtrate is evaporated in a vacuum to provide tert-butyl 4- (1-methoxy-1-oxopropan-2-yl) piperazine-1-carboxylate (1.80g, 123%) as a colorless oil, which is directly used in the next step.

[0331] 1 H NMR(300MHz, CDCl3)1.33(d,3H),1.46(s,9H),2.45-2.75(m,4H),3.25-3.60(m,5H),3.72(s,3H).m / z(ES+),[M+H] + =273.

[0332] Step 2

[0333] A solution of lithium hydroxide (0.158 g, 6.61 mmol) in water (5 mL) was added to a solution of tert-butyl 4-(1-methoxy-1-oxopropan-2-yl)piperazine-1-carboxylate (1.80 g, 6.61 mmol) in THF / MeOH 1:1 (10 mL). The resulting solution was stirred at 60° C. for 4 hours. The solvent was evaporated in vacuo. The residue was diluted with water (15 mL) and lyophilized to provide lithium 2-(4-(tert-butoxycarbonyl)piperazine-1-yl)propanoate, (1.60 g, 91%) as a white solid.

[0334] 1 H NMR (300MHz, D2O) 1.13 (d, 3H), 1.35 (s, 9H), 2.40-2.55 (m, 4H), 2.89 (q, 1H), 3.26-3.47 (m, 4H).m / z (ES+), [M+H] + =259.

[0335] Example 1

[0336] (R)-N-(3-(2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)-5-methylpyrimidin-4-yl)-1H-indol-7-yl)-2-(4-(2-hydroxyethyl)piperazin-1-yl)propanamide

[0337] Potassium carbonate (101 mg, 0.73 mmol) was added to (S)-2-bromo-N-(3-(2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)-5-methylpyrimidin-4-yl)-1H-indol-7-yl)propanamide, intermediate 21 (200 mg, 0.37 mmol) and 2-(piperazin-1-yl)ethanol in DMF (5 mL) at 0°C under nitrogen. The resulting mixture was stirred at 0°C for 18 hours, then cooled to room temperature, filtered through celite and evaporated in vacuo. The product was purified by preparative non-chiral HPLC on an XBridge C18 OBD column using a gradient of 41%-58% acetonitrile in water (0.05% NH3xH2O) over 7 min at a flow rate of 30 mL / min. The product was collected and evaporated in vacuo to afford (R)-N-(3-(2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)-5-methylpyrimidin-4-yl)-1H-indol-7-yl)-2-(4-(2-hydroxyethyl)piperazin-1-yl)propanamide (100 mg, 50%) as a white solid.

[0338] 1H NMR (300MHz, CD3OD) δ1.47 (d, 3H), 2.47 (s, 3H), 2, 85-3.43 (m, 13H), 3.45-3.60 (m, 1H), 3.86 (t, 2H), 7.06 (t, 1H), 7.20 (d, 1H) ), 7.30-7.54(m, 1H), 7.54-7.72(m, 1H), 7.94(s, 1H), 8.14(d, 1H), 8.31(s, 1H), 8.47(bs, 1H), 8.58(t, 1H).m / z(ES+), [M+H] + =596.

[0339] Example 2

[0340] (R)-N-(3-(2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)-5-methylpyrimidin-4-yl)-1H-indol-7-yl)-2-(4-methylpiperazin-1-yl)propanamide

[0341] DIPEA (13.9 mL, 78.08 mmol) was added in one portion to (R)-2-(4-methylpiperazin-1-yl)propanoic acid dihydrochloride, intermediate 22 (3.34 g, 13.64 mmol) and 3-(2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)-5-methylpyrimidin-4-yl)-1H-indol-7-amine, intermediate 11 (4.00 g, 9.72 mmol) in DCM (70 mL) at 25°C. The resulting solution was stirred at 25°C for 10 minutes. 1-Propanephosphonic acid cyclic anhydride T3P (50 wt%) (12.37 g, 19.44 mmol) was then added dropwise at 0°C. The solution was stirred at 0°C for 1 hour and then concentrated in vacuo. The residue was purified by C18-flash chromatography using a 5%-60% MeOH aqueous gradient as the mobile phase. To the 4-(4-(2-fluoro-3-(methylsulfonyl)phenyl)amino)-5-methylpyrimidine-4-yl)-1H-indol-7-yl)-2-(4-methylpiperazine-1-yl)propionamide (1.85g, 30%) was added in 4%EtOH and 40mL / min of CO. The residue was purified by preparative chiral-HPLC on ChiralCel OD-H (20x250mm). Enantiomer was detected using a wavelength of 220nm. Main isomer (isomer 1) was collected to provide (R)-N-(3-(2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)-5-methylpyrimidine-4-yl)-1H-indol-7-yl)-2-(4-methylpiperazine-1-yl)propionamide (1.85g, 30%), as a yellow solid.

[0342] 1H NMR (300MHz, DMSO-d6) δ1.26 (d, 3H), 2.16 (s, 3H), 2.30-2.75 (m, 11H), 3.25 (s, 3H), 3.27-3.40 (m, 1H), 6.97 (t, 1H), 7.3 0-7.48(m, 2H), 7.48-7.65(m, 1H), 8.03(d, 1H), 8.13(d, 1H), 8.23-8.40(m, 2H), 9.16(s, 1H), 9.66(s, 1H), 11.38(s, 1H).

[0343] 19 F NMR(282MHz, DMSO-d6)δ-121.22.m / z(ES+), [M+H] + =566.

[0344] The procedure described in Example 2 was repeated using the intermediates shown to give Examples 3-5 described in Table 10 below:

[0345] Table 10

[0346]

[0347] a T3P was added at room temperature.

[0348] b The reaction mixture is evaporated to dryness and redissolved in EtOAc or DCM (50 mL) and washed with saturated NaHCO (2x100 mL) and brine (2x100 mL). The organic layer is dried over NaSO, filtered and evaporated in vacuo. The residue is purified by preparative TLC using DCM / MeOH 10: 1 or 20: 1 as eluent.

[0349] c The crude product was purified by preparative chiral-HPLC on a ChiralPak IA (21.2 x 150 mm, 5 μm) column using 50% hexane (0.1% DEA) in IPA and a flow rate of 20 mL / min. Compounds were detected at wavelengths of 220 and 254 nm. The major isomer was collected and evaporated in vacuo.

[0350] d Reaction time: 2 hours

[0351] e Purification was performed by achiral preparative HPLC on a XBridge C18 OBD column using an increasing gradient of acetonitrile in water (0.05% NH3xH2O).

[0352] fChiral purification on Phenomenex Lux 5u Cellulose-4, AXIA Packed (250x21.2mm, 5μm) was performed at a flow rate of 20mL / min for 30min using 50% hexane in EtOH / MeOH 35:15. Isomers were detected using wavelengths of 254 and 220nm. The major isomer was collected and evaporated in vacuo.

[0353] g On an XBridge C18OBD preparative column ( 5 μm, 19×250 mm) and purified by chiral preparative HPLC using an increasing gradient of acetonitrile in water (0.1% FA) at a flow rate of 20 mL / min. Compounds were detected at wavelengths of 220 and 254 nm.

[0354] Example 6

[0355] (S)-N-(3-(2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)-5-methylpyrimidin-4-yl)-1H-indol-7-yl)-2-(4-methylpiperazin-1-yl)propanamide

[0356] Isomer 2 is collected from the reaction of example 2 and evaporated in vacuo.Using the gradient of MeOH10%-60% in water (0.1% FA), residue is purified again by C18-flash chromatography.Pure fraction is evaporated in vacuo.Using 40%EtOH in CO2 and under 40mL / min flow rate, residue is re-purified by preparative SFC on ChiralCel OD-H (20x250mm).Isomer is detected using a wavelength of 220nm.Isomer 2 is collected, and is white solid to provide (S)-N-(3-(2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)-5-methylpyrimidine-4-yl)-1H-indol-7-yl)-2-(4-methylpiperazine-1-yl) propionamide (40mg).

[0357] 1 H NMR (400MHz, CD3OD) δ1.41 (d, 3H), 2.33 (s, 3H), 2.43 (s, 3H), 2.49-2.87 (m, 8H), 3.15 (s, 3H), 3.39 (q, 1H), 7.02 (t, 1 H), 7.14(dd, 1H), 7.28-7.38(m, 1H), 7.53-7.63(m, 1H), 7.91(s, 1H), 8.09(dd, 1H), 8.27(s, 1H), 8.51-8.61(m, 1H).

[0358] 19F NMR (400MHz, CD3OD) δ-125.65.m / z (ES+), [M+H] + =566.

[0359] Example 7

[0360] (R)-N-(3-(2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)-5-methylpyrimidin-4-yl)-1H-indol-7-yl)-2-((3S,5S)-3,4,5-trimethylpiperazin-1-yl)propanamide

[0361] Step 1

[0362] (R)-2-((3S,5S)-3,4,5-trimethylpiperazin-1-yl)propanoic acid dihydrochloride, Intermediate 26 (113.0 mg, 0.42 mmol) and di(1H-imidazol-1-yl)methanone (127 mg, 0.78 mmol) were dissolved in DMF (3 mL) and stirred at room temperature for 1 h. 3-(2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)-5-methylpyrimidin-4-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indol-7-amine, Intermediate 20 (90.0 mg, 0.17 mmol) was added and the mixture was stirred at 50° C. for 16 h. The reaction mixture was allowed to cool to room temperature, diluted with EtOAc (10.0 mL) and poured into saturated Na2CO3 (30 mL). The phase was shaken, separated and the aqueous phase was extracted with EtOAc (3x15mL). The combined organic extracts were filtered through a phase separator and evaporated in vacuo. The residue was purified by reverse phase preparative HPLC using a gradient (pH=3) of 5%-95% acetonitrile in 0.1M HCO2H (aqueous) on a Waters Sunfire C18 ODB (5 μm, 19x150 mm) column. The product fractions were collected and freeze-dried to provide (R)-N-(3-(2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)-5-methylpyrimidin-4-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indol-7-yl)-2-((3S, 5S)-3,4,5-trimethylpiperazine-1-yl)propionamide (125 mg, 104% (water present)) as a light yellow solid.

[0363] 1H NMR (500MHz, DMSO-d6) δ-0.07 (s, 9H), 0.85-0.92 (m, 2H), 0.98 (d, 6H), 1.24 (d, 3H), 2.17 (s, 3H), 2.20-2.33 (m, 2H), 2.39 (s, 3H), 2.64 (d, 2H), 2.72-2.82 (m, 2H), 3.10 (q, 1H), 3.2 5(s, 3H), 3.45-3.57(m, 2H), 5.68(d, 1H), 5.78(d, 1H), 7.06(t, 1H), 7.33(d, 1H), 7.40(t, 1H), 7.55(t, 1H), 8.16-8.22(m, 2H), 8.28(t, 1H), 8.33(s, 1H), 9.23(s, 1H), 9.45(s, 1H).

[0364] m / z(ES+), [M+H] + =724.

[0365] Step 2

[0366] (R)-N-(3-(2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)-5-methylpyrimidin-4-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indol-7-yl)-2-((3S,5S)-3,4,5-trimethylpiperazine-1-yl)propionamide (97.0mg, 0.13mmol) was dissolved in DCM (1.3mL) and TFA (0.25mL, 3,37mmol) was added. The reaction mixture was stirred at room temperature for 60h. The reaction was diluted with DCM and poured into saturated NaHCO (10mL). The phase was shaken, separated and the aqueous phase was extracted with DCM (3x5mL). The organic extracts were combined, filtered through a phase separator and concentrated in vacuo. The residue was purified by chiral SFC on a Celbarcoat (250x30mm, 5μm) column at 120 bar and 140mL / min flow rate using 35% EtOH / DEA 100:0.5 in CO. The product peak was detected at 270nm. The product was collected and evaporated in vacuo. The residue was repurified by SFC on a Waters BEH (5μm, 30x250mm) column using 20mM MeOH / NH mobile phase in CO. The product fractions were collected and lyophilized to provide (R)-N-(3-(2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)-5-methylpyrimidin-4-yl)-1H-indol-7-yl)-2-((3S,5S)-3,4,5-trimethylpiperazine-1-yl)propionamide, Example 7 (21mg, 27%).

[0367] 1 H NMR (600MHz, DMSO-d6) δ0.98 (d, 6H), 1.28 (d, 3H), 2.17 (s, 3H), 2.21-2.35 (m, 2H), 2.40(s, 3H), 2.62-2.69(m, 2H), 2.71-2.81(m, 2H), 3.19(q, 1H), 3.25(s, 3 H), 6.98(t, 1H), 7.35-7.44(m, 2H), 7.51-7.58(m, 1H), 8.03(d, 1H), 8.13(d, 1H ), 8.25-8.35(m, 2H), 9.17(s, 1H), 9.57(s, 1H), 11.39(s, 1H).m / z(ES+), [M+H] + =594.

[0368] Example 8

[0369] (R)-N-(3-(5-fluoro-2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)pyrimidin-4-yl)-1H-indol-7-yl)-2-((3S,5S)-3,4,5-trimethylpiperazin-1-yl)propanamide

[0370] (R)-2-((3S,5S)-3,4,5-trimethylpiperazine-1-yl)propanoic acid dihydrochloride, intermediate 26 (199 mg, 0.73 mmol) and 1,1′-carbonyldiimidazole (91 mg, 0.56 mmol) were dissolved in DMF (2 mL) and stirred at room temperature for 1.5 hr. 3-(5-fluoro-2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)pyrimidin-4-yl)-1H-indole-7-amine, intermediate 18 (202 mg, 0.49 mmol) was added and the reactants were heated to 60° C. for 3 h. The reactants were allowed to cool to room temperature. DCM (25 mL) was added and the organic phase was washed with 8% NaHCO (3×25 mL), dried with a phase separator and evaporated in vacuo. Use in H o / ACN / NH the gradient of 25%-65% acetonitrile in 95 / 5 / 0.2 buffer, flow velocity is 100mL / min, on XBridgeC18 post (10 μ m, 250x50mm), by preparative HPLC purification residue.Compound is detected by UV at 229nm.Collect product and freeze-dry, to obtain (R)-N-(3-(5-fluoro-2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)pyrimidine-4-yl)-1H-indol-7-yl)-2-((3S, 5S)-3,4,5-trimethylpiperazine-1-yl) propionamide, example 8 (188mg, 65%, 99.4%de), is white solid.

[0371] 1 H NMR (500MHz, DMSO-d6) δ0.98 (d, 6H), 1.28 (d, 3H), 2.17 (s, 3H), 2.2-2.34 ( m, 2H), 2.65 (d, 2H), 2.7-2.81 (m, 2H), 3.19 (q, 1H), 3.27-3.34 (m, 3H), 7.0 3(t, 1H), 7.38-7.5(m, 2H), 7.58-7.66(m, 1H), 8.14-8.25(m, 2H), 8.28(d, 1H), 8.43(d, 1H), 9.45(s, 1H), 9.62(s, 1H), 11.60(s, 1H).m / z(ES+), [M+H] + =598.3.

[0372] Example 9

[0373] (R)-2-((3S,5S)-3,5-dimethylpiperazin-1-yl)-N-(3-(2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)-5-methylpyrimidin-4-yl)-1H-indol-7-yl)propanamide, Isomer 1

[0374] Step 1

[0375] 3-(2-((2-Fluoro-3-(methylsulfonyl)phenyl)amino)-5-methylpyrimidin-4-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indol-7-amine, Intermediate 20 (225 mg, 0.42 mmol), lithium 2-((3S,5S)-4-(tert-butoxycarbonyl)-3,5-dimethylpiperazin-1-yl)propanoate, Intermediate 55 (143 mg, 0.50 mmol) and pyridine (0.088 mL, 1.04 mmol) were dissolved in DCM (5.0 mL) and the resulting reaction mixture was cooled to 0° C. 2,4,6-tripropyl-1,3,5,2,4,6-trioxatriphosphine 2,4,6-trioxide, T3P (0.371 mL, 1.25 mmol) was added to the cooled reaction mixture and the reaction mixture was slowly allowed to reach room temperature. The reaction was stirred for 16h. The reaction was quenched with water, diluted with DCM (5mL), poured into 10% NaCO (30mL), shaken, separated each phase, and aqueous phase was extracted with DCM (3x10mL). The combined organic extracts were filtered through a phase separator and evaporated in a vacuum. Use 45%-95% acetonitrile gradient in H2O / ACN / NH3 95 / 5 / 0.2 buffer, flow rate of 100mL / min, on XBridge C18 posts (10 μm, 250x50mm), the residue was purified by preparative HPLC. Compound was detected by UV at 270nm. The product fractions were collected and lyophilized to afford (2S,6S)-tert-butyl 4-(1-((3-(2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)-5-methylpyrimidin-4-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indol-7-yl)amino)-1-oxopropan-2-yl)-2,6-dimethylpiperazine-1-carboxylate (256 mg, 76%) as a solid.

[0376] 1 H NMR (500MHz, DMSO-d6) δ-0.08 (d, 9H), 0.78-0.97 (m, 2H), 1.18-1.31 (m, 9H), 1.39 (s, 9H) ), 2.32-2.47(m, 5H), 2.61-2.78(m, 2H), 3.18-3.36(m, 4H), 3.42-3.57(m, 2H), 3.77-3.8 9(m, 2H), 5.70(d, 1H), 5.75-5.86(m, 1H), 7.06(t, 1H), 7.27-7.45(m, 2H), 7.55(t, 1H), 8.14-8.23(m,2H),8.27(t,1H),8.33(s,1H),9.24(s,1H),9.53(d,1H).m / z(ES+),[M+H]+ =810.

[0377] Step 2

[0378] To (2S,6S)-tert-butyl 4-(1-((3-(2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)-5-methylpyrimidin-4-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indol-7-yl)amino)-1-oxopropan-2-yl)-2,6-dimethylpiperazine-1-carboxylate (179.8 mg, 0.22 mmol) in DCM (2.0 mL) was added TFA (0.5 mL, 6.73 mmol) and the mixture was stirred at room temperature for 96 h. The reaction was diluted with DCM, quenched by adding water, poured into saturated NaHCO (10 mL), shaken, the phases separated, and the aqueous phase was extracted with EtOAc (3x5 mL). The combined organic extracts were filtered through a phase separator and concentrated in vacuo. The isomers were separated by chiral SFC on a Chiralpak IB (250x30 mm, 5 μm) column using 30% EtOH / DEA 100:0.5 in CO at 120 bar and a flow rate of 150 mL / min. Isomer 1 was collected and evaporated in vacuo to afford (R)-2-((3S,5S)-3,5-dimethylpiperazin-1-yl)-N-(3-(2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)-5-methylpyrimidin-4-yl)-1H-indol-7-yl)propanamide Isomer 1, Example 9 (50 mg, 41%, 97% ee).

[0379] 1 H NMR (500MHz, CDCl3) δ1.22-1.33(m, 6H), 1.39(d, 3H), 2.19-2.36(m, 2H), 2.43(s, 3H), 2.69-2.8(m, 2H), 3.14-3.28(m, 4H), 3.29-3.41(m, 2H), 6.77 (d, 1H), 7.12 (t, 1H), 7.20-7.31 (m, 1H), 7.38 (s, 1H), 7.50 (t, 1H), 7.73 ( d, 1H), 8.20 (d, 1H), 8.31 (s, 1H), 8.99 (t, 1H), 9.83 (s, 1H), 11.45 (s, 1H). There is one exchangeable proton which is not observed.

[0380] Example 10

[0381] (S)-2-((3S,5S)-3,5-dimethylpiperazin-1-yl)-N-(3-(2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)-5-methylpyrimidin-4-yl)-1H-indol-7-yl)propanamide

[0382] Isomer 2 from the synthesis of Step 2 of Example 9 was collected and evaporated in vacuo to give (S)-2-((3S,5S)-3,5-dimethylpiperazin-1-yl)-N-(3-(2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)-5-methylpyrimidin-4-yl)-1H-indol-7-yl)propanamide, Example 10 (48 mg, 36%, 90% ee).

[0383] 1 H NMR (500 MHz, CDCl3) δ 1.24-1.32 (m, 6H), 1.35 (d, 3H), 2.33-2.47 (m, 5H), 2.61-2.78 (m, 2H), 3.24 (s, 3H), 3.33-3.44 (m, 3H), 6.79 (d, 1H), 7.11 (t, 1H), 7.2-7.31 (m, 1H), 7.38 (d, 1H), 7.50 (t, 1H), 7.72 (d, 1H), 8.19 (d, 1H), 8.31 (s, 1H), 8.99 (t, 1H), 9.87 (s, 1H), 11.45 (s, 1H). One exchangeable proton was not observed.

[0384] Example 11

[0385] (R)-2-((3S,5S)-3,5-dimethylpiperazin-1-yl)-N-(3-(5-fluoro-2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)pyrimidin-4-yl)-1H-indol-7-yl)propanamide Isomer 1

[0386] Step 1

[0387] 3-(5-Fluoro-2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)pyrimidin-4-yl)-1H-indol-7-amine, Intermediate 18 (318 mg, 0.77 mmol), lithium 2-((3S,5S)-4-(tert-butoxycarbonyl)-3,5-dimethylpiperazin-1-yl)propanoate, Intermediate 55 (235 mg, 0.80 mmol) and DIPEA (0.535 mL, 3.06 mmol) were dissolved in DMF (2 mL) and 2-(3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)-1,1,3,3-tetramethylisouronium hexafluorophosphate (V) (306 mg, 0.80 mmol) was added. The reaction was heated to 50° C. for 1.5 hours and then cooled to ambient temperature. The reaction mixture is diluted with DCM (25mL) and 5%NaCO (aqueous) (25mL), shaken and separated. The aqueous phase is extracted with DCM (2x25mL). The organic phase merged is dried with NaSO, filtered and evaporated in a vacuum. Use the gradient of 45%-85% acetonitrile in HO / ACN / NH 95 / 5 / 0.2 buffer, through 20 minutes, flow rate is 100mL / min, on XBridge C18 post (10 μm, 250x50mm), pass through preparation HPLC purification compound. Detect compound at 230nm by UV. Collect product and freeze-dry. Under 120 bar and under 70ml / min flow rate, use 35%EtOH / DEA 100 in CO: 0.5 as eluent, by using the chiral SFC on Celbarcoat (250x20mm, 5 μm) post, non-corresponding isomers are separated. Diastereomers were detected at 300nm. The first eluting compound was collected and evaporated in vacuo as isomer 1. The residue was dissolved in acetonitrile / water and freeze-dried to obtain (2S, 6S)-tert-butyl 4-(1-((3-(5-fluoro-2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)pyrimidin-4-yl)-1H-indol-7-yl)amino)-1-oxopropan-2-yl)-2,6-dimethylpiperazine-1-carboxylate isomer 1 (62.0mg, 25.3%, 99.9%de) as a white solid.

[0388] 1H NMR (500MHz, DMSO-d6) δ1.19-1.34 (m, 9H), 1.39 (s, 9H), 2.40 (dd, 2H), 2.75 (dd, 2H), 3.26-3.37 (m, 4H), 3.75-3.87 (m, 2H), 7.0 4 (t, 1H), 7.39-7.51 (m, 2H), 7.62 (t, 1H), 8.14-8.25 (m, 2H), 8.28 (d, 1H), 8.44 (d, 1H), 9.45 (s, 1H), 9.68 (s, 1H), 11.54 (s, 1H).

[0389] m / z(ES+), [M+H] + =684.3.

[0390] Step 2

[0391] Tert-butyl (2S,6S)-4-(1-((3-(5-fluoro-2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)pyrimidin-4-yl)-1H-indol-7-yl)amino)-1-oxopropan-2-yl)-2,6-dimethylpiperazine-1-carboxylate (62 mg, 0.09 mmol) was dissolved in DCM (4 mL) and TFA (1 mL, 12.98 mmol) was added. The reaction was stirred at room temperature for 1 h and then evaporated in vacuo. The residue was dissolved in DCM (25 mL), 8% NaHCO3 (aq) (25 mL), shaken and the phases separated. The aqueous phase was extracted with DCM (25 mL). The combined organic phases were dried using a phase separator and evaporated in vacuo. The residue was purified by SFC on a Waters BEH 2-EP (5 μm, 30x250 mm) column using MeOH / NH 20 mM as eluent. The product was collected and evaporated in vacuo to afford (R)-2-((3S,5S)-3,5-dimethylpiperazin-1-yl)-N-(3-(5-fluoro-2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)pyrimidin-4-yl)-1H-indol-7-yl)propanamide, Example 11 (32.7 mg, 61.8%).

[0392] 1H NMR (600MHz, DMSO-d6) δ1.06 (d, 6H), 1.26 (d, 3H), 2.12-2.21 (m, 2H), 2.61 (dd, 2H), 3.06-3.14 (m, 2H), 3.20 (q, 1H), 3.30 (s, 3H), 7.03 (t, 1H), 7.4 1(d,1H),7.46(t,1H),7.59-7.65(m,1H),8.16-8.24(m,2H),8.27(d,1H) ,8.43(d,1H),9.45(s,1H),9.65(s,1H),11.63(bs,1H).m / z(ES+),[M+H] + =584.2.

[0393] Example 12

[0394] (S)-2-((3S,5S)-3,5-dimethylpiperazin-1-yl)-N-(3-(5-fluoro-2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)pyrimidin-4-yl)-1H-indol-7-yl)propanamide Isomer 2

[0395] Step 1

[0396] The second eluting compound from the reaction of Example 11 Step 1 was collected and evaporated in vacuo. The residue was dissolved in acetonitrile / water - the white solid disintegrated. The solid was filtered, washed with acetonitrile / water and dried in vacuo to afford (2S,6S)-tert-butyl 4-(1-((3-(5-fluoro-2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)pyrimidin-4-yl)-1H-indol-7-yl)amino)-1-oxopropan-2-yl)-2,6-dimethylpiperazine-1-carboxylate Isomer 2 (89 mg, 36.3%, 99.3% de) as a white solid.

[0397] 1 H NMR (500MHz, DMSO-d6) δ1.18-1.31 (m, 9H), 1.39 (s, 9H), 2.44 (dd, 2H), 2.69 (dd, 2H), 3.26-3.36 (m, 3H), 3.49 (q, 1H), 3.78-3.89 (m, 2H ), 7.03 (t, 1H), 7.38-7.51 (m, 2H), 7.62 (t, 1H), 8.15-8.24 (m, 2H), 8.27 (d, 1H), 8.44 (d, 1H), 9.45 (s, 1H), 9.73 (s, 1H), 11.60 (s, 1H).

[0398] m / z(ES+), [M+H] + =684.2.

[0399] Step 2

[0400] Tert-butyl (2S,6S)-4-(1-((3-(5-fluoro-2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)pyrimidin-4-yl)-1H-indol-7-yl)amino)-1-oxopropan-2-yl)-2,6-dimethylpiperazine-1-carboxylate isomer 2 (89 mg, 0.13 mmol) was dissolved in DCM (4 mL) and TFA (1 mL, 12.98 mmol) was added. The reaction was stirred at room temperature for 1 h and then evaporated in vacuo. The residue was dissolved in DCM (25 mL), 8% NaHCO3 (aqueous) (25 mL), shaken and the phases separated. The aqueous phase was extracted with DCM (25 mL). The combined organic phases were dried with a phase separator and evaporated in vacuo. The residue was dissolved in DMSO and purified by SFC on a Waters BEH 2-EP (5 μm, 30x250 mm) column using MeOH / NH 20 mM as eluent. The product was collected and evaporated in vacuo to provide (S)-2-((3S,5S)-3,5-dimethylpiperazine-1-yl)-N-(3-(5-fluoro-2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)pyrimidin-4-yl)-1H-indol-7-yl)propanamide, Example 12 (32.4 mg, 42.6%).

[0401] 1 H NMR (600MHz, DMSO-d6) δ1.06 (d, 6H), 1.19 (d, 3H), 2.21 (dd, 2H), 2.52-2.59 (m, 2H), 3.08-3.17 (m, 2H), 3.30 (s, 3H), 3.37-3.5 (m, 1H), 7.03 ( t, 1H), 7.40 (d, 1H), 7.46 (t, 1H), 7.58-7.67 (m, 1H), 8.13-8.23 (m, 2H ), 8.26 (d, 1H), 8.43 (d, 1H), 9.45 (s, 1H), 9.72 (s, 1H), 11.67 (bs, 1H).

[0402] m / z(ES+), [M+H] + =584.2.

[0403] Example 13

[0404] (S)-N-(3-(2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)-5-methylpyrimidin-4-yl)-1H-indol-7-yl)-2-(4-methylpiperazin-1-yl)butanamide,

[0405] DIPEA (2.54 mL, 14.58 mmol) was added to lithium 2-(4-methylpiperazin-1-yl)butanoate, intermediate 65 (1.81 g, 9.72 mmol) and 3-(2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)-5-methylpyrimidin-4-yl)-1H-indol-7-amine, intermediate 11 (2.00 g, 4.86 mmol) in DCM (50 mL) at 15°C under nitrogen. The mixture was stirred for 10 mins, T3P (50% in EtOAc) (6.18 g, 9.72 mmol) was added dropwise at 0°C, and the reaction was stirred at 0°C for 1 hour. The solvent was then concentrated in vacuo. The residue was purified by fast C18 flash chromatography using a gradient of 5%-80% MeOH in water (NH4HCO3). The pure fractions were evaporated to dryness. On SunFire preparative C18OBD column (5 μm, 30x100mm), a water mixture (containing NH4HCO3) in acetonitrile with gradually decreasing polarity is used as eluent, and the residue is repurified by preparative HPLC. The fraction containing the desired compound is evaporated in a vacuum. Use 50%IPA (0.1%DEA) in CO2 and at a flow rate of 150mL / min, the enantiomers are separated by preparative chiral SFC on ChiralPak AD-H (50x250mm, 5 μm) column. Use UV to detect enantiomers at 254nm. The first eluting isomer was collected and evaporated in vacuo to provide (S)-N-(3-(2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)-5-methylpyrimidin-4-yl)-1H-indol-7-yl)-2-(4-methylpiperazin-1-yl)butanamide, Example 13 (200 mg, 7%, 96.4% ee) as a white solid.

[0406] 1 H NMR (400 MHz, CD3OD) δ 1.05 (t, 3H), 1.77-1.99 (m, 2H), 2.30 (s, 3H), 2.43 (s, 3H), 2.45-2.90 (m, 8H), 3.11-3.23 (m, 4H), 7.02 (t, 1H), 7.18 (d, 1H), 7.32 (t, 1H), 7.52-7.62 (m, 1H), 7.91 (s, 1H), 8.06-8.15 (m, 1H), 8.27 (s, 1H), 8.51-8.61 (m, 1H). No exchangeable protons were observed. 19 F NMR (400MHz, CD3OD) δ-125.77.m / z (ES+), [M+H] + =580.

[0407] Example 14

[0408] (R)-N-(3-(2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)-5-methylpyrimidin-4-yl)-1H-indol-7-yl)-2-(4-methylpiperazin-1-yl)butanamide

[0409] The second eluting isomer from the synthesis of Example 13 was collected and evaporated in vacuo to provide (R)-N-(3-(2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)-5-methylpyrimidin-4-yl)-1H-indol-7-yl)-2-(4-methylpiperazin-1-yl)butanamide Isomer 2, Example 14 (200 mg, 7%, 92.8% ee) as a white solid.

[0410] 1 H NMR (400 MHz, CD3OD) 61.05 (t, 3H), 1.77-1.99 (m, 2H), 2.30 (s, 3H), 2.43 (s, 3H), 2.45-2.95 (m, 8H), 3.11-3.23 (m, 4H), 7.02 (t, 1H), 7.18 (d, 1H), 7.33 (t, 1H), 7.52-7.62 (m, 1H), 7.91 (s, 1H), 8.06-8.15 (m, 1H), 8.27 (s, 1H), 8.51-8.61 (m, 1H). No exchangeable protons were observed. 19 F NMR (400MHz, CD3OD) δ-125.72.m / z (ES+), [M+H] + =580.

[0411] The procedures of Examples 13 and 14 above were repeated using the intermediates indicated to give Examples 15-18 described in Table 11 below:

[0412] Table 11

[0413]

[0414]

[0415] a No reverse phase HPLC purification was used.

[0416] b The isomers were separated by chiral SFC on a Chiralpak AS-H (50x250mm, 5μm) column using 50% MeOH (0.1% DEA) in CO2 as the mobile phase and at a flow rate of 150 mL / min. The desired isomer was collected and evaporated in vacuo.

[0417] cDMF was used as solvent.

[0418] d The compound was purified by preparative HPLC on a XBridge Prep C18 OBD column (5 μm, 19×150 mm) using decreasingly polar mixtures of water in acetonitrile (containing 0.1% formic acid) as eluent. The fractions containing the desired compound were evaporated in vacuo.

[0419] e These isomers were separated by preparative chiral SFC on a ChiralPak AD-H (20x250mm, 5μm) column using 45% IPA (0.1% DEA) in CO2 and at a flow rate of 40mL / min. Isomers were detected using UV at 220nm. The desired isomer was collected and evaporated in vacuo.

[0420] Example 19

[0421] (S)-N-(3-(2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)-5-methylpyrimidin-4-yl)-1H-indol-7-yl)-2-((3S,5S)-3,4,5-trimethylpiperazin-1-yl)butanamide

[0422] Under nitrogen, 3-(2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)-5-methylpyrimidin-4-yl)-1H-indol-7-amine, intermediate 11 (300 mg, 0.73 mmol) was added to lithium 2-((3S,5S)-3,4,5-trimethylpiperazin-1-yl)butanoate, intermediate 49 (313 mg, 1.46 mmol), 1-propanephosphonic acid cyclic anhydride, T3P (50% in EtOAc) (928 mg, 1.46 mmol) and DIPEA (1.019 mL, 5.83 mmol) in DCM (1 mL). The resulting solution was stirred at 25° C. for 1 hour. The reaction mixture was diluted with DCM (50 mL), washed with saturated NaHCO3 (2×100 mL), brine (2×100 mL), dried over Na2SO4, filtered and evaporated in vacuo. The residue was purified by preparative TLC using DCM / MeOH 10:1. The product fraction was evaporated in vacuo. Using 50%IPA (0.1%DEA) in hexane as mobile phase and at a flow rate of 15mL / min, the diastereomers were separated by preparative chiral HPLC on ChiralPak-AD-H-SL001 (20x250mm) columns. UV was used to detect diastereomers at 254 and 220nm. The first eluting isomer was collected and evaporated in vacuo to provide (S)-N-(3-(2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)-5-methylpyrimidin-4-yl)-1H-indol-7-yl)-2-((3S, 5S)-3,4,5-trimethylpiperazine-1-yl)butyramide, Example 19 (30mg, 24%, 99.9%ee), as a white solid.

[0423] 1 H NMR (300 MHz, CD3OD) δ 1.07 (t, 3H), 1.17 (d, 6H), 1.75-1.98 (m, 2H), 2.39 (s, 3H), 2.45 (s, 3H), 2.52-2.70 (m, 2H), 2.89 (dd, 2H), 2.93-3.10 (m, 2H), 3.11-3.25 (m, 4H), 7.03 (t, 1H), 7.17 (dd, 1H), 7.35 (dd, 1H), 7.54-7.64 (m, 1H), 7.93 (s, 1H), 8.10 (dd, 1H), 8.29 (s, 1H), 8.52-8.62 (m, 1H). No exchangeable protons were observed.

[0424] 19 F NMR(282MHz, DMSO-d6)δ-121.25.m / z(ES+), [M+H] + =608.

[0425] Example 20

[0426] (R)-N-(3-(2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)-5-methylpyrimidin-4-yl)-1H-indol-7-yl)-2-((3S,5S)-3,4,5-trimethylpiperazin-1-yl)butanamide

[0427] The second eluting isomer from the synthesis of Example 19 was collected and evaporated in vacuo to provide (R)-N-(3-(2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)-5-methylpyrimidin-4-yl)-1H-indol-7-yl)-2-((3S,5S)-3,4,5-trimethylpiperazin-1-yl)butanamide Isomer 2, Example 20

[0428] (5 mg, 4%, 90% ee) as a white solid.

[0429] 1 H NMR (300 MHz, CD3OD) δ 1.09 (t, 3H), 1.25-1.45 (m, 6H), 1.70-1.98 (m, 2H), 2.45 (s, 3H), 2.74 (s, 3H), 2.98-3.13 (m, 2H), 3.16 (s, 3H), 3.15-3.60 (m, 5H), 7.03 (t, 1H), 7.21 (d, 1H), 7.35 (t, 1H), 7.53-7.65 (m, 1H), 7.93 (s, 1H), 8.10 (d, 1H), 8.30 (s, 1H), 8.50-8.65 (m, 1H). No exchangeable protons were observed.

[0430] 19 F NMR(282MHz, DMSO-d6)δ-121.11.m / z(ES+), [M+H] + =608.

[0431] The procedures of Example 19 and Example 20 above were repeated using the intermediates indicated to give Examples 21-23 described in Table 12 below:

[0432] Table 12

[0433]

[0434]

[0435] aUse the gradient of 30%-55% acetonitrile in water (0.05% NH3H2O) and elution at 30mL / min flow rate, by the preparative HPLC on XBridge Prep C18OBD column (5 μm, 19x150mm) purify residue again. Under the wavelength of 220 and 254nm, detect this compound. Collect the fraction containing the desired compound and evaporate in vacuum.

[0436] b These isomers were separated by preparative chiral HPLC on a Phenomenex Lux 5u Cellulose-4, AXIA Packed (250x21.2mm, 5μm) column using hexane (0.1% DEA) / EtOH / MeOH 50:35:15 and a flow rate of 220 mL / min. The desired isomer was collected and evaporated in vacuo.

[0437] c Purify by preparative HPLC on a XBridge Prep C18 OBD column (5 μm, 19×150 mm) using decreasingly polar mixtures of water in acetonitrile (containing 0.1% NH 4 HCO 3 ) as eluent. Fractions containing the desired compound were evaporated in vacuo.

[0438] Example 24

[0439] (R)-N-(3-(2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)-5-methylpyrimidin-4-yl)-1H-indol-7-yl)-2-(piperazin-1-yl)propanamide

[0440] Step 1

[0441] Under nitrogen, DIPEA (0.637 mL, 3.65 mmol) was added to 3-(2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)-5-methylpyrimidin-4-yl)-1H-indol-7-amine, intermediate 11 (500 mg, 1.22 mmol), lithium 2-(4-(tert-butoxycarbonyl)piperazin-1-yl)propanoate, intermediate 66 (628 mg, 2.43 mmol), EDC (349 mg, 1.82 mmol) and HOBT (279 mg, 1.82 mmol) in DMF (10 mL). The resulting solution was stirred at 25 °C for 15 hours. The reaction mixture was poured into water (75 mL) and extracted with EtOAc (2x75 mL). The combined organic layers were washed with brine (3x100 mL), dried over Na2SO4, filtered and evaporated in vacuo. The residue was purified by preparative TLC using DCM / MeOH 8:1 to afford tert-butyl 4-(1-((3-(2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)-5-methylpyrimidin-4-yl)-1H-indol-7-yl)amino)-1-oxopropan-2-yl)piperazine-1-carboxylate (440 mg, 55.6%) as a light yellow solid. m / z (ES+), [M+H] + =652.

[0442] Step 2

[0443] At 20°C, TFA (0.050 mL, 0.64 mmol) was added dropwise to tert-butyl 4-(1-((3-(2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)-5-methylpyrimidin-4-yl)-1H-indol-7-yl)amino)-1-oxopropan-2-yl)piperazine-1-carboxylate (420 mg, 0.64 mmol) in DCM (20 mL). The resulting solution was stirred at 20°C for 2 hours. The solvent was evaporated in vacuo. The residue was diluted with DCM (50 mL), washed with NaHCO (2x50 mL), and the organic layer was evaporated in vacuo. The enantiomers were separated by preparative chiral HPLC on Phenomenex Lux 5u Cellulose-4, AXIA Packed (250 x 21.2 mm, 5 μm) using 100% MeOH (0.1% DEA) as eluent and 20 mL / min flow rate. Isomers were detected at wavelengths of 254 and 220 nm. The first eluting isomer was collected and evaporated in vacuo to provide (R)-N-(3-(2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)-5-methylpyrimidin-4-yl)-1H-indol-7-yl)-2-(piperazine-1-yl)propionamide Isomer 1, Example 24 (53 mg, 27%, 99.9% ee), as a white solid.

[0444] 1 H NMR (400 MHz, DMSO-d6) δ 1.26 (d, 3H), 2.41 (s, 3H), 2.45-2.65 (m, 4H), 2.73-2.85 (m, 4H), 3.22-3.40 (m, 4H), 6.98 (t, 1H), 7.35-7.50 (m, 2H), 7.50-7.62 (m, 1H), 8.03 (s, 1H), 8.14 (d, 1H), 8.25-8.37 (m, 2H), 9.18 (s, 1H), 9.73 (s, 1H), 11.48 (bs, 1H). One exchangeable proton was not observed.

[0445] 19 F NMR(376MHz, DMSO-d6)-121.21.m / z(ES+), [M+H] + =552.

[0446] Example 25

[0447] (S)-N-(3-(2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)-5-methylpyrimidin-4-yl)-1H-indol-7-yl)-2-(piperazin-1-yl)propanamide

[0448] The second eluting isomer from the reaction of Example 24, Step 2 was collected and evaporated in vacuo to provide (S)-N-(3-(2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)-5-methylpyrimidin-4-yl)-1H-indol-7-yl)-2-(piperazin-1-yl)propanamide, Example 25 (47 mg, 24%, 92.6% ee) as a white solid.

[0449] 1 H NMR (300 MHz, DMSO-d6) δ 1.25 (d, 3H), 2.39 (s, 3H), 2.43-2.65 (m, 4H), 2.68-2.85 (m, 4H), 3.22-3.40 (m, 4H), 6.97 (t, 1H), 7.35-7.50 (m, 2H), 7.50-7.62 (m, 1H), 8.02 (s, 1H), 8.12 (d, 1H), 8.25-8.37 (m, 2H), 9.17 (s, 1H), 9.69 (s, 1H), 11.43 (bs, 1H). One exchangeable proton was not observed.

[0450] 19 F NMR(282MHz, DMSO-d6)-121.20.m / z(ES+), [M+H] +=552.

[0451] Example 26

[0452] (R)-2-((3R,5R)-3,5-dimethylpiperazin-1-yl)-N-(3-(2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)-5-methylpyrimidin-4-yl)-1H-indol-7-yl)butanamide

[0453] Step 1

[0454] DIPEA (1.02 mL, 5.83 mmol) was added in one portion to lithium 2-((3R,5R)-4-(tert-butoxycarbonyl)-3,5-dimethylpiperazin-1-yl)butanoate, Intermediate 56 (438 mg, 1.46 mmol) and 3-(2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)-5-methylpyrimidin-4-yl)-1H-indol-7-amine, Intermediate 11 (300 mg, 0.73 mmol) in DCM (5 mL) at 25°C. The resulting solution was stirred at 25°C for 10 mins. 1-Propanephosphonic acid cyclic anhydride T3P (928 mg, 1.46 mmol) was added dropwise at 0°C and the reaction was stirred for 1 hour. The reaction mixture was concentrated in vacuo. The residue was purified by preparative TLC using MeOH / DCM 1:10 to afford (2R,6R)-tert-butyl 4-(1-((3-(2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)-5-methylpyrimidin-4-yl)-1H-indol-7-yl)amino)-1-oxobutan-2-yl)-2,6-dimethylpiperazine-1-carboxylate (200 mg, 39.5%) as a yellow solid.

[0455] 1 H NMR (400 MHz, CD3OD) δ 1.03-1.11 (m, 3H), 1.18-1.52 (m, 15H), 1.81-1.92 (m, 2H), 2.35-2.80 (m, 5H), 2.82-2.93 (m, 2H), 3.15 (s, 3H), 3.75-3.99 (m, 2H), 4.08-4.21 (m, 1H), 7.02 (t, 1H), 7.18 (dd, 1H), 7.32 (t, 1H), 7.52-7.61 (m, 1H), 7.91 (d, 1H), 8.09 (d, 1H), 8.26 (s, 1H), 8.51-8.61 (m, 1H). No exchangeable protons were observed. A mixture of diastereomers.

[0456] m / z(ES+), [M+H] + =694.

[0457] Step 2

[0458] TFA (5 mL, 64.90 mmol) was added to (2R,6R)-tert-butyl 4-(1-((3-(2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)-5-methylpyrimidin-4-yl)-1H-indol-7-yl)amino)-1-oxobutan-2-yl)-2,6-dimethylpiperazine-1-carboxylate (370 mg, 0.53 mmol) in DCM (20 mL) at 25°C and the resulting mixture was stirred at room temperature for 2 hours. The solvent was concentrated in vacuo. The residue was purified by reverse phase preparative chromatography on an XBridge Prep C18 OBD column (5 μm, 19×150 mm) at a flow rate of 30 mL / min over 7 minutes using a gradient of 30-50% acetonitrile in water (0.03% NH 3 H 2 O). Compounds were detected using wavelengths of 220 and 254 nm. Using 50%EtOH (0.1%DEA) in hexane, at 15mL / min flow rate through 85min, by the preparative chiral HPLC on ChiralPak-AD-H-SL001 (20x250mm), diastereomers are separated. Use the wavelength detection compound of 220 and 254nm. Collect the first eluting compound and evaporate in vacuo to provide R-2-((3R, 5R)-3,5-dimethylpiperazine-1-yl)-N-(3-(2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)-5-methylpyrimidine-4-yl)-1H-indol-7-yl)butyramide, example 26 (78mg, 28%, 99.0%ee).

[0459] 1 H NMR (400MHz, CD3OD) δ1.09 (t, 3H), 1.41 (d, 6H), 1.80-2.00 (m, 2H), 2.44 (s, 3H), 2.77(dd, 2H), 3.07(dd, 2H), 3.15(s, 3H), 3.28-3.40(m, 1H), 3.55-3.7 2(m, 2H), 7.02(t, 1H), 7.23(d, 1H), 7.33(t, 1H), 7.53-7.62(m, 1H), 7.92(d , 1H), 8.05-8.13(m, 1H), 8.28(s, 1H), 8.40-8.49(m, 2H), 8.50-8.60(m, 1H).

[0460] 19 F NMR (376MHz, CD3OD) δ-125.59.m / z (ES+), [M+H] + =594.

[0461] Example 27

[0462] (S)-2-((3R,5R)-3,5-dimethylpiperazin-1-yl)-N-(3-(2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)-5-methylpyrimidin-4-yl)-1H-indol-7-yl)butanamide

[0463] The second eluting compound from the reaction of Example 26 Step 2 was collected and evaporated in vacuo to provide (S)-2-((3R,5R)-3,5-dimethylpiperazin-1-yl)-N-(3-(2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)-5-methylpyrimidin-4-yl)-1H-indol-7-yl)butanamide Example 27 (30.0 mg, 13%, 99.9% ee) as a white solid.

[0464] 1 H NMR (400 MHz, CD3OD) δ 1.07 (t, 3H), 1.22 (d, 6H), 1.80-1.93 (m, 2H), 2.40-2.58 (m, 5H), 2.81 (dd, 2H), 3.07-3.18 (m, 4H), 3.19-3.29 (m, 2H), 7.03 (t, 1H), 7.19 (d, 1H), 7.35 (t, 1H), 7.53-7.63 (m, 1H), 7.94 (s, 1H), 8.05-8.15 (m, 1H), 8.29 (s, 1H), 8.52-8.62 (m, 1H). No exchangeable protons were observed. m / z (ES+), [M+H] + =594.

[0465] The procedures of Examples 26 and 27 above were repeated with the indicated intermediates to give Examples 28-33 described in Table 13 below:

[0466] Table 13

[0467]

[0468]

[0469]

[0470]

[0471] a The reaction mixture from step 1 was diluted with EtOAc or DCM (300 mL), washed with water (150 mL) and brine (125 mL). The organic layer was dried over Na2SO4, filtered and evaporated in vacuo. The residue was purified by preparative TLC using DCM / MeOH 20:1 or 30:1.

[0472] b The isomers were separated by preparative chiral HPLC on a Phenomenex Lux 5u Cellulose-4, AXIA Packed (250x21.2mm, 5μm) column using hexane: EtOH: MeOH 50: 35: 15 as mobile phase and 20mL / min flow rate. Compounds were detected using wavelengths of 254 and 220nm. The desired isomer was collected and evaporated in vacuo.

[0473] c Step 2: Use 15%-45% acetonitrile in water (10mmol / L NH4HCO3) as mobile phase and 25mL / min flow rate, by preparative HPLC purification on XBridge Shield RP18 OBD column (5μm, 19x150mm). Use wavelength 254 and 220nm to detect compound. The fraction containing the desired compound is evaporated in vacuo.

[0474] d Use 100% MeOH (0.1% DEA) as mobile phase, and with the flow rate of 20mL / min through 21min, by the preparative chiral HPLC on (R, R)-WHELK-O1-Kromasil (50x250mm, 5 μm), the isomer is separated. Use the wavelength of 254 and 220nm to detect the isomer. Collect the required isomer and evaporate in vacuum.

[0475] e Step 2: Purify by preparative HPLC on a XBridge Prep C18 OBD column (5 μm, 19 x 150 mm) using decreasingly polar mixtures of water in acetonitrile (containing 0.05% formic acid) as eluent. Fractions containing the desired compound were evaporated in vacuo.

[0476] Example 34

[0477] (S)-N-(3-(5-fluoro-2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)pyrimidin-4-yl)-1H-indol-7-yl)-3-methoxy-2-(4-methylpiperazin-1-yl)propanamide

[0478] Lithium 3-methoxy-2-(4-methylpiperazin-1-yl)propanoate, Intermediate 48 (430 mg, 2.06 mmol), 2-(3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)-1,1,3,3-tetramethylisouronium hexafluorophosphate (V) (785 mg, 2.06 mmol) and DIPEA (1.068 mL, 6.11 mmol) were dissolved in DMF (10 mL) and stirred at room temperature for 5 min, and then 3-(5-fluoro-2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)pyrimidin-4-yl)-1H-indol-7-amine, Intermediate 18 (635 mg, 1.53 mmol) was added. The reaction was stirred at room temperature for 2 h, then diluted with DCM (75 mL) and 5% Na2CO3 (aq) (50 mL), shaken and the phases separated. The aqueous phase is extracted with DCM (2x50mL). The combined organic phase is dried with a phase separator, filtered and evaporated in a vacuum. Using 15%-65% acetonitrile gradient in H2O / ACN / NH395 / 5 / 0.2 buffer, with a flow rate of 100mL / min through 20 minutes, by the preparative HPLC purification compound on XBridge C18 column (10 μm, 250x50mm). Detect compound at 220nm by UV. Collect product peak and freeze-dry. Then crystallize from acetonitrile, and collect solid by filtration, wash with a minimum amount of acetonitrile and dry in a vacuum. At 150 bar and 140mL / min flow rate, use 25%IPA / DEA 100 in CO2: 0.5, by chiral SFC on CelluCoat (250x30mm, 5μm) column, enantiomers are separated. Detect enantiomers by UV at 270nm. The first eluting enantiomer was collected and lyophilized to provide N-(3-(5-fluoro-2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)pyrimidin-4-yl)-1H-indol-7-yl)-3-methoxy-2-(4-methylpiperazin-1-yl)propanamide, Example 34 (213 mg, 23%, 99.9% ee) as a white solid.

[0479] 1H NMR (500MHz, DMSO-d6) δ2.14 (s, 3H), 2.24-2.44 (m, 4H), 2.56-2.67 (m, 2H), 2.68-2.8(m, 2H), 3.24-3.35(m, 6H), 3.50(t, 1H), 3.67(dd, 1H), 3.79(dd, 1 H), 7.04(t, 1H), 7.41-7.55(m, 2H), 7.62(t, 1H), 8.19(t, 1H), 8.22-8.32(m ,2H),8.44(d,1H),9.46(s,1H),9.84(s,1H),11.47(s,1H).m / z(ES+),[M+H] + =600.2.

[0480] Example 35

[0481] (R)-N-(3-(5-fluoro-2-(2-fluoro-3-(methylsulfonyl)phenylamino)pyrimidin-4-yl)-1H-indol-7-yl)-3-methoxy-2-(4-methylpiperazin-1-yl)propanamide

[0482] The second eluting enantiomer from Example 34 was collected and lyophilized. The residue was recrystallized by stirring a suspension in EtOH / water (3:1) (5 mL), heated to 70°C using an oil bath and seed crystals were added. The oil bath temperature was then set to 23°C and the suspension was allowed to slowly reach room temperature. Stirring was continued for 5 days to give a milky slurry containing short needle-shaped crystals mixed with longer needle-shaped crystals. The suspension was heated to 70°C under stirring, then the heating and stirring were turned off, and the mixture was allowed to slowly reach room temperature (2x). Only intact long needle-shaped crystals were present. The suspension was left to stand for a week without stirring. The solid was filtered off and dried in vacuo at 40 °C to provide (R)-N-(3-(5-fluoro-2-(2-fluoro-3-(methylsulfonyl)phenylamino)pyrimidin-4-yl)-1H-indol-7-yl)-3-methoxy-2-(4-methylpiperazin-1-yl)propanamide, Example 35 (186 mg, 20%, 99.4% ee) as white needle crystals.

[0483] 1H NMR (500MHz, DMSO-d6) δ2.14 (s, 3H), 2.23-2.45 (m, 4H), 2.57-2.67 (m, 2H), 2.69-2.78 (m, 2H), 3.26-3.34 (m, 6H), 3.50 (t, 1H), 3.67 (dd, 1H), 3.79(dd, 1H), 7.03(t, 1H), 7.4-7.55(m, 2H), 7.62(t, 1H), 8.13-8.33(m, 3H), 8.44(d, 1H), 9.46(s, 1H), 9.84(s, 1H), 11.48(s, 1H). 19 F NMR (470MHz, DMSO-d6) δ-120.52, -147.75.m / z (ES+), [M+H] + =600.5.

[0484] The sample of Example 35 was mounted on a single crystal silicon (SSC) wafer mount and powder X-ray diffraction was recorded using a θ-θ PANalytical X'Pert PRO (the wavelength of the X-ray was The sample was scanned from 2-50° 2θ using a PIXCEL detector (effective length 3.35° 2θ) with a 0.013° step size and a 233 sec step size measurement time. The characteristic peak positions of the crystals are listed in Table 14 below (determined by XRPD) and are as follows: Figure 1 As shown:

[0485] Table 14 - Five largest characteristic peaks of Example 35:

[0486]

[0487] Those skilled in the art will understand that the diffraction pattern data presented herein should not be interpreted as absolute and that any crystalline form that provides a powder diffraction pattern substantially consistent with those disclosed herein falls within the scope of the disclosure herein (for further information see Jenkins, R & Snyder, RL "Introduction to X-Ray Powder Diffractometry", John Wiley & Sons, 1996).

[0488] Example 36

[0489] (S)-N-(3-(2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)-5-methylpyrimidin-4-yl)-1H-indol-7-yl)-2-(4-methyl-1,4-diazepan-1-yl)butanamide

[0490] HATU ((1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate) (832 mg, 2.19 mmol) was added to 3-(2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)-5-methylpyrimidin-4-yl)-1H-indol-7-amine in DMF (1 mL), intermediate 11 (300 mg, 0.73 mmol) was added to 1H-indol-7-amine (300 mg, 0.73 mmol). ol), lithium 2-(4-methyl-1,4-diazepan-1-yl)butanoate, intermediate 58 (511 mg, 2.55 mmol) and DIPEA (1.273 mL, 7.29 mmol). The resulting solution was stirred at 25°C for 16 hours. The reaction was performed by XBridge HPLC using a gradient of 30%-55% acetonitrile in water (0.03% NH3H2O) as the eluent and a flow rate of 30 mL / min. The crude product was purified by reverse phase preparative chromatography on a Prep C18 OBD column (5 μm, 19x150 mm). Compounds were detected at wavelengths of 220 and 254 nm. Enantiomers were separated by chiral SFC on a (R, R) WHELK-015 / 100 Kromasil (250x21.1 mm) column using 50% MeOH / acetonitrile 1:1 (0.1% DEA) in CO2 and a flow rate of 50 mL / min; Compounds were detected at a wavelength of 220 nm. The first eluting isomer was collected and evaporated in vacuo to provide (S)-N-(3-(2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)-5-methylpyrimidin-4-yl)-1H-indol-7-yl)-2-(4-methyl-1,4-diazepan-1-yl)butanamide, Example 36 (40 mg, 6%, 99.9% ee).

[0491] 1 H NMR (400 MHz, CD3OD) δ 1.08 (t, 3H), 1.72-2.02 (m, 4H), 2.38-2.50 (m, 6H), 2.70-2.85 (m, 4H), 2.88-3.10 (m, 4H), 3.15 (s, 3H), 3.27-3.40 (m, 1H), 7.02 (t, 1H), 7.26 (d, 1H), 7.34 (t, 1H), 7.52-7.65 (m, 1H), 7.92 (s, 1H), 8.08, (d, 1H), 8.28 (s, 1H), 8.52-8.63 (m, 1H). No exchangeable protons were observed.

[0492] 19 F NMR (376MHz, CD3OD) δ-125.64.m / z (ES+), [M+H] + =594.

[0493] Example 37

[0494] (R)-N-(3-(2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)-5-methylpyrimidin-4-yl)-1H-indol-7-yl)-2-(4-methyl-1,4-diazepan-1-yl)butanamide

[0495] The second eluting isomer from the synthesis of Example 36 was collected and evaporated in vacuo to provide (R)-N-(3-(2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)-5-methylpyrimidin-4-yl)-1H-indol-7-yl)-2-(4-methyl-1,4-diazepan-1-yl)butanamide, (40 mg, 6%, 99.9% ee).

[0496] 1 H NMR (400 MHz, CD3OD) δ 1.07 (t, 3H), 1.73-2.03 (m, 4H), 2.39-2.49 (m, 6H), 2.68-2.83 (m, 4H), 2.88-3.09 (m, 4H), 3.15 (s, 3H), 3.27-3.40 (m, 1H), 7.02 (t, 1H), 7.25 (d, 1H), 7.34 (t, 1H), 7.52-7.62 (m, 1H), 7.92 (s, 1H), 8.08, (d, 1H), 8.28 (s, 1H), 8.50-8.63 (m, 1H). No exchangeable protons were observed. 19 F NMR (376MHz, CD3OD) delta -125.70.

[0497] m / z(ES+), [M+H] + =594.

[0498] The procedures of Examples 36 and 37 above were repeated using the intermediates shown to give Examples 38-45 described in Table 15 below:

[0499] Table 15

[0500]

[0501]

[0502]

[0503]

[0504]

[0505] a The reaction mixture was poured into water (50 mL) and extracted with EtOAc (2 x 75 mL). The combined organic layers were dried over Na2SO4, filtered and evaporated in vacuo. The residue was purified by preparative TLC using petroleum ether / EtOAc 10:1.

[0506] b The crude product was purified by reverse phase preparative chromatography on a SunfirePrep C18 OBD column (19 x 150 mm, 5 μm) using 35%-50% acetonitrile in water (0.03% NH 3 H 2 O) and a flow rate of 20 mL / min.

[0507] c Purify by preparative HPLC on a XBridge Prep C18 OBD column (5 μm, 19 x 150 mm) using decreasingly polar mixtures of water in acetonitrile containing 0.5% formic acid as eluent.Fraction containing the desired compound were evaporated in vacuo.

[0508] d The isomers were separated by preparative chiral HPLC on a Phenomenex Lux 5u Cellulose-4, AXIA Packed (250x21.2mm, 5μm) column using 50% hexane (0.1% DEA) in EtOH / MeOH 35:15 as mobile phase and 20mL / min flow rate. The isomers were detected using wavelengths of 254 and 220nm. The desired isomer was collected and evaporated in vacuo.

[0509] e The residue was purified by preparative TLC using DCM / MeOH 10:1, 8:1 or 7:1.

[0510] f The isomers were separated by preparative chiral HPLC on Chiralpak IC (20x250mm, 5μm) using 100% MeOH and 18mL / min flow rate. Compounds were detected using wavelengths of 254 and 220nm. The desired isomer was collected and evaporated in vacuo.

[0511] gThe isomers were separated by preparative chiral HPLC on ChiralPak IA (21.2 x 150 mm, 5 μm) using 100% MeOH (modified with DEA) as mobile phase. The desired isomer was collected and evaporated in vacuo.

[0512] Example 46

[0513] (R)-N-(3-(5-fluoro-2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)pyrimidin-4-yl)-1H-indol-7-yl)-2-(4-methyl-1,4-diazepan-1-yl)propanamide

[0514] 2-(4-methyl-1,4-diazepan-1-yl)propionic acid dihydrochloride, intermediate 47 (175 mg, 0.68 mmol) and CDI (84 mg, 0.52 mmol) were dissolved in DMF (2 mL) and stirred at room temperature for 1.5 h. 3-(5-fluoro-2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)pyrimidin-4-yl)-1H-indole-7-amine, intermediate 18 (187 mg, 0.45 mmol) was added and the reaction was heated to 60 ° C for 4 h. The reactants were allowed to cool to room temperature. DCM (25 mL) was added and the organic phase was washed with 8% NaHCO (3x25 mL), dried with a phase separator and evaporated in vacuo. Use 25%-70% acetonitrile gradient in H2O / ACN / NH395 / 5 / 0.2 buffer, with the flow rate of 100mL / min through 20 minutes, by the preparative HPLC purification compound on XBridge C18 post (10 μm, 250x50mm).Detect compound by UV at 228nm.Collect product and freeze-dry.Use 40%IPA / DEA100:0.5 in CO2 as eluent and 140ml / min flow rate under 120 bar, by the chiral SFC on CelluCoat (250x30mm, 5μm) post, enantiomers are separated.Detect compound by UV at 270nm.Collect the first eluting compound and evaporate in vacuum. Using 25%-70% acetonitrile gradient in H2O / ACN / NH395 / 5 / 0.2 buffer, with a flow rate of 19mL / min through 20 minutes, by the preparative HPLC purification residue on XBridgeC18 posts (10 μm, 250x19mm).Compound is detected at 228nm by UV.Product fractions are collected and lyophilized to obtain (R)-N-(3-(5-fluoro-2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)pyrimidine-4-yl)-1H-indol-7-yl)-2-(4-methyl-1,4-diazepan-1-yl)propionamide, Example 46 (40mg, 30%, 99.9%ee), is a white solid.

[0515] 1 H NMR (500MHz, DMSO-d6) δ1.25 (d, 3H), 1.71-1.82 (m, 2H), 2.26 (s, 3H), 2.52-2.67 (m, 4H), 2.77-2.89 (m, 4H), 3.23-3.39 (m, 3H), 3.57 (q, 1 H), 7.03(t, 1H), 7.37-7.51(m, 2H), 7.62(t, 1H), 8.13-8.24(m, 2H), 8.27(d, 1H), 8.44(d, 1H), 9.45(s, 1H), 9.77(s, 1H), 11.61(bs, 1H). 19 F NMR (470MHz, DMSO-d6) δ-120.55, -147.73.m / z (ES+), [M+H] + =584.4.

[0516] Example 47

[0517] (S)-2-((R)-2,4-dimethylpiperazin-1-yl)-N-(3-(2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)-5-methylpyrimidin-4-yl)-1H-indol-7-yl)propanamide

[0518] Step 1

[0519] 3-(2-((2-Fluoro-3-(methylsulfonyl)phenyl)amino)-5-methylpyrimidin-4-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indol-7-amine, Intermediate 20 (300 mg, 0.55 mmol) and lithium 2-((R)-2,4-dimethylpiperazin-1-yl)propanoate, Intermediate 69 (103 mg, 0.55 mmol) were suspended in DCM (5 mL) and pyridine (0.134 mL, 1.66 mmol) was added. The mixture was cooled to 0 °C and 2,4,6-tripropyl-1,3,5,2,4,6-trioxatriphosphine 2,4,6-trioxide, T3P (0.989 mL, 1.66 mmol) was added dropwise. The reaction mixture was stirred at 22 °C for 1 h. Another portion of 2-((R)-2,4-dimethylpiperazine-1-yl) lithium propionate, intermediate 53 (20 mg, 0.11 mmol) and T3P (200 μL, 0.34 mmol) were added. The mixture was stirred for 30 min. The reaction mixture was diluted with DCM (15 mL) and quenched with saturated NaHCO3 (5 mL) and stirred at room temperature for 5 min. The organic layer was separated and the aqueous layer was extracted with DCM (2x5 mL). The combined organic phases were dried over MgSO4, filtered and concentrated under reduced pressure to provide 2-((R)-2,4-dimethylpiperazine-1-yl)-N-(3-(2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)-5-methylpyrimidin-4-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indol-7-yl)propionamide (377 mg, 96%).

[0520] m / z(ES+), [M+H] + =710.5.

[0521] Step 2

[0522] 2-((R)-2,4-dimethylpiperazin-1-yl)-N-(3-(2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)-5-methylpyrimidin-4-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indol-7-yl)propanamide (335 mg, 0.47 mmol) was dissolved in DCM (3.5 mL), cooled with an ice bath, and TFA (1.083 mL, 14.16 mmol) was added. The reaction mixture was stirred at room temperature overnight. DCM (5 mL) was added followed by TFA (1 mL) and stirring was continued for 5 h. The reaction mixture was then heated at 40 °C overnight. DCM (25 mL) was added followed by NaHCO (10 mL) and MeOH (1 mL). The organic layer was separated and the aqueous layer was extracted with DCM (2 x 20 mL). The combined organic phases were dried over MgSO, filtered and evaporated in vacuo. The residue was redissolved in DCM (25mL), saturated NaHCO (10mL) and MeOH (1mL), shaken and the organic layer was separated. The aqueous layer was extracted with DCM (2x20mL). The combined organic phase was dried over MgSO, filtered and evaporated in vacuo. Using 20%-80% acetonitrile gradient in H2O / ACN / NH3 95 / 5 / 0.2 buffer, with a flow rate of 19mL / min over 20 minutes, by the preparative HPLC purification residue on XBridge C18 columns (10 μm, 250x19mm). Collect compounds at 269nm by UV and evaporate in vacuo. Use 35% EtOH / TEA 100: 0.5 in CO2 as mobile phase and 80mL / min flow rate at 120 bar, by chiral SFC on Chiralpak IB (30x250mm, 5 μm) column, diastereomers are separated. The compound was detected by UV at 260 nm. The first eluting isomer was collected and evaporated in vacuo to provide (S)-2-((R)-2,4-dimethylpiperazin-1-yl)-N-(3-(2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)-5-methylpyrimidin-4-yl)-1H-indol-7-yl)propanamide, Example 47 (20 mg, 8%, 99.9% de).

[0523] 1H NMR (500MHz, DMSO-d6) δ1.03 (d, 3H), 1.30 (d, 3H), 1.86 (t, 1H), 2.07-2.23 (m, 4H), 2.40(s, 3H), 2.54-2.63(m, 2H), 2.68-2.78(m, 1H), 2.79-2.91(m, 2H), 3.25(s, 3H), 3.69(q, 1H), 6.97(t, 1H), 7.32-7.47(m, 2H), 7.49-7.61(m, 1H), 8.03(d, 1H), 8.13( d, 1H), 8.22-8.35 (m, 2H), 9.17 (s, 1H), 9.65 (s, 1H), 11.38 (s, 1H). m / z (ES+), [M+H] + =580.4.

[0524] Example 48

[0525] (R)-2-((R)-2,4-dimethylpiperazin-1-yl)-N-(3-(2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)-5-methylpyrimidin-4-yl)-1H-indol-7-yl)propanamide

[0526] The second eluting isomer from the reaction of Example 47, Step 2 was collected and evaporated in vacuo to provide (R)-2-((R)-2,4-dimethylpiperazin-1-yl)-N-(3-(2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)-5-methylpyrimidin-4-yl)-1H-indol-7-yl)propanamide (22 mg, 9%, 99.2% de).

[0527] 1 H NMR (500MHz, DMSO-d6) δ1.11 (d, 3H), 1.16 (d, 3H), 2.02 (t, 1H), 2.11-2.23 (m, 4H), 2.4 0(s, 3H), 2.44-2.49(m, 1H), 2.54-2.66(m, 3H), 2.66-2.78(m, 1H), 3.25(s, 3H), 3.76-3 .89(m, 1H), 6.97(t, 1H), 7.27(d, 1H), 7.40(t, 1H), 7.51-7.59(m, 1H), 8.00(s, 1H), 8. 14(d,1H),8.23-8.36(m,2H),9.16(s,1H),9.58(s,1H),11.37(s,1H).m / z(ES+),[M+H] + =580.4.

[0528] Example 49

[0529] (R)-2-((R)-2,4-dimethylpiperazin-1-yl)-N-(3-(5-fluoro-2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)pyrimidin-4-yl)-1H-indol-7-yl)propanamide

[0530] (R)-2-((R)-2,4-dimethylpiperazin-1-yl)propanoic acid dihydrochloride, intermediate 27 (573 mg, 2.21 mmol) and CDI (275 mg, 1.70 mmol) were stirred in DMF (2 mL) at room temperature for 1 h (gas evolution). 3-(5-Fluoro-2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)pyrimidin-4-yl)-1H-indol-7-amine, intermediate 18 (816 mg, 1.47 mmol) dissolved in DMF (2 mL) was added and the reaction was stirred at 50 °C for 5 h. The reaction was diluted with DCM (25 mL) and 5% Na2CO3 (aqueous) (25 mL), shaken and the phases separated. The aqueous phase was extracted with DCM (2x25 mL). The combined organic phases were dried with a phase separator and concentrated in vacuo. Using 15%-65% acetonitrile gradient in H2O / ACN / NH3 95 / 5 / 0.2 buffer, with a flow rate of 100mL / min through 20 minutes, by the preparative HPLC purification residue on XBridge C18 posts (10 μm, 250x50mm). Compound was detected by UV at 235nm. The product is lyophilized to provide (R)-2-((R)-2,4-dimethylpiperazine-1-yl)-N-(3-(5-fluoro-2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)pyrimidine-4-yl)-1H-indol-7-yl)propionamide, Example 49 (234mg, 32%), is a white solid.

[0531] 1 H NMR (500MHz, DMSO-d6) δ1.11 (d, 3H), 1.16 (d, 3H), 2.02 (t, 1H), 2.1-2.23 (m, 4H), 2. 42-2.54(m, 1H), 2.54-2.67(m, 3H), 2.67-2.78(m, 1H), 3.25-3.36(m, 3H), 3.77-3.88 (m, 1H), 7.03 (t, 1H), 7.28 (d, 1H), 7.46 (t, 1H), 7.57-7.68 (m, 1H), 8.15-8.24 (m, 2H) ,8.29(d,1H),8.43(d,1H),9.45(s,1H),9.63(s,1H),11.55(s,1H).m / z(ES+),[M+H] + =584.3.

[0532] Example 50

[0533] (S)-2-((R)-2,4-dimethylpiperazin-1-yl)-N-(3-(2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)-5-methylpyrimidin-4-yl)-1H-indol-7-yl)butanamide

[0534] 3-(2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)-5-methylpyrimidin-4-yl)-1H-indol-7-amine, intermediate 11 (387 mg, 0.94 mmol) and 2-((R)-2,4-dimethylpiperazin-1-yl)butanoic acid dihydrochloride, intermediate 46 (300 mg, 1.10 mmol) were suspended in anhydrous DCM (25 mL) and pyridine (0.3 mL, 3.71 mmol) was added. The mixture was cooled to 0 ° C in an ice bath and T3P (1.5 mL, 2.52 mmol) was added dropwise. The ice bath was removed and the reaction mixture was stirred at 23 ° C for 20 min. The reaction mixture was quenched with saturated NaHCO3 (20 mL) and stirred at 23 ° C for 30 min. The organic layer was separated and the aqueous phase was extracted with DCM (2x20 mL). The combined organic phases were filtered through a phase separator and evaporated in vacuo. Using 20%-70% acetonitrile gradient in H2O / ACN / NH395 / 5 / 0.2 buffer, with a flow rate of 100mL / min through 25 minutes, by the preparative HPLC purification residue on XBridge C18 posts (10 μm, 250x50mm). Compound was detected by UV at 269nm. The first eluting isomer was collected and lyophilized to provide (S)-2-((R)-2,4-dimethylpiperazine-1-yl)-N-(3-(2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)-5-methylpyrimidin-4-yl)-1H-indol-7-yl)butyramide, Example 50 (205mg, 37%).

[0535] 1H NMR (500MHz, DMSO-d6) δ0.97 (t, 3H), 1.10 (d, 3H), 1.65-1.77 (m, 2H), 1.77-1.87 (m, 1H), 1 .91-2.01(m, 1H), 2.11(s, 3H), 2.40(s, 3H), 2.55-2.67(m, 2H), 2.67-2.77(m, 1H), 2.81-2. 94(m, 2H), 3.25(s, 3H), 3.55(t, 1H), 6.97(t, 1H), 7.40(t, 1H), 7.47(d, 1H), 7.5-7.58(m, 1H), 8.05(d, 1H), 8.12(d, 1H), 8.24-8.34(m, 2H), 9.17(s, 1H), 9.62(s, 1H), 11.20(s, 1H).

[0536] m / z(ES+), [M+H] + =594.4.

[0537] Example 51

[0538] (R)-2-((R)-2,4-dimethylpiperazin-1-yl)-N-(3-(2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)-5-methylpyrimidin-4-yl)-1H-indol-7-yl)butanamide

[0539] The second eluting isomer from the Example 50 reaction was collected and lyophilized to provide (R)-2-((R)-2,4-dimethylpiperazin-1-yl)-N-(3-(2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)-5-methylpyrimidin-4-yl)-1H-indol-7-yl)butanamide, Example 51 (210 mg, 38%).

[0540] 1 H NMR (500MHz, DMSO-d6) δ0.95 (t, 3H), 1.13 (d, 3H), 1.57-1.69 (m, 1H), 1.72-1.86 (m, 1H) , 2.00-2.09(m, 1H), 2.09-2.23(m, 4H), 2.38-2.58(m, 6H), 2.72-2.81(m, 1H), 2.81-2.91 (m, 1H), 3.25 (s, 3H), 3.44-3.53 (m, 1H), 6.98 (t, 1H), 7.35-7.45 (m, 2H), 7.51-7.6 (m, 1H ), 8.03(d, 1H), 8.13(d, 1H), 8.24-8.36(m, 2H), 9.16(s, 1H), 9.61(s, 1H), 11.32(s, 1H).

[0541] m / z(ES+), [M+H] + =594.4.

[0542] The procedure of Examples 50-51 above was repeated using the intermediates shown to give Examples 52-57 described in Table 16 below

[0543] Table 16

[0544]

[0545]

[0546]

[0547]

[0548] a Add more T3Ps in parts.

[0549] b After 1 h at 0 °C, DIPEA (0.9 mL, 5.15 mmol) and additional T3P (3.0 mL, 5.04 mmol) were added in small portions to the reaction mixture at room temperature over 3 h.

[0550] Example 58

[0551] (R)-2-((S)-2,4-dimethylpiperazin-1-yl)-N-(3-(2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)-5-methylpyrimidin-4-yl)-1H-indol-7-yl)propanamide

[0552] Step 1

[0553] 3-(2-((2-Fluoro-3-(methylsulfonyl)phenyl)amino)-5-methylpyrimidin-4-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indol-7-amine, Intermediate 20 (210 mg, 0.39 mmol) and lithium 2-((S)-2,4-dimethylpiperazin-1-yl)propanoate, Intermediate 51 (97 mg, 0.44 mmol, ~84% wt) were suspended in DCM (10 mL) and pyridine (0.10 mL, 1.24 mmol) was added. The mixture was cooled to 0°C and T3P (0.9 mL, 1.51 mmol, 50% wt in EtOAc) was added dropwise. The reaction mixture was stirred at 22°C for 1 hour. Add 2-((S)-2,4-dimethylpiperazine-1-yl) lithium propionate, intermediate 51 (24 mg, 0.11 mmol), followed by T3P (0.2 mL, 0.34 mmol) and stir the reaction mixture at 22 ° C for 30 min. The reaction mixture was quenched with saturated NaHCO3 (20 mL) and stirred at 22 ° C for 15 min. The organic layer was separated and the aqueous layer was extracted with DCM (2x10 mL). The combined organic phases were filtered through a phase separator and concentrated in vacuo. The diastereomers were separated by chiral SFC on a CelluCoat (5 μm, 250x30 mm) column using 32% EtOH / DEA 100: 0.5 in CO2 at 120 bar and 140 mL / min flow rate. Compounds were detected by UV at 220 nm. The first eluting isomer was collected and evaporated in vacuo to provide 2-((S)-2,4-dimethylpiperazin-1-yl)-N-(3-(2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)-5-methylpyrimidin-4-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indol-7-yl)propanamide Isomer 1 (125 mg, 45%, 99.9% de).

[0554] 1H NMR (500MHz, DMSO-d6) δ-0.09 (s, 9H), 0.77-0.89 (m, 1H), 0.92-1.17 (m, 4H), 1.25 (d, 3H), 1.81 -1.95(m,1H),2.13(s,3H),2.22-2.34(m,1H),2.39(s,3H),2.43-2.62(m,3H),2.67-2.86(m,2 H), 3.07-3.65(m, 6H), 5.72(d, 1H), 5.87(d, 1H), 7.05(t, 1H), 7.35-7.48(m, 2H), 7.51-7.6(m, 1H), 8.15(d, 1H), 8.19(s, 1H), 8.23-8.31(m, 1H), 8.31-8.41(m, 1H), 9.23(s, 1H), 9.86(s, 1H).

[0555] Step 2

[0556] 2-((S)-2,4-dimethylpiperazin-1-yl)-N-(3-(2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)-5-methylpyrimidin-4-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indol-7-yl)propanamide Isomer 1 (123 mg, 0.17 mmol) was dissolved in anhydrous DCM (2 mL) and TFA (3 mL) was added. The reaction mixture was stirred at ambient temperature for 19 h. DCM (10 mL) was added followed by NaHCO (10 mL) and MeOH (1 mL). The organic layer was separated and the aqueous layer was extracted with a mixture of DCM / MeOH 5:1 (2x6 mL). The combined organic phases were filtered through a phase separator and concentrated in vacuo. Using 20%-80% acetonitrile gradient in H2O / ACN / NH395 / 5 / 0.2 buffer, with a flow rate of 19mL / min through 20 minutes, by the preparative HPLC purification residue on XBridge C18 posts (10 μm, 250x19mm). Compound detected by UV at 269nm. Collect product and freeze-dry, to provide (R)-2-((S)-2,4-dimethylpiperazine-1-yl)-N-(3-(2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)-5-methylpyrimidine-4-yl)-1H-indol-7-yl) propionamide, Example 58 (63mg, 63%), is a white solid.

[0557] 1H NMR (500MHz, DMSO-d6) δ1.03 (d, 3H), 1.30 (d, 3H), 1.86 (t, 1H), 2.08-2.22 (m, 4H), 2.40(s, 3H), 2.46-2.62(m, 2H), 2.68-2.78(m, 1H), 2.79-2.91(m, 2H), 3.25(s, 3H), 3.69(q, 1H), 6.97(t, 1H), 7.33-7.45(m, 2H), 7.5-7.59(m, 1H), 8.03(s, 1H), 8.12( d, 1H), 8.25-8.36 (m, 2H), 9.16 (s, 1H), 9.64 (s, 1H), 11.36 (s, 1H).m / z (ES+), [M+H] + =580.3.

[0558] Example 59

[0559] (S)-2-((S)-2,4-dimethylpiperazin-1-yl)-N-(3-(2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)-5-methylpyrimidin-4-yl)-1H-indol-7-yl)propanamide Isomer 2

[0560] Step 1

[0561] The second eluting isomer from the reaction of Example 58 Step 1 was collected and evaporated in vacuo to provide 2-((S)-2,4-dimethylpiperazin-1-yl)-N-(3-(2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)-5-methylpyrimidin-4-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indol-7-yl)propanamide Isomer 2 (120 mg, 43%, 99.7% de).

[0562] 1 H NMR (500MHz, DMSO-d6) δ-0.09 (s, 9H), 0.81-0.91 (m, 1H), 0.95-1.16 (m, 7H), 1.95 (t, 1H), 2.03-2.18(m, 4H), 2.33-2.43(m, 4H), 2.43-2.57(m, 1H), 2.58-2.72(m, 3H), 3.25(s, 3H), 3 .4-3.56(m,2H),3.84(s,1H),5.73(d,1H),5.87(d,1H),7.04(t,1H),7.40(t,1H),7.48(d , 1H), 7.55(t, 1H), 8.11-8.22(m, 2H), 8.27(t, 1H), 8.33(s, 1H), 9.23(s, 1H), 9.84(s, 1H).

[0563] Step 2

[0564] 2-((S)-2,4-dimethylpiperazin-1-yl)-N-(3-(2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)-5-methylpyrimidin-4-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indol-7-yl)propanamide Isomer 2 (118 mg, 0.17 mmol) was dissolved in anhydrous DCM (2 mL) and TFA (3 mL) was added. The reaction mixture was stirred at ambient temperature for 19 hours. DCM (10 mL) was added followed by NaHCO (10 mL) and MeOH (1 mL). The organic layer was separated and the aqueous layer was extracted with a mixture of DCM / MeOH 5:1 (2x6 mL). The combined organic phases were filtered through a phase separator and concentrated in vacuo. Using 20%-80% acetonitrile gradient in H2O / ACN / NH3 95 / 5 / 0.2 buffer, with a flow rate of 19mL / min through 20 minutes, by the preparative HPLC purification residue on XBridge C18 posts (10 μm, 250x19mm). Compounds were detected by UV at 269nm. Product fractions were lyophilized to provide (S)-2-((S)-2,4-dimethylpiperazine-1-yl)-N-(3-(2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)-5-methylpyrimidin-4-yl)-1H-indol-7-yl)propionamide, Example 59 (74mg, 77%), as a white solid.

[0565] 1 H NMR (500MHz, DMSO-d6) δ1.12 (d, 3H), 1.16 (d, 3H), 2.02 (t, 1H), 2.15 (s, 3H), 2.16-2. 22(m, 1H), 2.40(s, 3H), 2.43-2.48(m, 1H), 2.54-2.66(m, 3H), 2.67-2.77(m, 1H), 3.25 (s, 3H), 3.76-3.88 (m, 1H), 6.97 (t, 1H), 7.27 (d, 1H), 7.40 (t, 1H), 7.51-7.59 (m, 1H), 8.00 (s, 1H), 8.14 (d, 1H), 8.26-8.34 (m, 2H), 9.16 (s, 1H), 9.58 (s, 1H), 11.36 (s, 1H).

[0566] m / z(ES+), [M+H] + =580.5.

[0567] Example 60

[0568] (R)-2-((S)-2,4-dimethylpiperazin-1-yl)-N-(3-(2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)-5-methylpyrimidin-4-yl)-1H-indol-7-yl)butanamide

[0569] Step 1

[0570] Lithium 2-((S)-2,4-dimethylpiperazine-1-yl)butyrate, intermediate 52 (104 mg, 0.52 mmol) and 3-(2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)-5-methylpyrimidin-4-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indol-7-amine, intermediate 20 (210 mg, 0.39 mmol) were dissolved in DCM (10 mL) and pyridine (0.1 mL, 1.24 mmol) was added followed by T3P (1.0 mL, 1.68 mmol). The reaction mixture was stirred at 22 °C overnight. The reaction mixture was quenched with NaHCO3 (15 mL), stirred for another 10 min, and extracted with DCM (3x7 mL). The combined organic phases were filtered through a phase separator and concentrated in vacuo. The residue was purified by preparative HPLC on a XBridge C18 column (10 μm, 250x50mm) using a 20-80% acetonitrile gradient in H2O / ACN / NH395 / 5 / 0.2 buffer at a flow rate of 100 mL / min over 20 minutes. The compound was detected by UV at 269 nm. The pure fractions were combined and lyophilized. The diastereomers were separated by chiral SFC on a Chiralpak IB (30x250mm, 5 μm) column using 23% EtOH / DEA 100:0.5 in CO2 at 120 bar and 150 mL / min flow rate. The compound was detected by UV at 270 nm. The first eluting isomer was collected and evaporated in vacuo to provide 2-((S)-2,4-dimethylpiperazin-1-yl)-N-(3-(2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)-5-methylpyrimidin-4-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indol-7-yl)butanamide Isomer 1 (69 mg, 24%, 99.3% de).

[0571] 1H NMR (500MHz, DMSO-d6) δ-0.08 (s, 9H), 0.80-0.96 (m, 2H), 0.99 (t, 3H), 1.06 (d, 3H), 1.6 3-1.87(m, 3H), 2.06-2.16(m, 4H), 2.39(s, 3H), 2.56(d, 2H), 2.73-2.86(m, 3H), 3.25(s , 3H), 3.31(s, 1H), 3.47-3.56(m, 2H), 5.78(dd, 2H), 7.05(t, 1H), 7.37-7.44(m, 2H), 7. 52-7.59 (m, 1H), 8.13-8.21 (m, 2H), 8.28 (t, 1H), 8.33 (s, 1H), 9.23 (s, 1H), 9.61 (s, 1H).

[0572] Step 2

[0573] 2-((S)-2,4-dimethylpiperazin-1-yl)-N-(3-(2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)-5-methylpyrimidin-4-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indol-7-yl)butanamide Isomer 1 (67 mg, 0.09 mmol) was dissolved in DCM (2 mL) and TFA (3 mL) was added. The reaction mixture was stirred at 22 ° C for 17 h. DCM (10 mL) and NaHCO (15 mL) were added, shaken, the phases were separated, and the aqueous layer was extracted with DCM (2x5 mL). The combined organic phases were filtered through a phase separator and concentrated in vacuo. Use in H2O / ACN / NH3 20%-80% acetonitrile gradient in 95 / 5 / 0.2 buffer, with the flow rate of 19mL / min through 20 minutes, by on XBridge C18 post (10 μ m, 250x 19mm) by preparative HPLC purification residue. Detect compound by UV at 269nm. Collect product peak and freeze-drying, to provide (R)-2-((S)-2,4-dimethylpiperazine-1-yl)-N-(3-(2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)-5-methylpyrimidine-4-yl)-1H-indol-7-yl) butyramide, example 60 (31mg, 56%), is white solid.

[0574] 1H NMR (500MHz, DMSO-d6) δ0.97 (t, 3H), 1.10 (d, 3H), 1.62-1.88 (m, 3H), 1.97 (t, 1H), 2.1 1(s, 3H), 2.39(s, 3H), 2.55-2.67(m, 2H), 2.67-2.77(m, 1H), 2.82-2.95(m, 2H), 3.25(s , 3H), 3.56(t, 1H), 6.97(t, 1H), 7.40(t, 1H), 7.48(d, 1H), 7.55(t, 1H), 8.05(d, 1H), 8. 12(d,1H),8.24-8.37(m,2H),9.16(s,1H),9.63(s,1H),11.22(s,1H).m / z(ES+),[M+H] + =594.4.

[0575] Example 61

[0576] (S)-2-((S)-2,4-dimethylpiperazin-1-yl)-N-(3-(2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)-5-methylpyrimidin-4-yl)-1H-indol-7-yl)butanamide

[0577] Step 1

[0578] The second eluting isomer from Example 60, Step 1 was collected and evaporated in vacuo to provide 2-((S)-2,4-dimethylpiperazin-1-yl)-N-(3-(2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)-5-methylpyrimidin-4-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indol-7-yl)butanamide (133 mg, 47%, 95.9% de).

[0579] 1H NMR (500MHz, DMSO-d6) δ-0.09 (s, 9H), 0.82-0.91 (m, 1H), 0.92-1.02 (m, 4H), 1.12 (d, 3H), 1.53-1.66 (m, 1H) ,1.69-1.84(m,1H),1.91-2.02(m,1H),2.02-2.1(m,1H),2.12(s,3H),2.39(s,3H),2.43-2.66(m,4H),2.74 -2.84(m,1H),3.25(s,3H),3.48-3.56(m,3H),5.77(d,1H),5.84(d,1H),7.05(t,1H),7.40(t,1H),7.49(d, 1H), 7.52-7.59(m, 1H), 8.15(d, 1H), 8.18(s, 1H), 8.24-8.31(m, 1H), 8.33(s, 1H), 9.23(s, 1H), 9.73(s, 1H).

[0580] Step 2

[0581] 2-((S)-2,4-dimethylpiperazin-1-yl)-N-(3-(2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)-5-methylpyrimidin-4-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indol-7-yl)butanamide Isomer 2 (131 mg, 0.18 mmol) was dissolved in DCM (2 mL) and TFA (3 mL) was added. The reaction mixture was stirred at 22 ° C for 17 h. DCM (10 mL) and NaHCO (15 mL) were added and shaken, the phases were separated, and the aqueous layer was extracted with DCM (2x5 mL). The combined organic phases were filtered through a phase separator and concentrated in vacuo. The residue was purified by preparative HPLC on an XBridge C18 column (10 μm, 250 19 mm) at a flow rate of 19 mL / min over 20 minutes using a 20%-80% acetonitrile gradient in H2O / ACN / NH3 95 / 5 / 0.2 buffer. The compound was detected by UV at 269 nm. The product was collected and lyophilized to provide (S)-2-((S)-2,4-dimethylpiperazine-1-yl)-N-(3-(2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)-5-methylpyrimidin-4-yl)-1H-indol-7-yl)butyramide Isomer 2, Example 61 (65 mg, 60%), as a white solid.

[0582] 1H NMR (500MHz, DMSO-d6) δ0.95 (t, 3H), 1.13 (d, 3H), 1.56-1.70 (m, 1H), 1.72-1.85 (m, 1H), 2.01-2.09(m, 1H), 2.09-2.23(m, 4H), 2.34-2.58(m, 6H), 2.73-2.81(m, 1H), 2.81-2.91( m, 1H), 3.25 (s, 3H), 3.45-3.54 (m, 1H), 6.98 (t, 1H), 7.36-7.46 (m, 2H), 7.50-7.59 (m, 1H ), 8.03(d, 1H), 8.13(d, 1H), 8.25-8.37(m, 2H), 9.16(s, 1H), 9.62(s, 1H), 11.33(s, 1H).

[0583] m / z(ES+), [M+H] + =594.5.

[0584] Example 62

[0585] (R)-3-Ethoxy-N-(3-(2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)-5-methylpyrimidin-4-yl)-1H-indol-7-yl)-2-(4-methylpiperazin-1-yl)propanamide

[0586] At 0°C, DIPEA (688 μl, 3.94 mmol) was added once to (R)-3-ethoxy-2-(4-methylpiperazine-1-yl) lithium propionate, intermediate 63 (237 mg, 1.09 mmol) and 3-(2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)-5-methylpyrimidin-4-yl)-1H-indole-7-amine, intermediate 11 (180 mg, 0.44 mmol) in DCM (1 mL). The resulting solution was stirred at 0°C for 10 min. 1-Propanephosphonic acid cyclic anhydride, T3P (835 mg, 1.31 mmol) was then added dropwise at 0°C. The solution was stirred at room temperature for 1 hour. The reaction mixture was diluted with DCM (50 mL), washed with saturated NaHCO3 (2x50 mL) and brine (2x50 mL). The organic layer was dried over Na2SO4, filtered and evaporated in vacuo. The residue was purified by preparative TLC using DCM / MeOH 20:1 as eluent. The product (50% ee) was purified by preparative chiral HPLC on Chiralpak IA (20x250mm, 5μm) using 20% ​​IPA in MTBE (0.1% DEA) as eluent at a flow rate of 20mL / min over 19 minutes. The product was detected at wavelengths of 254 and 220nm. The major isomer was collected to provide (R)-3-ethoxy-N-(3-(2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)-5-methylpyrimidin-4-yl)-1H-indol-7-yl)-2-(4-methylpiperazine-1-yl)propanamide, Example 62 (40mg, 15%, 99.7%ee) as a white solid.

[0587] 1 H NMR (300MHz, CD3OD) δ1.21 (t, 3H), 2.33 (s, 3H), 2.42 (s, 6H), 2.50-2.73 (m, 4H), 2.74-3.02 (m, 2H), 3.15 (s, 3H), 3.45-3.65 (m, 3H), 3.86 (d d, 1H), 3.97 (dd, 1H), 7.02 (t, 1H), 7.13 (d, 2H), 7.31 (t, 1H), 7.49-7.63 (m, 1H), 7.90 (s, 1H), 8.10 (d, 1H), 8.25 (s, 1H), 8.47-8.52 (m, 1H). 19 F NMR (282MHz, CD3OD) δ-125.71.m / z (ES+), [M+H] + =610.

[0588] Example 63

[0589] (R)-3-Ethoxy-N-(3-(5-fluoro-2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)pyrimidin-4-yl)-1H-indol-7-yl)-2-(4-methylpiperazin-1-yl)propanamide

[0590] The procedure described above for Example 62 was repeated using intermediates 18 and 63 to give Example 63 (80 mg, 24%, 97.9% ee) as a white solid.

[0591] Purify by preparative chiral HPLC on ChiralPak-AD-H-SL002, (20x250mm) using 50% IPA in hexane (0.1% DEA) at a flow rate of 14 mL / min for 56 minutes. Compounds were detected at 254 and 220 nm. The major isomer was evaporated in vacuo.

[0592] 1 H NMR (300MHz, CD30D) δ1.21 (t, 3H), 2.32 (s, 3H), 2.45-2.72 (m, 4H), 2.73-3.02 (m, 4H), 3.21 (s, 3H), 3.44-3.66 (m, 3H) , 3.78-4.04(m, 2H), 7.00-7.21(m, 2H), 7.42(t, 1H), 7.58-7.73(t, 1H), 8.16(s, 1H), 8.23-8.37(m, 2H), 8.42(t, 1H).

[0593] No exchangeable protons observed 19 F NMR (282MHz, CD3OD) δ-149.01, -124.61

[0594] m / z(ES+), [M+H] + =614.

[0595] Example 64

[0596] (R)-3-(Benzyloxy)-N-(3-(2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)-5-methylpyrimidin-4-yl)-1H-indol-7-yl)-2-(4-methylpiperazin-1-yl)propanamide

[0597] Step 1

[0598] Sodium 3-(benzyloxy)-2-(4-methylpiperazin-1-yl)propanoate, Intermediate 64 (317 mg, 0.93 mmol) and 3-(2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)-5-methylpyrimidin-4-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indol-7-amine, Intermediate 20 (448 mg, 0.83 mmol) were suspended in ethyl acetate (20 mL) and pyridine (0.25 mL, 3.09 mmol) was added. The reaction mixture was cooled to 0°C. T3P (1.0 mL, 1.68 mmol, 50% wt in ethyl acetate) was added dropwise. The reaction mixture was stirred at 0°C for 10 min and then at 22°C for 4 h. The reaction mixture was cooled to 0°C, T3P (1.0 mL, 1.68 mmol) was added dropwise and stirred at 22°C for 3 h. The reaction mixture is cooled to 0°C again, T3P (0.5mL, 0.84mmol) is added dropwise and stirred for 2h at 22°C. The reaction mixture is cooled to 0°C again, T3P (0.5mL, 0.84mmol) is added dropwise and stirred for 16h at 22°C. Water (5mL) is added and the mixture is stirred for 30min at 22°C. NaHSO4 (20mL) is added, followed by DCM (10mL) and each phase is separated. The aqueous phase is extracted with DCM (2x10mL). The combined organic phases were dried over Na2SO4, filtered and concentrated under vacuum to provide 3-(benzyloxy)-N-(3-(2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)-5-methylpyrimidin-4-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indol-7-yl)-2-(4-methylpiperazin-1-yl)propanamide (690 mg, quantitative), which was directly carried into the next step. m / z (ES+), [M+H] + =802.3.

[0599] Step 2

[0600] 3-(Benzyloxy)-N-(3-(2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)-5-methylpyrimidin-4-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-indol-7-yl)-2-(4-methylpiperazin-1-yl)propanamide Isomer 2 (600 mg, 0.75 mmol) was dissolved in anhydrous DCM (3 mL) and TFA (3 mL, 26 mmol) was added to the stirred solution at ambient temperature. The reaction mixture was stirred at 22 ° C for 4 h. TFA (2 mL) was added and the reaction mixture was stirred at 22 ° C for 3 days. TFA (2 mL) was added and stirring was continued for 4 days. TFA (2 mL) was added and the mixture was stirred at 22 ° C overnight. DCM (20 mL) was added and the mixture was neutralized with saturated NaHCO (50 mL) and MeOH (3 mL) was added. The organic layer is separated and the aqueous phase is extracted with 10% MeOH / DCM (2x11mL). The combined organic phase is filtered through a phase separator, then filtered with a small plug of silica, which is washed with a mixture of DCM and MeOH. The combined filtrate is concentrated in a vacuum. Using 20%-80% acetonitrile gradient in H2O / ACN / NH395 / 5 / 0.2 buffer, with a flow rate of 100mL / min over 30 minutes, the residue is purified by preparative HPLC on a XBridge C18 column (10 μm, 250x50mm). Compounds are detected by UV at 269nm. Product peaks are collected and freeze-dried. Using 100% MeOH 100: 0.1 as eluent and at a flow rate of 40mL / min, enantiomers are separated by preparative chiral HPLC on a Lux C4 column (30x250mm, 5 μm). Compounds are detected by UV at 260nm. The second eluting isomer is collected and evaporated in vacuo.Use at H2O / ACN / NH3 25%-75% acetonitrile gradient in 95 / 5 / 0.2 buffer, with the flow velocity of 100mL / min through 25 minutes, by the preparative HPLC purification residue on XBridge C18 posts (10 μm, 250x50IDmm).Detect compound by UV at 270nm.Pure fraction is freeze-dried, to provide (R)-3-(benzyloxy)-N-(3-(2-((2-fluoro-3-(methylsulfonyl) phenyl) amino)-5-methylpyrimidine-4-yl)-1H-indol-7-yl)-2-(4-methylpiperazine-1-yl) propionamide, example 64 (161mg, 32%), is solid.

[0601] 1H NMR (500MHz, DMSO-d6) δ2.15 (s, 3H), 2.26-2.44 (m, 7H), 2.59-2.69 (m, 2H), 2.71- 2.82(m, 2H), 3.25(s, 3H), 3.58(t, 1H), 3.79(dd, 1H), 3.91(dd, 1H), 4.54(s, 2H), 6.98 (t, 1H), 7.24-7.36 (m, 5H), 7.40 (t, 1H), 7.44 (d, 1H), 7.52-7.58 (m, 1H), 8.0 1(d, 1H), 8.14(d, 1H), 8.26-8.33(m, 2H), 9.17(s, 1H), 9.83(s, 1H), 11.21(s, 1H).

[0602] m / z(ES+), [M+H] + =672.5.

[0603] Example 65

[0604] (S)-3-(Benzyloxy)-N-(3-(2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)-5-methylpyrimidin-4-yl)-1H-indol-7-yl)-2-(4-methylpiperazin-1-yl)propanamide

[0605] The first eluting isomer from the reaction of Example 64 Step 2 was collected and evaporated in vacuo. The residue was dissolved in acetonitrile / water and lyophilized to provide (S)-3-(benzyloxy)-N-(3-(2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)-5-methylpyrimidin-4-yl)-1H-indol-7-yl)-2-(4-methylpiperazin-1-yl)propanamide Example 65 (63 mg, 12%) as a solid.

[0606] 1 H NMR (500MHz, DMSO-d6) δ2.15 (s, 3H), 2.27-2.44 (m, 7H), 2.59-2.69 (m, 2H), 2.72-2.8 2(m, 2H), 3.25(s, 3H), 3.58(t, 1H), 3.79(dd, 1H), 3.91(dd, 1H), 4.54(s, 2H), 6.98(t, 1H), 7.24-7.37(m, 5H), 7.40(t, 1H), 7.44(d, 1H), 7.51-7.58(m, 1H), 8.01(d, 1H), 8.1 4(d,1H),8.26-8.33(m,2H),9.17(s,1H),9.83(s,1H),11.21(s,1H).m / z(ES+),[M+H] + =672.4.

[0607] Example 66

[0608] (R)-N-(3-(5-fluoro-2-(2-fluoro-3-(methylsulfonyl)phenylamino)pyrimidin-4-yl)-1H-indol-7-yl)-3-methoxy-2-(piperazin-1-yl)propanamide

[0609] Step 1

[0610] At 25 ℃, under air, potassium carbonate (4.21g, 30.45mmol) is added to methyl 2-bromo-3-methoxypropionate (3g, 15.23mmol) and tert-butyl piperazine-1-carboxylate (3.12g, 16.75mmol) in acetonitrile (60mL). The resulting mixture is stirred at room temperature for 15 hours. The reaction mixture is filtered through diatomite and the filter cake is washed with other acetonitrile. The filtrate is combined and the solvent is removed under reduced pressure. The crude product is purified by flash alumina chromatography, and the elution gradient is a solution of 0 to 100% EtOAc in petroleum ether. The pure fraction is evaporated to dryness, to provide tert-butyl 4- (1,3-dimethoxy-1-oxopropan-2-yl) piperazine-1-carboxylate (2.300g, 50.0%), in a colorless oil.

[0611] m / z(ES+), [M+H] + =303.

[0612] Step 2

[0613] Lithium hydroxide (0.238 g, 9.92 mmol) was added to a slurry of tert-butyl 4-(1,3-dimethoxy-1-oxopropan-2-yl)piperazine-1-carboxylate (1.0 g, 3.31 mmol) in a solvent mixture of MeOH (5 mL), THF (5.00 mL) and water (25 mL), then stirred at room temperature for 1 hour. The solvent was concentrated in vacuo to provide crude lithium 2-(4-(tert-butoxycarbonyl)piperazine-1-yl)-3-methoxypropanoate (1.200 g) as a yellow solid. m / z (ES+), [M+H] + =289.

[0614] Step 3

[0615] At room temperature, 2,4,6-tripropyl-1,3,5,2,4,6-trioxatriphosphine (5398mg, 9.99mmol) is added to intermediate 33 (415mg, 1.00mmol), 2-(4-(tert-butoxycarbonyl) piperazine-1-yl)-3-methoxy propionic acid lithium (588mg, 2.00mmol) and DIPEA (1.745mL, 9.99mmol)) in DCM (30mL), then at room temperature stir overnight.Reactant is diluted with water (100mL), extracted with DCM (3x20mL).The organic phase merged is washed with water (10mL) and salt solution (10mL), then use Na2SO4Drying, filter and concentrate in a vacuum. The crude product was purified by preparative HPLC (XBridgePrep C18 OBD column, 5μ silica, 19 mm diameter, 150 mm length) using decreasingly polar mixtures of water (containing 0.05% NH3) and MeCN as eluents. Fractions containing the desired compound were evaporated to dryness to provide tert-butyl 4-(1-((3-(5-fluoro-2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)pyrimidin-4-yl)-1H-indol-7-yl)amino)-3-methoxy-1-oxopropan-2-yl)piperazine-1-carboxylate (305 mg, 44.5%) as a yellow solid. m / z (ES+), [M+H] + =686.

[0616] Step 4

[0617] Tert-butyl 4-(1-((3-(5-fluoro-2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)pyrimidin-4-yl)-1H-indol-7-yl)amino)-3-methoxy-1-oxopropan-2-yl)piperazine-1-carboxylate (300 mg, 0.44 mmol) was added to a solution of 1:3 TFA-DCM (10 mL) and then stirred at room temperature for 1 h. The solvent was then concentrated in vacuo and the crude product was purified by preparative HPLC (XBridgePrep C18 OBD column, 5μ silica, 19 mm diameter, 150 mm length) using decreasingly polar mixtures of water (containing 0.1% formic acid) and MeCN as eluents. The appropriate fractions were concentrated to dryness to afford N-(3-(5-fluoro-2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)pyrimidin-4-yl)-1H-indol-7-yl)-3-methoxy-2-(piperazin-1-yl)propanamide (200 mg, 78%) as a yellow solid. The compound was further purified by preparative chiral-HPLC on a chiralpak ID-3 column, eluting isocratically with 10% MeOH in MTBE (modified with 0.1% DEA) as the eluent. The fractions containing the first eluting compound were concentrated to dryness to provide Example 66, (R)-N-(3-(5-fluoro-2-(2-fluoro-3-(methylsulfonyl)phenylamino)pyrimidin-4-yl)-1H-indol-7-yl)-3-methoxy-2-(piperazin-1-yl)propanamide (39.0 mg, 19.43%) as a white solid.

[0618] 1 H NMR (300MHz, DMSO-d6) δ2.50 (s, 3H), 2.68-2.71 (m, 2H), 2.80-2.90 (m, 6H), 3.30 (s, 3H), 3.62-3.69 (m, 2H), 3.76-3.83 (m, 1H), 7.00 -7.06 (t, 1H), 7.44-7.49 (t, 1H), 7.60-7.65 (m, 2H), 8.16-8.27 (m, 3H), 8.40-8.44 (m, 2H), 9.47 (s, 1H), 10.25 (s, 1H), 12.20 (s, 1H).

[0619] m / z(ES+), [M+H] + =586.

[0620] Example 67

[0621] The fractions of the second eluting isomer of Example 66 were concentrated to dryness to provide Example 67, (S)-N-(3-(5-fluoro-2-(2-fluoro-3-(methylsulfonyl)phenylamino)pyrimidin-4-yl)-1H-indol-7-yl)-3-methoxy-2-(piperazin-1-yl)propanamide (35.0 mg, 17.50%) as a white solid.

[0622] 1 H NMR (300MHz, DMSO-d6) δ2.50 (s, 3H), 2.73 (m, 2H), 2.83-2.92 (m, 6H), 3.30 (s, 3H), 3.64-3.69 (m, 2H), 3.76-3.82 (m, 1H), 7.00-7. 06 (t, 1H), 7.44-7.49 (t, 1H), 7.60-7.65 (m, 2H), 8.16-8.27 (m, 3H), 8.41-8.44 (m, 2H), 9.47 (s, 1H), 10.30 (s, 1H), 12.29 (s, 1H).

[0623] m / z(ES+), [M+H] + =586.

[0624] Example 68: Enzyme inhibition studies

[0625] Enzyme inhibition studies were performed using recombinant JAK1 (amino acids 866-1154, Life Technologies, #PV4774, Carlsbad, CA), JAK2 (amino acids 831-1132, AstraZeneca R&D Boston), or JAK3 (amino acids 781-1124, AstraZeneca R&D Boston) in buffer conditions of 50 mM HEPES pH 7.3, 1 mM DTT, 0.01% Tween-20, 50 μg / ml BSA, and 10 mM MgCl. JAK enzymes were expressed in insect cells as N-terminal GST fusions and purified by glutathione affinity and size exclusion chromatography. Enzymes were tested at their approximate high end of physiological ATP of 5 mM in the presence of inhibitors given at 30, 3, 0.3, 0.03, 0.003, and 0 μM final test concentrations.

[0626] For JAK1, 4 nM enzyme was incubated with 1.5 μM peptide substrate (FITC-C6-KKHTDDGYMPMSPGVA-NH2 (SEQ ID NO: 1), Intonation, Boston, MA). For JAK2, 0.3 nM enzyme was incubated with 1.5 μM peptide substrate (5FAM-GEEPLYWSFPAKKK-NH2 (SEQ ID NO: 2), Intonation, Boston, MA). For JAK3, 0.1 nM enzyme was incubated with 1.5 μM peptide substrate (5FAM-GEEPLYWSFPAKKK-NH2 (SEQ ID NO: 2), Intonation, Boston, MA). Phosphorylated and non-phosphorylated peptides were separated and quantified by Caliper LC3000 system (Caliper Life Sciences, MA) for calculation of percent inhibition. The results of this test are shown in Table 17.

[0627] Example 69: Cellular interleukin-induced JAK-STAT6-luciferase assay (pSTAT6)

[0628] A stable cell line based on U937 monocytes was generated with a luciferase reporter gene incorporated into the genome under the control of the STAT6 promoter (U937-STAT6-Luc). Cells were grown in suspension in growth medium (RPMI 1640 with GlutaMAX and 25 mM Hepes, 10% FCS, 1% sodium, 1% non-essential amino acids and 0.5 mg / ml geneticin (for selection)) at 37°C and 5% CO2.

[0629] The cells were collected by centrifugation at 250 g for 5 minutes and resuspended in assay buffer (20 mM HEPES, 1× HBSS and 0.1% BSA) to 1000 cells / μl. To stimulate the cells, interleukin (IL-13) was used, also dissolved in assay buffer to 300 pM or 7 nM, respectively. This gave 150 pM and 3.5 nM, respectively, in the final assay, inducing E max Test and control compounds were applied to assay plates (low vol white 384-well plates) at 5 nl / well in DMSO in serial dilutions from 10 mM to 0.5 nM.

[0630] 4 μl of cells and 4 μl of interleukin (IL-13) were added to each well, the plate was sealed and incubated at 37°C for 4 1 / 2h, then incubate at room temperature for 30min. The assay was developed by adding 4μl / well of SteadyGlo (Promega) and the plate was read 20 minutes later on an Envision plate reader with a fluorescence filter.

[0631] In the assay, compounds were therefore diluted 1600-fold, and dose-response curves for inhibition of interleukin-induced signaling determined the IC of the compounds. 50 This assay determines the IC 50 The range was 2 nM to 2 μM of compound relative to control and test compound.

[0632] Table 17

[0633]

[0634]

[0635] Example 70 - In vivo dose titration study of alopecia areata

[0636] Compounds within the scope of the present disclosure were orally administered to C3H / HeJ mice with established alopecia areata (AA) at increasing doses until significant hair growth was observed. Hair growth was expressed as a hair index score (HIS) based on weekly assessments and compared to healthy mice (full hair = HIS of 300) and mice with complete AA (no hair = HIS of 0).

[0637] A. Animal Group

[0638] Group 1 - (n=6) Alopecia areata mice treated group

[0639] Group 2 - (n=6) Untreated alopecia areata mice (control group)

[0640] Group 3 - (n=6) healthy controls

[0641] B. Treatment

[0642] All three groups were kept in 6×6 macrolon cages in the facility, using a 12±12h light / dark cycle, 21°C±2°C and 55%±15% relative humidity. Rodent food and water were provided ad libitum. Photos were taken before the start of the study and just before termination. Body weight (BW) and HIS were monitored once a week. Once a day, mice in Group 1 were fed 5 g of crushed rodent chow soaked with the compound of Example 35 in 10 mL of tap water, with a stepwise increase in dose (BW and HIS were monitored once a week):

[0643] 1. Feed at 0.5 mg / kg body weight (BW) for 2 weeks,

[0644] 2. Feed at 2.5 mg / kg body weight (BW) for 2 weeks, and

[0645] 3. Feed at 12.5 mg / kg body weight (BW) for 2 weeks.

[0646] C. Termination

[0647] 1-2 hours after the last dose at the highest concentration of the compound of Example 35, significant hair growth was observed and hair growth scores were recorded, and mice in Group 1 were sacrificed. Blood was collected from behind the eye into EDTA-coated tubes (Multivette 300, Sarstedt) and kept on ice. Plasma was obtained by centrifugation (4°C, 4000G, 5 minutes), and 50 μL was transferred to a 96-well NUNC plate and stored at -20°C until analysis of drug concentration by LC-MSMS.

[0648] D. Results

[0649] The results for all three groups are Figure 2 The data are presented in a graph with HIS on the Y-axis and time (weeks) on the X-axis.

[0650] E. Results

[0651] The mean plasma exposure (total concentration) of the compound of Example 35 at termination was 338 nM, and HIS=218.

[0652] These results show that:

[0653] 1. The compound of Example 35 produced the desired response at the highest dose, although a longer treatment time was required to achieve a HIS=300.

[0654] 2. 12.5 mg / kg BW would be the preferred dose for the full experiment (12 weeks), showing full effect (HIS=300).

[0655] Example 71 - In vivo pharmacodynamic properties study in OVA pneumonia model

[0656] Brown Norway rats were sensitized and challenged with chicken ovarian albumin (OVA). (Clinical and Experimental Allergy, 37 (2007) 973-988). The reduction in airway inflammation in the lungs of OVA-challenged Brown Norway rats was measured after inhalation of a dose of a micronized compound within the scope of the present disclosure as the percent reduction in eosinophils in the bronchoalveolar lavage (BAL) compared to challenged but untreated rats using the following procedure. As a model control, an intravenous overdose (2×300 μg / kg) of the model reference compound Budesonide was used.

[0657] A. Animal Group

[0658] 74 animals were divided into 8 experimental groups and treated as follows:

[0659] Group 1 (Saline / Saline / Air), n=6 - Sham (Saline) sensitization on Day 0 (S1) and Day 7 (S2) and Sham (Saline) challenge on Day 14 (P1). Treatment - Room air

[0660] Group 2 (OVA / Saline / Lactose), n=8 - Sensitization with Al(OH)3 / OVA mixture on days 0 (S1) and 7 (S2), followed by iv sham (saline) challenge on day 14 (P1). Treatment - DPI lactose.

[0661] Group 3 (OVA / OVA / Lactose), n=12 - Sensitization with A1(OH)3 / OVA mixture followed by IV injection on day 0 (S1) and day 7 (S2). OVA challenge treatment on day 14 (P1) - DPI lactose.

[0662] Group 4 (OVA / OVA / Example 35), n=10 - Sensitization with Al(OH)3 / OVA mixture followed by IV injection on day 0 (S1) and day 7 (S2). OVA challenge treatment on day 14 (P1) - DPI. Compound of Example 35, target dose 0.03 μg / kg

[0663] Group 5 (OVA / OVA / Example 35), n=10 - Sensitization with Al(OH)3 / OVA mixture followed by IV injection on day 0 (S1) and day 7 (S2). OVA challenge treatment on day 14 (P1) - DPI. Compound of Example 35, target dose 0.3 μg / kg

[0664] Group 6 (OVA / OVA / Example 35), n=10 - Sensitization with Al(OH)3 / OVA mixture followed by IV injection on day 0 (S1) and day 7 (S2). OVA challenge treatment on day 14 (P1) - DPI. Compound of Example 35, target dose 3 μg / kg

[0665] Group 7 (OVA / OVA / Example 35), n=10 - Sensitization with Al(OH)3 / OVA mixture followed by IV injection on day 0 (S1) and day 7 (S2). OVA challenge treatment on day 14 (P1) - DPI. Compound of Example 35, target dose 30 μg / kg

[0666] Group 8 (OVA / OVA / Budesonide), n=8 - Sensitization with Al(OH)3 / OVA mixture followed by intravenous injection on day 0 (S1) and day 7 (S2). OVA challenge treatment on day 14 (P1) - Budesonide (model reference compound) was injected intravenously at 2x300 μg / kg, twice a day on day 14.

[0667] B. Experimental Procedure

[0668] Before the first sensitization (S1), body weight (BW) was recorded and the tails of all rats were marked with identification numbers. BW was additionally recorded before S2 and before the termination point (D15). BAL was determined for all animals. At the time of termination, the performer (investigator) was blinded to the status of the individual rats.

[0669] i. Sensitization

[0670] Rats were injected subcutaneously (sc) with a mixture of OVA / Al(OH)3 (100 μg OVA: 100 mg Alum in 1 ml saline / rat), and rats were injected intraperitoneally (ip) with 0.5 ml pertussis toxin / rat (0.1 μg / ml) on days 0 and 7. Sham sensitization was performed with subcutaneous and intraperitoneal injections of isotonic saline of the same volume and strategy.

[0671] ii. Administration of Compounds

[0672] Dry Powder Inhalation (DPI) Procedure

[0673] Each exposure system includes a flow-through exposure inhalation chamber, a rat restraint tube and a modified Wright Dust Feed mechanism. The aerosol concentration in the inhalation chamber of each dose level is measured by sampling through a filter at one of the inhalation ports (AP40, 47mm, Millipore). The different doses of the compound of Example 35 are achieved by changing the exposure time while keeping the concentration of the test article and the flow rate in the exposure chamber constant. The rats of Groups 2 and 3 are exposed to lactose (Battelle chamber) in the restraint tube. Assuming that the exposure duration is 2-10 minutes and the body weight is 250g, the target inhalation dose (μg / kg) is calculated using the following formula:

[0674]

[0675] Where C = aerosol concentration (μg / L). RMV: Respiratory Minute Volume (L / min) = 4.19 × BW (g) 0.66 / 1000 (McMahon 1977) D = duration of exposure. BW body weight (kg).

[0676] Based on the filtration analysis results, the lung load (lung dose) can be calculated as follows:

[0677] Lung dose = inhaled dose * lung deposition fraction

[0678] Intratracheal administration of the model reference compound (budesonide)

[0679] Rats were weighed one day before OVA challenge. At the time of challenge, rats were anesthetized with an isoflurane mixture (air and 4% isoflurane) in a supine position at a 30°-40° angle and instilled with vehicle or compound. This intratracheal instillation was performed by using a modified metal cannula with a push ball at the end. Rats were placed in a cage in a supine position with their heads up until they regained consciousness. Reference compounds were administered twice daily, with the second daily dose being given 6 hours after the first daily dose. Instillation volume: 0.25 mL / rat.

[0680] iii. Stimulation (induced with OVA)

[0681] Blood (0.2 ml) was collected from the lingual vein 5 minutes (5′) before OVA challenge and plasma (60 μl / well) was collected on a 96-deep well plate. Provocation occurred on day 14 (P1) and was performed 2 hours after compound administration. Rats were anesthetized with an isoflurane mixture (air and 4% isoflurane), placed in the supine position at an angle of 30°-40°, and instilled with isotonic saline or OVA (0.1 mg / ml). This intratracheal instillation was performed using a modified metal cannula with a push ball at the end. Rats were placed in a cage in a supine position with their heads up until they regained consciousness. Sham challenge was performed with an intravenous infusion of isotonic saline of the same volume and strategy. Infusion volume: 0.25mL / rat .

[0682] iv. Termination and bronchoalveolar lavage

[0683] After OVA excitation 22 hours later (P1), rats were intraperitoneally injected with 1ml pentobarbital (50mg / ml) to euthanize them. Blood was taken from the internal jugular vein in a tube coated with EDTA, centrifuged (Rotanta 46R, 480xg, 10 minutes, 20°C), and plasma samples were collected in 2×96-deep well plates (60μl / well) placed on dry ice, and stored below-70°C for further analysis. Bronchoalveolar lavage (BAL) was performed by manually perfusing the whole lung with PBS. After trachea exposure, a polyethylene tube (PE120) was inserted and ligated with sutures. The tube was connected to a syringe, pre-filled with 4.2ml PBS at room temperature, slowly injected into the lungs, and continued for 10 seconds in the lungs. Fluid was collected again in a syringe by slow aspiration. This process was performed twice. Final BAL fluid was transferred to a test tube (4ml, polypropylene (PP)). Weigh the BAL sample tube (assuming that 1ml of BALF is equal to 1g). BAL was kept on ice until centrifugation (Rotanta 46R, 300xg, 10 minutes, 4°C). After centrifugation, the supernatant was divided into 4×96-well plates (0.1 ml / well) placed on dry ice, stored and stored below -70°C until medium analysis. The cell pellet was then resuspended in 0.5 ml PBS and kept on ice until the cells were counted. The total number and differential number of cells were counted using a semi-automatic SYSMEX XT-1800i Vet (Sysmex, Kobe Japan) and the gating program: BALrOVAi.

[0684] C. Results

[0685] Based on the filter analysis, the following lung doses (μg / kg body weight) were achieved for micronized Example 35:

[0686] Group 4: 0.08

[0687] Group 5: 0.11

[0688] Group 6: 0.6

[0689] Group 7: 4.76

[0690] The results are presented as bar graphs with p-values ​​above, as an alternative ns indicating not significant, and with Figure 3 The reduction in eosinophils in each experimental group was 3% compared with the untreated group (OVA / OVA).

[0691] These results show that:

[0692] 1. At lung doses of 0.08, 0.11, 0.6 and 4.76 μg / kg, the compound of Example 35 reduced eosinophils in BAL by 7% (not significant), 28% (not significant), 68% (p<0.01) and 61% (p<0.01).

[0693] 2. OVA induction (Group 3) significantly increased the number of eosinophils in BAL.

[0694] 3. The compound of Example 35 significantly reduced the presence of eosinophils in a dose-dependent manner, with a maximum inhibition of 68% compared to the OVA control (Group 3), and a plateau of inhibition was observed from a dose of 0.6 μg / kg.

[0695] 4. Overdose of the model reference compound budesonide 2*300 mg / kg (Group 8) showed an inhibition rate of eosinophils of 97%, which is within the range observed for this model.

Claims

1. A compound which is 3-(5-fluoro-2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)pyrimidin-4-yl)-1H-indol-7-amine:

2. A crystalline form of (R)-N-(3-(5-fluoro-2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)pyrimidin-4-yl)-1H-indol-7-yl)-3-methoxy-2-(4-methylpiperazin-1-yl)propanamide, whose powder X-ray diffraction pattern contains peaks at °2θ of 7.6, 12.7, 14.8, 19.3 and 25.

5.

3. A crystalline form of (R)-N-(3-(5-fluoro-2-((2-fluoro-3-(methylsulfonyl)phenyl)amino)pyrimidin-4-yl)-1H-indol-7-yl)-3-methoxy-2-(4-methylpiperazin-1-yl)propanamide having a powder X-ray diffraction pattern substantially as shown in Figure 1.

4. Use of a crystalline form as claimed in claim 2 or claim 3 in the preparation of a medicament for treating a JAK1-related disorder.

5. The use according to claim 4, wherein the JAK1-related disorder is selected from type 1 diabetes, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis, asthma, atopic dermatitis, autoimmune thyroid disease, ulcerative colitis, Crohn's disease, COPD, vitiligo and alopecia areata.

6. Use of a pharmaceutical composition comprising a crystalline form as claimed in claim 2 or claim 3 for the preparation of a medicament for treating a JAK1-related disorder.

7. The use according to claim 6, wherein the JAK1-related disorder is selected from type 1 diabetes, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis, asthma, atopic dermatitis, autoimmune thyroid disease, ulcerative colitis, Crohn's disease, COPD, vitiligo and alopecia areata.